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General introduction
“The soul is born old and grows young; that’s life’s comedy. However, the body is 
born young and grows old; that’s life’s tragedy.” Oscar Wilde (1854-1900)
Aging
Aging is characterized by changes in human appearance, for example turning grey, 
getting wrinkles, losing elasticity and becoming slower. Aging classically is defined 
as the progressive loss of function accompanied by decreasing fertility and increasing 
mortality.1 The biological process that underlies the progressive loss of function is an 
accumulation of damage to somatic cells.1,2 Several intrinsic and extrinsic stressors 
may lead to injuries of the body. The main theory concerning aging addresses the 
accumulation of risk factors (e.g. physical inactivity, high fat diet) and accumulation 
of damage that remains after restoration. Although most of the injury acquired during 
life is repairable (e.g. scratches or bruises), the repair is often not flawless and little 
damage remains after injury.1 As a consequence, risk factors and damage accumulate 
gradually over time resulting in organ dysfunction (e.g. increased arterial stiffness, 
diminished endothelial function or atherosclerosis) that may lead to symptomatic 
diseases (e.g. myocardial infarction) and ultimately to increased vulnerability and 
death (Figure 1.1).2
Worldwide demographics are changing and people are growing older. It is expected 
that the next 30 years, the number of individuals older than 65 years will increase from 
2.5 million to 4.6 million in the Netherlands.3 That will be more than 25% of the total 
Figure 1.1 Conceptual presentation of aging with the progressive loss of function 
and increased vulnerability. Adapted from Rothman, 1976.2
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Dutch population (Figure 1.2). Furthermore, the number of frail older individuals also 
increases from approximately 650.000 individuals nowadays to approximately 
1.000.000 individuals by the year 2030.3 Frail older individuals are an extremely 
vulnerable group and preventive medicine to encourage and maintain a healthy and 
independent living is crucial for preventing older individuals to become frail and care 
dependent.
With advancing age the incidence of chronic diseases, such as cardiovascular 
diseases, increases.4,5 Despite multiple interventions and reduction in death rates 
over the last few decades, cardiovascular diseases remain the leading cause of 
morbidity and mortality in modern societies, and especially in the aging population.6,7
In this chapter, the physiological changes will be reviewed that occur with aging, 
especially cardiovascular and cerebrovascular changes, the influence of physical 
activity thereon, and the role of advanced glycation endproducts (AGEs) in 
physiological aging. Furthermore, the impact of AGEs on the vascular system, 
possible interventions to reduce the negative influence of AGEs and the novel agent 
the AGE-crosslink breaker Alagebrium will be discussed. At the end of this chapter, 
the aims and outline of this thesis will be addressed.
Figure 1.2 Representation of the expected increase in the older population in the 
Netherlands, expressed as the percentage individuals (>65 years, 65-80 years 
and >80 years) of the total population in the Netherlands. Source: Centraal Bureau 
voor de Statistiek,3 August 2013
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Aging and physical (in)activity
Aging is associated with a gradual loss of organ function and increased risk for 
development of diseases. Large differences exist between individuals in the speed of 
aging and related morbidity rates due to different coping strategies to minimize the 
accumulation of risk factors and damage. Besides genetic influences, environmental 
and lifestyle habits play important roles in disease development. An important 
lifestyle factor is physical inactivity, which is strongly related to cardiovascular 
diseases.8-10 It has been demonstrated that sedentary aging leads to marked 
cardiovascular dysfunction.4,11-13 In contrast, lifelong exercise and elevated physical 
fitness seem to protect against cardiovascular diseases.5,14-16.5,10,17-19 Improvements 
in physical fitness, especially among those who are the least fit, are associated with 
substantial health gains.9,20 Consequently, physical exercise training is widely 
recommended as a primary or adjunctive therapy for reducing cardiovascular risk.21 
Nevertheless, most older individuals prefer daily life activities (e.g. walking, cycling 
and gardening) rather than participation in exercise training programs.22 Furthermore, 
a decline in physical fitness occurs with physiological aging. This age-associated 
decline may be delayed or slowed in those who are engaged in regular vigorous 
aerobic exercise, but it appears to be inevitable, regardless of (pre-existing) fitness 
level and exercise status.23 This reduction in physical fitness results in a decrease in 
functional capacity that contributes to a loss of independence, increased incidence 
of disability, and reduced quality of life with age.23 Therefore, it is crucial to remain 
physically fit, especially for the older population to maintain a healthy and independent 
living. 
Aging and cardiovascular changes
It is well known that advancing age is a major and independent risk factor for the 
development of cardiovascular diseases.4,5 Even with presumably healthy aging the 
risk for development of cardiovascular diseases increases. An increased exposure 
time to risk factors, and thus having a longer time of risk factor and damage 
accumulation, and occult cardiovascular adaptations explain part of this rise in 
cardiovascular diseases with aging.4 A wide array of adverse changes to the arteries 
contribute to the increased risk of cardiovascular diseases with aging. These changes 
include structural changes such as thickening of the intima media and stiffening of 
the arterial walls, and functional changes like the development of vascular endothelial 
dysfunction.4,5 These parameters will be discussed separately in the text below.
14
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Increased intima media thickness
Intima-media thickness (IMT) is the thickness of the tunica intima and tunica media, 
the innermost two layers of the arterial wall, see Figure 1.3. Intima media thickness 
correlates well with major cardiovascular risk factors and an increased IMT is an 
independent predictor of future cardiovascular events.24-28 Even in healthy older 
individuals without clinical cardiovascular diseases, the carotid artery IMT increases 
markedly.29,30
Since the carotid artery is easily accessible due to the anatomical position, and since 
it is a usual location for the development of atherosclerosis, the carotid artery IMT is 
used most frequently in clinical practice and scientific studies as a surrogate marker 
for cardiovascular diseases.28,32 In addition, the carotid artery is an elastic artery with 
relatively small muscular media,33 and thus an increased IMT of the carotid artery is 
considered to represent mainly intima thickening.34 Measurements of the IMT are 
usually performed noninvasively by using B-mode ultrasound (Figure 1.3).24,35 
Numerous studies have shown that non-invasive measures of the carotid artery IMT 
can be measured with high reproducibility.24-28
Figure 1.3 On the left side is a B-mode ultrasound image of the carotid artery 
seen during the ultrasound measurement. The rectangular box shows the area 
where the intima media thickness can be measured offline. On the right is a 
schematic cross-sectional view of an artery with the intima, media and adventitia 
layers, and endothelial lining (adapted from Libby et al.31).
15
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Arterial stiffness
Besides intima media thickening, generalized arterial stiffening is another important 
consequence of aging that significantly contributes to the increased risk for 
developing cardiovascular diseases in older individuals.36,37 Arterial compliance 
represents the capacity of an artery to expand in response to a change in (blood) 
pressure and is primarily determined by the intrinsic elastic properties of the artery.38 
Vascular aging is strongly associated with elastin depletion and fragmentation, as 
well as with collagen deposition.37,39 These changes result in increased arterial 
stiffness, allowing smaller diameter expansions in response to elevations in blood 
pressure, that leads to clinical manifestations of a rise in systolic blood pressure and 
an increase in pulse pressure (systolic – diastolic blood pressure).40,41 The increase 
in systolic blood pressure and pulse pressure affects the cardiac function by inducing 
left ventricular hypertrophy and reduced left ventricular performance.42 Furthermore, 
increased arterial stiffness induces altered vascular wall properties such as intima 
media thickening.43 Numerous studies have indicated that increased arterial stiffness 
is an independent predictor for future cardiovascular events.4,44,45
Beside (systolic) blood pressure measurements and calculation of pulse pressure, 
pulse wave velocity (PWV) is a more accurate method to measure arterial stiffness. 
Pulse wave velocity is measured noninvasively using ultrasound echo Doppler or 
tonometry. It is calculated as the distance (ΔD) traveled by a pulse wave divided by the 
time (Δt) taken to travel this distance: PWV = ΔD/Δt (m/s).46,47 A higher PWV indicates 
an increased stiffness of the conduit arteries.46,47
Increased arterial stiffness does not solely depend on structural changes of the 
arterial wall, but is also influenced by the endothelial function to regulate the vascular 
smooth muscle tone which is also impaired with aging.4,48,49
Endothelial (dys)function 
The vascular endothelium is a single layer of cells lining blood vessels that plays a 
key role in regulating the function and health of arteries.50,51 The endothelium 
represents a dynamic interface between the intima of the vasculature and the blood 
flow (Figure 1.3).31,52 It is an important regulatory organ that modulates the tone of the 
underlying vascular smooth muscle cells and maintains cardiovascular homeostasis.53 
Endothelial dysfunction, on the other hand, represents a key step in the early 
development of atherosclerosis which can ultimately lead to clinical manifestations of 
cardiovascular diseases.54 Age-associated endothelial dysfunction is, at least partly, 
mediated by reduced nitric oxide (NO) bioavailability.5,55 This is due to an imbalance 
between the production and removal of nitric oxide. Oxidative stress and inflammation 
are other mechanisms by which aging leads to reduced nitric oxide bioavailability 
and thereby reduced endothelium dependent vasodilation.42,56,57 Vascular oxidative 
stress develops with aging as a result of increased production of reactive oxygen 
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species, while antioxidant defense mechanisms remain similar or attenuate.58 Several 
factors are known to influence endothelial function, including regular aerobic exercise, 
dietary factors (e.g. high fat diet), body fatness and fat distribution, and conventional 
(e.g. smoking, hypertension, diabetes) and non-conventional risk factors for 
cardiovascular diseases. Examples of non-conventional risk factors are inflammatory 
markers, such as high sensitive C-reaction protein (hs-CRP) or the accumulation of 
glycated proteins, also known as advanced glycation end-products or AGEs. These 
will be discussed later in this chapter.
Endothelial dysfunction can be measured in different vascular beds, e.g. conduit and 
resistance arteries, in different limbs, e.g. upper and lower limbs, and using different 
techniques. A frequently used noninvasive technique to measure endothelial function of 
conduit arteries is the method of flow mediated dilation (FMD). This technique is based 
on the characteristics that (healthy) arteries dilate in response to an increase in shear 
stress (increase in blood flow) as a results of an increase in the endothelium derived 
nitric oxide. The nitric oxide differs to the smooth muscle cells causing a relaxation of 
the smooth muscle cells and thus a vasodilation and increase in arterial diameter.59,60
Another technique to examine endothelial function is by using venous occlusion 
plethysmography to quantify changes in limb volume from changes in limb blood 
flow using mercury-in-silastic strain gauges.61 Changes in blood flow can be induced 
by intra-arterial infusion of vasoactive drugs, e.g. nitric oxide donors like sodium 
nitroprusside, endothelium dependent agents like acetylcholine or vasoconstricting 
agents like L-NMMA.62 Depending on the type and dose of the vasoactive drugs, in 
combination with the structural and functional properties of the conduit and resistance 
arteries, the blood flow increases or decreases resulting in a change of limb volume 
that is registered by the mercury-in-silastic strain gauges. This method to examine 
endothelial function is considered to be the “gold standard”.63,64
The arm-model is used more often to examine the endothelial function than the 
leg-model. It is known that upper and lower limb vasculature demonstrate different 
vascular responses to shear 65,66 and pharmacological vasoactive substances.67,68 
Studies have reported that the endothelial function of the brachial artery correlates 
well with the coronary artery vasomotor function.69-71 This correlation is less well 
established for the lower limb endothelial function and coronary arterial function. 
Nevertheless, since the lower limb demonstrates a higher incidence of clinical 
vascular diseases and more symptomatic atherosclerosis in older individuals, we will 
be studying this vascular bed.
Arterial stiffness and endothelial dysfunction
Even though structural properties, arterial stiffening, and functional properties, endo thelial 
function, of the vasculature seem to be different, studies have reported interactions 
17
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between the two in which arterial stiffening leads to endothelial disturbances and 
these in turn worsen arterial stiffening.37,56 Given the increasing number of older 
individuals and associated health care burden, effective strategies are needed for the 
prevention and treatment of age-related arterial stiffening and endothelial dysfunction 
to attenuate the development of cardiovascular diseases and improve healthy, 
independent aging.
Aging and cerebrovascular changes
Besides age-related changes in the cardiovascular system, the cerebrovascular 
system also encounters age-related changes. Most of these changes are inherent to 
the cardiovascular changes, such as arterial stiffening and endothelial dysfunction.72 
The main goal of the cerebrovascular system is to maintain a stable cerebral blood 
flow during all circumstances. In order to maintain a stable cerebral blood flow, the 
cerebral circulation has an autoregulatory system based on myogenic, metabolic, 
and neurogenic mechanisms that adapt cerebrovascular resistance in response to 
alterations in blood pressure.73 The term cerebral autoregulation, first introduced by 
Lassen in 1959,74 refers to the ability of the brain to keep cerebral blood flow constant 
despite changes in blood pressure. Besides cerebral autoregulation, cerebrovascu-
lar reactivity to carbon dioxide (CO2) is also involved in optimizing cerebral blood 
flow. Cerebrovascular CO2 reactivity describes adaptations of cerebral blood flow to 
changes in arterial carbon dioxide, which is a very potent cerebral vasodilator and 
constrictor.75,76 Both cerebral autoregulation and cerebrovascular CO2 reactivity are 
directly related to the perfusion and oxygenation of the brain tissue and therefore to 
human brain function.77,78 
Cerebral autoregulation has been shown to remain stable in participants up to the 
age of 75 years.76,79,80 The effects with aging above the age of 75 years have not 
been examined, and the effects of aging on cerebrovascular CO2 reactivity are less 
clear. Cerebrovascular pathology, on the other hand, is known to occur in the aging 
population. Reduced cerebral blood flow in older individuals 79-81 may result in 
stroke,82 and it is a major risk factor for the development of neurodegenerative 
diseases, such as Alzheimer’s disease.83 Furthermore, reduced blood flow and cere-
brovascular CO2 reactivity are not only risk factors for the development of neurode-
generative diseases, patients with early stage Alzheimer’s disease also have a 
reduced cerebral blood flow, increased cerebrovascular resistance and reduced 
cerebrovascular CO2 reactivity.77,84 Thus, age-related cerebrovascular changes play 
an important role in age-related disease pathology.
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Impact of physical activity on age-related  
vascular changes
Arterial stiffness and endothelial dysfunction develop over time and can ultimately 
manifest in clinical cardiovascular and cerebrovascular diseases. Since arterial 
stiffness and endothelial dysfunction are precursors in the process of cardiovascular 
diseases, it would be desirable to intervene in time to delay or improve arterial 
stiffness and endothelial function in order to postpone the development of clinical 
vascular diseases.
Influence on cardiovascular parameters
Physical exercise is said to be the best method to improve healthy independent aging. 
Prior research has demonstrated an independent, dose-dependent, inverse association 
between physical fitness and cardiovascular diseases amongst individuals with and 
without clinical cardiovascular diseases.85-87 The beneficial effects of physical activity 
on the cardiovascular system can not only be explained by changes in (traditional) 
cardiovascular risk factors, such as blood pressure, body composition, glucose 
metabolism or cholesterol level, but may also be due to arterial remodeling and/or 
improvement of endothelial function.88 Even after accounting for traditional risk factors, 
such as blood pressure, lipids, and diabetes, the inverse relation between physical 
activity and risk for cardiovascular diseases persists.86,89 A large study performed by 
Mora et al.10 reported that differences in traditional risk factors explain about 59% of the 
exercise associated reduction in cardiovascular risk, with inflammatory biomarkers 
making the largest contribution, followed by blood pressure, lipids, and body mass 
index. Part of this unexplained risk factor gap (41%) could be explained by the beneficial 
effects of physical activity on vascular structure and/or function, such as improved 
arterial stiffness and endothelial function (Figure 1.4).88 
 It is known that older individuals who have been exercising most of their lives do 
not endure the age-related increase in arterial stiffness 38,90 or decrease in endothelial 
function 15,16 to the same extend as sedentary older individuals. Furthermore, aerobic 
exercise training improves arterial stiffness 38 and endothelium function, in middle- 
aged and older men, both with and without clinical presentations of cardiovascular 
diseases.15,91
Influence on cerebrovascular parameters
The beneficial effects of exercise training on cardiovascular function, also applies to 
cerebrovascular function by enhancing cerebral blood flow and cerebrovascular CO2 
reactivity. A study by Ainslie et al. reported that the cerebral blood flow velocity is 
higher in endurance trained individuals compared with sedentary peers, independent 
of age.81 Murrel et al. showed that a 12-week training intervention induced an increase 
19
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in cerebrovascular CO2 reactivity, both in young and older individuals.92 Even though 
data concerning the influence of physical activity and exercise training on cerebro-
vascular function is not overwhelming, the positive influence of physical activity and 
exercise training seems to be reinforced.
Aging and advanced glycation end-products
Formation of advanced glycation end-products (AGEs)
Besides age per se and lifestyle factors, such as physical inactivity, another 
mechanism involved in the age-related vascular changes is the (lifelong) accumulation 
of advanced glycation end-products, also known as AGEs. In 1912 the French 
chemist Louis Maillard described for the first time the non-enzymatic chemical 
reaction, also known as the Maillard reaction, between reducing sugars, such as 
glucose, and amino groups on proteins to form protein-protein crosslinks and 
complex yellow-brown pigment on a crème brûllée or roasted turkey for instance.93 
His thoughts that this process was not only applicable to the food industry, but that 
Figure 1.4 Differences in cardiovascular risk factors explain approximately 59% of 
the cardiovascular risk reduction associated with physical activity. This suggests 
that about 40% of the reduction in cardiovascular risk attributable to physical activity 
remains unexplained. Possibly, physical activity has a direct effect on the structural 
and functional properties of the vascular system that may explain (part of) this risk 
factor gap (adapted from Mora et al. 2007 10 and Thijssen et al. 2010 88).
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this process might also play an important role in the pathological complications of 
diabetes mellitus, has taken approximately 80 years before it reached awareness in 
clinical medicine. Nowadays, evidence has emerged that the pathological effects of 
advanced glycation end-products (AGEs) are not only relevant in the presence of 
diabetes mellitus, but also play a role with physiological aging and the development 
of cardiovascular diseases.94
The Maillard reaction begins when a reducing sugar non-enzymatically reacts with a 
biological amine from a protein, lipid or amino acid to produce a Schiff base (Figure 
1.5).94 This initial reaction usually takes a few hours to occur, is swift, highly reversible 
and dependent on the concentrations of available glucose.95,96 A Schiff base can 
undergo further chemical rearrangements over several weeks to form a more stable 
glycated protein, an Amadori product. An example of an Amadori product is the 
glycated hemoglobin HbA1c that clinician use as an indicator of the average blood 
glucose level over the past 6 to 12 weeks.97,98 The Amadori product, which is still 
reversible but far more stable than the Schiff base, can over a period of several 
months to years undergo structural rearrangements through a series of reactions 
such as oxidation, dehydration and degradation to form irreversible complex 
arrangements of crosslinked proteins called Advanced Glycation Endproducts or 
AGEs.99,100 Unlike the Schiff base and Amadori product, AGEs are permanently 
bound and can irreversibly crosslink proteins. Due to the irreversible nature of AGEs, 
they accumulate gradually with aging.101,102
Figure 1.5 Schematic overview of the Maillard reaction with formation of AGE-
crosslinks.
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Impact of AGEs on the vascular system
Due to the nature of glycosylation, this process has long been thought to be related 
to patients with diabetes mellitus with high levels of glucose. Nowadays, it becomes 
more apparent that this is a physiological process that occurs in every human being, 
which consequently contributes to the aging phenotype.103,104 The physiological 
consequences of the Maillard reaction have been described in multiple reviews.98,104-107 
The main mechanisms by which AGEs lead to cardiovascular diseases are by 
increasing arterial stiffness and inducing endothelial dysfunction.
Arterial stiffness
Crosslinking of extracellular matrix proteins is essentially a physiological phenomenon.98 
It strengthens tissues enduring tissue integrity, without compromising flexibility. 
Advanced glycation endproducts, however, can covalently bind on long-lived proteins 
and form additional crosslinks between matrix proteins, like collagen and elastin.106 
The excessive crosslinking caused by AGE accumulation undermines the flexibility 
of matrix proteins. This results in prominent stiffening of the extracellular matrix 
and stiffening of the cardiovascular system, e.g. arterial and myocardial stiffening 
(Figure 1.6).94,98,101,105 Due to the continuous accumulation of AGEs and irreversible 
crosslinking to proteins, aging is accompanied with a gradual increase in cardio-
vascular stiffening.94,95,99,103 
Endothelial dysfunction
AGE formation not only changes the physiological properties of (long-lived) proteins, 
but also induces cellular dysfunction through interaction with cell surface receptors. 
There are many AGE receptors, but the most important one is the Receptor for AGE 
(RAGE). RAGE was identified in 1992, and is still considered as a representative AGE 
receptor on endothelial cells.108,109 Activation of AGE receptors causes cascades of 
inflammatory responses and induction of oxidative stress. Furthermore, AGEs can 
quench nitric oxide inhibiting flow mediated release of nitric oxide, and AGEs induce 
expression the potent vasoconstrictor endothelin-1.42,95,106,107,110 These actions lead 
to endothelial dysfunction, which as mentioned before, precedes the development of 
atherosclerosis and increases the risk for development of cardiovascular and cerebro - 
vascular diseases.
22
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Interventions to reduce AGEs
The recognition that AGEs and AGE-crosslinks play important roles in arterial 
stiffening and endothelial dysfunction, is driving the search for novel agents that can 
interact with these AGEs and, consequently, lower the cardiovascular risk. Different 
approaches may be used to reduce the accumulation of AGEs and its deleterious 
effects (Table 1.1). The first approach is to reduce the intake of AGEs by limiting the 
amount of exogenous AGEs in food products 111 or by motivating individuals to quit 
smoking.112 A next approach is to diminish the formation of AGEs at one of the first 
steps in the Maillard reaction, e.g. by interventions to reduce the glucose level, 
especially in patients with diabetes mellitus, or by inhibiting the transfer from the Shiff 
base to Amadori products. Another step is to break down the formed AGEs and AGE-
crosslinks, for example by using the phase II drug Alagebrium. Another approach is 
to prevent the deleterious effects of AGEs by blocking the receptors for AGEs. 
Interventions that have been examined most extensively are aminoguanide, which 
will be discussed briefly, and Alagebrium, which will be discussed in more detail.
Figure 1.6 AGE-crosslinks increase the risk for cardiovascular diseases by 
increasing arterial stiffening and endothelial dysfunction.
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Inhibition of AGE formation using aminoguanide
In 1986 Brownlee et al showed that aminoguanide prevented both the formation of 
AGEs and the formation of glucose-derived collagen crosslinks in vitro.113 Even 
though, aminoguanide seemed promising in the first few trials to reduce microvascular 
and macrovascular complications in patients with diabetes,114,115 trials were terminated 
early due to unfavorable perceived risk-to-benefit ratio’s 115 with pro-oxidant activities 116 
and inhibition of nitric oxide synthase.117,118
AGE-crosslink breaker Alagebrium
In search of novel agents that would decrease arterial stiffening and improve 
endothelial dysfunction to lower cardiovascular risk, a new agent was created to 
specifically break already formed AGE-crosslinks.119 This drug, ALT-711, also known 
as Alagebrium, a thiazolium derivative (3-phenyacyl-4,5-dimethylthiazolium chloride), 
breaks established AGE-crosslinks between proteins.120 By cleaving AGE-crosslinks, 
Alagebrium may have the ability to restore compliance of aged and/or diabetic 
vascular tissue and myocardium. 
The pathophysiological mechanism in combination with animal studies and initial 
phase I and II human studies have shown encouraging results in reducing cardio- 
vascular stiffness 120-127 and improving endothelial function,128 see Table 1.2.
(Pre)clinical trials with Alagebrium
The multicenter phase II clinical trials have examined over 1000 patients receiving 
Alagebrium for up to 9 months. The focus of most clinical trials has been on patients 
Table 1.1   Interventions to reduce the deleterious effects of AGEs
Reduce the intake of exogenous AGEs
· Reduce the intake of AGEs in food 
· Quit cigarette smoking
Inhibition of AGE formation
· Non-pharmaceutical interventions: lower blood glucose level, use of anti-oxidants
· Pharmaceutical intervention: aminoguanidine
Break already formed AGE-crosslinks
· Pharmaceutical intervention: phase II drug Alagebrium
Blockers of the Receptor for AGEs to prevent AGE-RAGE interaction
24
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Table 1.2  Shows an overview of the animal and patient studies that have been  
performed with Alagebrium
Animal studies Population Study design Dose of Alagebrium Main outcome
Wolffenbuttel et al. 121 Male Wistar rats with 9 weeks Four groups: 1 mg/kg body weight Reversion of diabetes-induced increased large artery stiffness
1998, PNAS streptozotocin-induced diabetes    Nondiabetic controls rats 3 weeks Decrease in collagen crosslinking measured in tail tendon
   Diabetic rats without Alagebrium, n = 13
   One group 1 week Alagebrium, n= 8-10
   One group  3 weeks Alagebrium, n = 8-10
Asif  et al. 122 Young and aged dogs Three groups: 1 mg/kg body weight Reduction in age-related left ventricular stiffness
2000, PNAS    Young dogs, n = 7 4 weeks
   Older dogs without Alagebrium, n = 5
    Older dogs with Alagebrium, n = 8
Vaitkevicius et al. 123 Older rhesus monkeys Single arm study, n = 6 1 mg/kg every other day Improvement in compliance of the large arteries and LV function
2001, PNAS  3 weeks  
Candido et al. 124 Male Sprague Dawley rats with Four groups: 10 mg/kg body weight Attenuation of diabetes-associated cardiac abnormalities in rats
2003, Circ Res 16 weeks streptozotocin-induced    Control rats, n = 11 16 weeks Improvement in LV weight
diabetes    Control rats with Alagebrium, n = 10 Decrease in myocardial collagen crosslinking and myocardial
   Diabetic rats without Alagebrium, n = 12    AGE accumulation
   Diabetic rats with Alagebrium, n = 10 Decreased LV RAGE gene expression
Guo et al. 125 Young and aged Sprague-Dawley Three groups: 10 mg/kg body weight Improvement of cardiac mass and diastolic function
2009, J Geront Biol Sci rats    Young rats, n = 10 16 weeks Decreased AGE accumulation in myocardial collagen
   Older rats without Alagebrium, n = 10 Increased anti-oxidant activity in the aging hearts
   Older rats with Alagebrium, n = 10
Steppan et al. 126 Young and aged Male Fisher 344 rats Five groups: 1 mg/kg body weight Alagebrium combined with exercise training improved systolic 
2012, Exp Geront    Young rats, n = 8 4 weeks    and diastolic cardiac function and arterial stiffness
    Older rats, n = 30, randomized  
into 4 groups
    Alagebrium/Placebo and with/without  
exercise training
Patient studies
Kass et al. 120 Systolic blood pressure >140mmHg Randomized placebo vs. Alagebrium 210 mg per day Lowered pulse pressure
2001, Circulation Pulse pressure >60mmHg Alagebrium n = 62; Placebo n = 31 8 weeks Improved large artery compliance and distensibility
Male & female; mean age 67 years
Little et al. 127 Diastolic heart failure Open label, single arm trial, n = 23 210 mg twice daily Regression of LV hypertrophy
2005, J Cardiac Failure Left ventricular ejection fraction ≥50%. 16 weeks Improvements in LV diastolic properties 
Male & female; mean age 71 years Subjective improvements in quality of life by the patients
Zieman et al. 128 Systolic blood pressure >140mmHg Single arm & single blind, n = 13 210 mg twice daily Improvement in brachial endothelial function
2007, J Hypertension Diastolic blood pressure <90mmHg 2 weeks placebo & 8 weeks Alagebrium 8 weeks
Pulse pressuer >60mmHg 
Male & Female; mean age 65 years
Hartog et al. 129 Chronic heart failure Randomized, double blind, placebo  
controlled
200 mg twice daily No improvement in exercise capacity or cardiac diastolic function
2011, Eur J Heart Failure Left ventricular ejection fraction <45%. Alagebrium n = 50; Placebo n = 52 9 months (36 weeks)
Male & Female; mean age 62 years
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Table 1.2  Shows an overview of the animal and patient studies that have been  
performed with Alagebrium
Animal studies Population Study design Dose of Alagebrium Main outcome
Wolffenbuttel et al. 121 Male Wistar rats with 9 weeks Four groups: 1 mg/kg body weight Reversion of diabetes-induced increased large artery stiffness
1998, PNAS streptozotocin-induced diabetes    Nondiabetic controls rats 3 weeks Decrease in collagen crosslinking measured in tail tendon
   Diabetic rats without Alagebrium, n = 13
   One group 1 week Alagebrium, n= 8-10
   One group  3 weeks Alagebrium, n = 8-10
Asif  et al. 122 Young and aged dogs Three groups: 1 mg/kg body weight Reduction in age-related left ventricular stiffness
2000, PNAS    Young dogs, n = 7 4 weeks
   Older dogs without Alagebrium, n = 5
    Older dogs with Alagebrium, n = 8
Vaitkevicius et al. 123 Older rhesus monkeys Single arm study, n = 6 1 mg/kg every other day Improvement in compliance of the large arteries and LV function
2001, PNAS  3 weeks  
Candido et al. 124 Male Sprague Dawley rats with Four groups: 10 mg/kg body weight Attenuation of diabetes-associated cardiac abnormalities in rats
2003, Circ Res 16 weeks streptozotocin-induced    Control rats, n = 11 16 weeks Improvement in LV weight
diabetes    Control rats with Alagebrium, n = 10 Decrease in myocardial collagen crosslinking and myocardial
   Diabetic rats without Alagebrium, n = 12    AGE accumulation
   Diabetic rats with Alagebrium, n = 10 Decreased LV RAGE gene expression
Guo et al. 125 Young and aged Sprague-Dawley Three groups: 10 mg/kg body weight Improvement of cardiac mass and diastolic function
2009, J Geront Biol Sci rats    Young rats, n = 10 16 weeks Decreased AGE accumulation in myocardial collagen
   Older rats without Alagebrium, n = 10 Increased anti-oxidant activity in the aging hearts
   Older rats with Alagebrium, n = 10
Steppan et al. 126 Young and aged Male Fisher 344 rats Five groups: 1 mg/kg body weight Alagebrium combined with exercise training improved systolic 
2012, Exp Geront    Young rats, n = 8 4 weeks    and diastolic cardiac function and arterial stiffness
    Older rats, n = 30, randomized  
into 4 groups
    Alagebrium/Placebo and with/without  
exercise training
Patient studies
Kass et al. 120 Systolic blood pressure >140mmHg Randomized placebo vs. Alagebrium 210 mg per day Lowered pulse pressure
2001, Circulation Pulse pressure >60mmHg Alagebrium n = 62; Placebo n = 31 8 weeks Improved large artery compliance and distensibility
Male & female; mean age 67 years
Little et al. 127 Diastolic heart failure Open label, single arm trial, n = 23 210 mg twice daily Regression of LV hypertrophy
2005, J Cardiac Failure Left ventricular ejection fraction ≥50%. 16 weeks Improvements in LV diastolic properties 
Male & female; mean age 71 years Subjective improvements in quality of life by the patients
Zieman et al. 128 Systolic blood pressure >140mmHg Single arm & single blind, n = 13 210 mg twice daily Improvement in brachial endothelial function
2007, J Hypertension Diastolic blood pressure <90mmHg 2 weeks placebo & 8 weeks Alagebrium 8 weeks
Pulse pressuer >60mmHg 
Male & Female; mean age 65 years
Hartog et al. 129 Chronic heart failure Randomized, double blind, placebo  
controlled
200 mg twice daily No improvement in exercise capacity or cardiac diastolic function
2011, Eur J Heart Failure Left ventricular ejection fraction <45%. Alagebrium n = 50; Placebo n = 52 9 months (36 weeks)
Male & Female; mean age 62 years
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with diabetes mellitus, systolic hypertension and heart failure. There are no studies 
examining the effects of Alagebrium in healthy (older) individuals. Even though 
patient population are more amendable to improvement with Alagebrium, the rational 
to study healthy older individuals in our study is well considered since it is known that 
healthy older individuals have stiffer arteries and decreased endothelial function 
compared with healthy young controls.4,5 Thus, favorable effects of improving arterial 
stiffness and endothelial function are certainly expected using Alagebrium.
Most patient studies using Alagebrium used short term application (8-16 
weeks),120,127,128 with the exception of one recent study using Alagebrium for 9 months 
in heart failure patients.129 However, short term use of AGE-crosslink breakers alone 
may not be sufficient to alter arterial stiffness formed by decades of accumulation of 
AGEs in healthy older individuals. The combination of AGE-crosslink breakers with 
exercise training, the latter having demonstrated to improve cardiovascular 
compliance in sedentary individuals,15,16,38 may be particularly effective in improving 
arterial stiffness and endothelial function in healthy older sedentary individuals. 
Preliminary work in rats suggested that the combination of exercise training and 
Alagebrium reverses age-related cardiovascular adaptations in rats.126 Whether 
AGE-crosslink breakers enhance the cardiovascular benefits from exercise training 
in humans is currently unknown. This leads us to the founding interests of this thesis.
Aims and outline of this thesis
General aim of this thesis
Advancing age, physical inactivity and accumulation of AGEs are important factors in 
the development of cardiovascular diseases. Increased arterial stiffness and 
endothelial function are known to play key roles in this age-related process. However, 
the effects of exercise training and the AGE-crosslink breaker Alagebrium on arterial 
stiffness and endothelial function in healthy older individuals have not been clarified 
yet. Therefore, the general aim of this thesis is to elucidate the individual and 
combined effects of exercise training and the AGE-crosslink breaker Alagebrium in 
older individuals on different aspects of the vascular system.
Outline of this thesis
The general aim has been translated in a series of experiments that are presented in 
the subsequent chapters of this thesis. First, we examined the impact of physical 
fitness level on arterial stiffness, endothelial function and cardiovascular risk in a 
group of older non-exercising individuals. It is known that exercise training is beneficial 
for the reduction of cardiovascular diseases.10,19,130 However, older individuals, who 
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are more prone to develop cardiovascular diseases, prefer daily life activities, such as 
gardening, low intensity cycling or walking, over exercise training to remain physically 
fit.22 It is currently unknown whether a lower or higher level of physical fitness, related 
to daily life activities, influences vascular characteristics and cardiovascular risk 
profile in healthy non-exercising older individuals. We hypothesized that a higher 
physical fitness level, related to more daily life activities, is associated with a lower 
arterial stiffness, better endothelial function and more favorable cardiovascular risk 
profile in older individuals. These results are discussed in Chapter 2.
Besides influences on cardiovascular function and cardiovascular risk profile, 
physical activity is also known to improve sleep quality in individuals with sleep 
disorders.131,132 Sleep quality deteriorates with age 133,134 and impaired sleep quality 
is a frequently reported medical complaint.135 Nevertheless, the influence of physical 
activity in older individuals without medical sleep disorders is unknown. Therefore, 
the aim of this study, that is described in Chapter 3, was to (1) investigate the 
relationship between physical fitness and daily energy expenditure with sleep 
efficiency in young adults and older participants, and (2) using a randomized 
controlled trial to examine the effects of a 12-month exercise training program on 
sleep quality measures, such as sleep onset latency and sleep efficiency, in a group 
of older participants. We hypothesized that a higher physical fitness level and a 
higher daily activity level are both associated with a better sleep efficiency and that 
12 months of exercise training will enhance sleep efficiency in healthy older 
participants.
The cerebrovascular function across different age ranges are examined in Chapter 4. 
Cerebral blood flow is the result of a delicate balance between blood supply, perfusion 
pressure and tissue oxygenation.76,77 While the effects of age-related deterioration 
on the cardiovascular system have been extensively examined, the influence of age 
on the cerebrovascular system has been examined far less. This chapter examines 
the effects of age on cerebral blood flow and cortical oxygenation by investigating the 
relationship between blood pressure, cerebral blood flow and cerebral cortical 
oxygenation in different age groups. We hypothesized that the cerebrovascular 
function, and thereby the cortical oxygenation, which is crucial for human brain 
function, are diminished in healthy older individuals compared with younger 
individuals.
In Chapter 5 we examine the effects of a 12-month intervention program with the 
AGE-crosslink breaker Alagebrium, alone and in combination with exercise training in 
a factorial design trial, on endothelial function, arterial stiffness and cardiovascular 
risk in healthy older individuals. Age-related changes in vessel characteristics lead to 
endothelial dysfunction and arterial stiffening.4,5 Furthermore, the formation of AGEs 
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decreases endothelial function and the accumulation of AGEs in the arterial wall 
increases arterial stiffening.94,95,103 Preliminary work in rats suggested that the 
combination of exercise training and an AGE-crosslink breaker reverses cardiovascular 
adaptations to advanced age in rats.126 Whether AGE-crosslink breakers enhance 
the cardiovascular benefits from exercise training in humans is currently unknown. 
The primary hypothesis was that both breaking AGE-crosslinks using Alagebrium 
and performing aerobic exercise training for one year improves endothelial function 
and arterial stiffness. Furthermore, we speculate that this effect is enhanced when 
both interventions are combined.
Finally, in Chapter 6 we combine and discuss the current knowledge and shine new 
light across the domain of AGEs and the AGE-crosslink breaker Alagebrium. 
Furthermore, we speculate on future interventions to enhance healthy aging to 
maintain independent living in the aging society.
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Abstract
Background: The level of physical fitness in exercising versus non-exercising 
individuals directly correlates with cardiovascular risk. Most older individuals prefer 
being active in daily life activities rather than performing exercise training. Whether 
differences in physical fitness in older, non-exercising individuals affect the cardio-
vascular risk profile and vascular function is currently unknown.
Methods: Forty older non-exercising individuals (age 69 ± 4 years), free of any overt 
disease, were included. Stratified for gender and age, participants were allocated to 
a lower physical fitness (VO2max 20.7 ± 2.4 mlO2/min/kg) or higher physical fitness 
group (VO2max 29.1 ± 2.8 mlO2/min/kg, p<0.001). Cardiovascular risk profile was 
calculated by using the Lifetime Risk Score. Vascular function was examined using 
venous occlusion plethysmography to assess blood flow changes in response to 
intra-arterial infusion of acetylcholine, sodium nitroprusside and NG-monomethyl- L-
arginine (L-NMMA).
Results: The higher physical fitness group showed a higher daily life activity level 
(accelerometry) compared with the lower physical fitness group (p=0.04). Lifetime 
Risk Score was significantly higher and blood flow ratio response to acetylcholine 
was significantly lower in the lower physical fitness group (p<0.001, p=0.04, 
respectively). Blood flow ratio responses to sodium nitroprusside and L-NMMA were 
similar between both groups.
Conclusions: A higher physical fitness in an older, non-exercising population was 
associated with a better cardiovascular risk profile and vascular function. This study 
supports a physiological basis that supports the beneficial effects of differences in 
physical fitness level related to daily life activities on cardiovascular health in older 
individuals. Therefore, older individuals should be encouraged to enhance their daily 
life activities.
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Introduction
Physical exercise training has strong protective effects on the cardiovascular system and 
decreases morbidity and mortality.1-3 The beneficial effects of exercise training are partly 
explained via improvements of the cardiovascular risk profile (i.e., blood pressure, lipids, 
weight balance, insulin/glucose regulation and inflammatory markers), but may also relate 
to a direct effect of physical exercise on the vasculature.2,4,5 Elevated physical fitness 
levels importantly contribute to cardiovascular risk reduction. In subjects with similar 
cardiovascular risk factors, those with a higher physical fitness level have a lower risk 
of cardiovascular morbidity and mortality.6 Therefore, the Lifetime Risk Score (LRS) 
incorporates physical fitness level and is found to be superior compared with the 
Framingham Risk Score to predict future cardiovascular events.7,8
Differences in physical fitness levels are present, even within those who do not 
regularly perform exercise training.9 Whether differences in physical fitness in older, 
non-exercising individuals contribute to differences in cardiovascular risk profile and 
vascular function is currently unknown. Therefore, the aim of the present study is to 
assess the effects of a lower or higher physical fitness level in older, non-exercising 
individuals on cardiovascular risk profile and vascular function. We hypothesize that 
a higher physical fitness due to more daily life activities is associated with a healthier 
cardiovascular risk profile and better vascular function in older individuals. Knowing 
the impact of daily life activities on cardiovascular health may alter and improve the 
lifestyle advices for older individuals.
Methods
Participants
Forty older individuals, who did not perform regular physical exercise training for 
the past 5-10 years, were recruited. All participants were 65 years or older without 
cardiovascular diseases or disorders that could compromise physical activity. The study 
was approved by the local Medical Ethics Committee and all participants gave written 
informed consent.
Experimental Design
The participants reported to our laboratory three times. First, participants were 
screened for general health and cardiovascular risk factors. On a separate day 
participants performed an incremental maximal bicycle exercise stress test to 
examine the maximal oxygen uptake (VO2max).10 Participants were then allocated to 
a lower (VO2max <25 mlO2/min/kg body weight) or higher (VO2max >25 mlO2/min/
kg body weight) physical fitness group, stratifying for gender and age. The division of 
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both groups below or above a VO2max of 25 mlO2/min/kg was based on the median 
value combining all 40 participants. On a separate day, which was at least 2 days 
after the maximal exercise stress test, vascular function was assessed using venous 
occlusion plethysmography and intra-arterial infusion of vaso-active substances. 
Furthermore, participants received an activity monitor to examine daily life activity 
levels across 7 consecutive days.
Measurements
General characteristics
All participants underwent clinical examination with measurements of height, weight, 
waist and hip circumference. A four-point skinfold thickness measurement was 
obtained in order to calculate fat percentage and lean body mass.11 Blood pressure 
and resting heart rate were measured three times in the supine position using a 
manual sphygmomanometer around the left arm after a 10 minute rest.
Incremental maximal bicycle exercise stress test
An incremental maximal exercise stress test on a bicycle ergometer (Lode, Excalibur 
Sport, Groningen, the Netherlands) was performed to measure maximal oxygen 
uptake (VO2max, mlO2/min/kg). After 3 minutes rest, participants started cycling at a 
workload of 50 Watt, which was increased by 10 Watt/minute. Continuous 
measurement of oxygen uptake (VO2) was performed using an automatic gas 
analyzer (Oxycon alpha, Jaeger, Breda, the Netherlands). Peak oxygen uptake was 
calculated as the average oxygen uptake during the last minute of the test and then 
scaled for body weight and lean body mass. Heart rate was measured continuously 
with a 12-lead ECG. Three out of the following 4 criteria had to be met, otherwise the 
test was repeated; clinical signs of exhaustion of the participant, respiratory quotient 
≥1.10, finishing within 10 beats of the maximum predicted heart rate (=220-age), and 
flattening of VO2 uptake curve (≤110 mL increase during the last minute).10
Daily life activities
A validated bi-axial accelerometer (SenseWear Pro3, BodyMedia, Pittsburg, PA, 
USA) was used to quantify daily life activities.12,13 The accelerometer was continuously 
worn around the right upper arm during 24 hours for 7 consecutive days. Data from 
the accelerometers were analyzed offline using the data from 7.00AM to 11.00PM 
from each day. Data were rejected if <90% of the data on a single day or less than 4 
days of data was collected.
Metabolic equivalent units (METs) were used to quantify the intensity of daily life 
activities. MET is a physiological measure expressing the ratio of intensity of physical 
activity to that of the reference metabolic rate 1 MET during quiet sitting.14 Moder-
ate-intensity activities are considered 3.0-5.9 METs and vigorous-intensity activities 
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are considered ≥6.0 METs.14 Besides the intensity of daily life activities, we also 
measured the duration (minutes) of activities with an intensity of ≥3 METs. Both 
intensity and duration of physical activities were averaged over the 7 days.
Cardiovascular risk profile
Venous blood samples were taken after an overnight fast to measure lipid levels (total 
cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and 
triglycerides), glucose and glycosylated haemoglobin (HbA1c). In addition, high 
sensitive C-reactive protein (hs-CRP) was examined as a measure of inflammation.
Arterial wall thickness of the left common carotid artery (CA) was measured using 
high-resolution echo ultrasonography with a 7.5 MHz linear array transducer (Picus, 
Pie Medical Benelux, Maastricht, the Netherlands) under standardized conditions. 
The left common carotid artery was measured 2 cm proximal to the bulbus.15 Four 
separate longitudinal ultrasound images were made with both arterial walls clearly 
displayed for 6 consecutive heartbeats to analyse off-line. Distance from lumen-intima 
interface to media-adventitia interface indicated the wall thickness.16 Values of the 
intima media thickness (IMT) were averaged from these 4 images after excluding the 
highest and lowest value of the 6 heartbeats per ultrasound image.
Framingham Risk Score (FRS) was calculated to estimate the percentage 10-year risk 
for general cardiovascular diseases.17 Predictors taken into account were age, 
gender, body mass index, diabetes mellitus, smoking, treated and untreated systolic 
blood pressure, and total and HDL cholesterol. Besides the more traditional FRS, we 
also calculated the novel Lifetime Risk Score (LRS) 7,8 with a 30-year risk prediction 
for cardiovascular disease mortality. It incorporates factors similar to the FRS, but 
also adds physical fitness level to the risk calculation.
Vascular function
To standardize this measurement, participants were asked to refrain from coffee, tea, 
alcohol, chocolate, vitamin C supplements or fruit 14 hours prior and fasting overnight 
prior to the examinations. Room temperature was set at 22 ± 1 °C.
The endothelial function of the lower limb was measured from resistance artery blood 
flow responses using venous occlusion plethysmography during intra-arterial infusion 
of vasoactive substances 18,19 in the upper leg, previously described in detail by 
Kooijman et al..20 Using a modified Seldinger technique, an intra-arterial cannula 
(Angiocath 16 gauge, Becton Dickinson, Sandy, Utah, USA) was introduced into the 
right common femoral artery at the level of the inguinal ligament under local 
anaesthesia (10 ml lidocaine 1%). This cannula was used for intra-arterial administration 
of three vaso-active substances by an automatic syringe infusion pump 
(CardinalHealth, Rolle, Switzerland) and for intra-arterial blood pressure monitoring 
(Type PX600F, Edwards Lifesciences Services GmbH, Unterschleissheim, Germany). 
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We infused the endothelium dependent vasodilator acetylcholine (ACh), the 
endothelium independent vasodilator sodium nitroprusside (SNP), and the nitric 
oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA). Rate of infusion was 
adjusted to leg volume that was determined by anthropometry as described and 
validated by Jones et al..21
Bilateral blood flow in the upper legs was measured by ECG-triggered venous 
occlusion plethysmography. Thigh occlusion cuffs (12cm) were connected to a rapid 
cuff inflator (Hokanson Inc., Bellevue, WA, USA), which simultaneously inflated the 
cuffs to a pressure of 50mmHg.22 Cuff inflation was triggered and sustained by the 
R-waves on the ECG during 8 heart cycles and subsequently deflated during 8 heart 
cycles. Mercury-in-silastic strain gauges (Hokanson Inc., Bellevue, WA, USA) were 
placed at mid thigh to quantify changes in leg volume from changes in upper leg 
blood flow.23 Calf circulation was occluded during substance infusion by inflating 
cuffs directly below the knee to suprasystolic values (≥220 mmHg) to avoid the 
use of high dosages with subsequent possible systemic effects of the vasoactive 
substances.20
After instrumentation and at least 45 minutes after cannulation of the femoral artery, 
infusion of the vaso-active substances started. Acetylcholine was administered at 1, 
4, 16, 32 and 64 μg/mL/dL leg volume, SNP 0.06, 0.20 and 0.60 μg/mL/dL leg volume, 
and L-NMMA 0.05, 0.10, 0.20 and 0.40 mg/mL/dL leg volume. The order of infusion 
was fixed and each substance was infused for 5 minutes. Two consecutive infusions 
were performed before deflating the lower leg cuffs to restore normal blood flow for 5 
minutes. During these 5 minutes of recovery, 0.9% saline (or 5% glucose during SNP 
measurements) was infused to maintain a constant flow rate. Between administration 
of different substances, a 20 minute rest period was inserted with continuous flow of 
0.9% saline.
Plethysmography data of both legs were digitalized with a sample frequency of 100 
Hz and analyzed offline by a customized computer program (MIDAC, Instrumental 
Department, Radboud University Medical Center, Nijmegen, the Netherlands). Upper 
leg blood flow (ml/min/dL leg volume) was calculated as the slope of the volume 
change curve over a 4-s interval, starting 2.5 seconds after the cuff inflation, to avoid 
inclusion of induced cuff artefacts.23 From each infusion dosage, the last 6-8 slopes 
were averaged to calculate the leg blood flow. To correct for systemic effects, blood 
flow ratio between the infusion and control leg was calculated.
Statistical Analysis
Statistical analysis was performed using the Statistical Package for the Social 
Sciences (SPSS, Chicago, IL, USA). Data are presented as mean ± standard 
deviation unless otherwise indicated. Differences between the lower and higher 
physical fitness group were analyzed with an unpaired t-test. The Linear Mixed Model 
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was used (Dose*Group) to compare changes in blood flow response and blood flow 
ratio to increasing dosages of each vasoactive substance (Dose) between both 
groups (Group). A Pearson correlation was used to correlate physical fitness in terms 
of VO2max per lean body mass with the maximal blood flow response. Statistical 
significance was set at a (2-sided) p-value ≤0.05.
Results
As a consequence of our allocation process, both groups consisted of 20 participants 
with an equal distribution in gender and age (Table 2.1). Daily minutes of moderate 
intensity activities and mean METs per day were significantly lower in the lower 
physical fitness group compared with the higher physical fitness group (Table 2.1).
Cardiovascular risk profile
The lower physical fitness group demonstrated a significantly higher body mass 
index, fat percentage, waist and hip circumference, waist-to-hip ratio, hs-CRP levels 
and Lifetime Risk Score compared with the higher physical fitness group (Table 2.2). 
No significant differences were observed between both groups in lean body mass, 
blood pressure, heart rate, lipid levels, glucose, HbA1c, carotid artery IMT or 
Framingham Risk Score (Table 2.2).
Table 2.1 Description of the lower and higher physical fitness (VO2max) group.
 Lower 
VO2max 
Higher 
VO2max
p-value
Number of participants 20 20  
Male : Female (n) 12 : 8 13 : 7 0.75
Age (years) 70 ± 3 69 ± 4 0.55
Daily minutes of moderate intensity activities¥ 79 ± 39 108 ± 43 0.04
Mean METs per day¥ 1.43 ± 0.21 1.59 ± 0.21 0.02
VO2 max (mlO2/min/kg) 20.7 ± 2.4 29.1 ± 2.8 <0.001
VO2 max per lean body mass (mlO2/min/kg) 31.2 ± 3.0 41.5 ± 4.6 <0.001
Maximal load (Watt) 133 ± 33 175 ± 41 <0.01
Data are presented as mean ± standard deviation. ¥ Due to technical problems daily life activity data 
could not be analyzed for two subjects. Thus, n=19 for the lower and n=19 for the higher VO2max group. 
Abbreviations: METs metabolic equivalent units.
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Vascular function
Due to technical problems, 4 participants (2 in each group) were excluded from 
analyses of vascular function. L-NMMA was only given to 24 participants in total.
The increase in blood flow to acetylcholine and sodium nitroprusside was significantly 
larger in the higher physical fitness group (Dose*Group p=0.03 and p=0.02, 
respectively for ACh and SNP) compared with the lower physical fitness group (Figure 
2.1). When presented as the blood flow ratio, a significantly larger increase during 
Table 2.2 Cardiovascular risk profile of the lower and higher physical fitness  
(VO2max) group.
 Lower VO2max Higher VO2max p-value
Body Mass Index (kg/m2) 27.4 ± 3.5 24.9 ± 2.2 0.01
Lean Body Mass (kg) 55.8 ± 11.4 52.6 ± 9.4 0.34
Fat percentage (%) 33.4 ± 6.8 29.6 ± 5.1 0.05
Waist circumference (cm) 99.8 ± 8.4 88.7 ± 8.6 <0.001
Hip circumference (cm) 105.1 ± 6.4 99.1 ± 3.9 <0.01
Waist-to-hip ratio 0.95 ± 0.05 0.90 ± 0.07 <0.01
Systolic blood pressure (mmHg) 132 ± 10 132 ± 14 1.00
Diastolic blood pressure (mmHg) 77 ± 7 79 ± 6 0.20
Heart rate (bpm) 63 ± 7 60 ± 8 0.23
Total cholesterol (mmol/l) 5.4 ± 0.6 5.4 ± 1.0 0.88
HDL (mmol/l) 1.3 ± 0.3 1.3 ± 0.3 0.90
LDL (mmol/l) 3.6 ± 0.7 3.6 ± 0.9 0.94
Triglycerides (mmol/l) 1.1 ± 0.3 1.1 ± 0.4 0.84
Glucose (mmol/l) 5.0 ± 0.4 5.0 ± 0.4 0.91
HbA1c (%) 5.7 ± 0.3 5.6 ± 0.3 0.44
Hs-CRP (mg/l) 3.0 ± 2.5 1.6 ± 1.7 0.05
IMT CA (μm) 714 ± 113 680 ± 99 0.32
Framingham Risk Score (%) 26 ± 16 24 ± 12 0.71
Lifetime Risk Score (%) 41.5 ± 5.1 30.1 ± 9.4 <0.001
Data are presented as mean ± standard deviation. Abbreviations: HDL high density lipoprotein, LDL 
low density lipoprotein, HbA1c glycolized hemoglobin, hs-CRP high sensitivity C-reactive protein, IMT 
CA intima media thickness carotid artery.
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infusion of acetylcholine was observed in the higher physical fitness group compared 
with the lower physical fitness group (Dose*Group p=0.04) (Figure 2.2). The increase 
in blood flow ratio in response to sodium nitroprusside, however, was not significantly 
different between both groups (p=0.17) (Figure 2.2). The magnitude of the decrease in 
blood flow and blood flow ratio in response to L-NMMA did not differ between both 
groups (Figures 2.1 and 2.2).
Correlation between physical fitness and vascular function
A significant correlation was observed between VO2max per lean body mass and the 
maximal blood flow response corrected for baseline blood flow to ACh (r=0.341, 
p=0.045), SNP (r=0.388, p=0.021), and L-NMMA (r=-0.450, p=0.031) (Figure 2.3).
Figure 2.1 Mean blood flow response (± SEM) of the infusion leg shows a 
significantly larger endothelium dependent and independent blood flow response 
to infusion of acetylcholine (* p=0.03) and sodium nitroprusside (* p=0.02) in the 
higher physical fitness group (  n=18) compared with the lower physical fitness group 
(  n=18). No differences were observed in contribution of nitric oxide to baseline 
vascular tone in response to L-NMMA infusion (n=10 higher physical fitness group 
and n=14 lower physical fitness group).
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Figure 2.2 Mean blood flow ratio infusion/control leg (± SEM) shows a 
significantly larger increase in the higher physical fitness group (  n=18) compared 
with the lower physical fitness group (  n=18) during infusion of acetylcholine 
(* p=0.04). No statistically significant differences were observed in blood flow ratio 
between both groups in response to infusion of sodium nitroprusside and L-NMMA 
(n=10 higher physical fitness group and n=14 lower physical fitness group).
Figure 2.3 A significant correlation was found between physical fitness (VO2max 
per lean body mass) and the maximal blood flow response corrected for baseline 
blood flow in response to acetylcholine (  n=36, long dashed correlation line), sodium 
nitroprusside (  n=36, short dashed correlation line) and L-NMMA (grey ∆ n=24, 
grey correlation line).
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Discussion
In this study we examined cardiovascular risk profile and vascular function in a 
homogenous group of non-exercising older individuals, who were allocated to a 
lower and higher physical fitness group. This study for the first time shows that a 
higher level of physical fitness, unrelated to exercise training, is associated with a 
better cardiovascular risk profile and a better vascular function in older individuals. 
Results of this study implicate that promotion of daily life activities can be a successful 
strategy to improve cardiovascular risk in the older population.
The marked differences in physical fitness between our groups cannot be explained 
by differences in exercise training as all subjects were non-exercisers for at least the 
past 5-10 years. Accelerometry data suggests that the differences in physical fitness 
may be related to differences in duration of daily moderate intensity activities (≥3 
METs) and in intensity of daily life activities (mean METs/day). This finding is 
strengthened by the results of McGuire & Ross 9 that both duration and intensity of 
incidental physical activity are positively associated with physical fitness. Although 
these correlations were not very strong, on average the higher physical fitness group 
spend half an hour per day more at moderate intensity physical activity level than the 
lower physical fitness group. In addition, the intensity of daily life activities was 
significantly higher in the higher physical fitness group.
Our most important finding is the higher blood flow response to acetylcholine in the 
higher physical fitness group, indicating a better vascular function of the lower limb 
resistance arteries in this group. The observation that physical fitness is positively 
related to vascular function, is further supported by the significant and positive 
correlations between physical fitness and blood flow responses to the vaso-active 
substances. This novel finding adds to previous studies that demonstrated that 
exercise training has a beneficial effect on forearm vascular function in healthy 
young,1,24-26 as well as in endurance trained older individuals.24-26 An important 
difference is that these studies compared either exercise trained subjects with 
sedentary peers, or included previously sedentary subjects that were examined 
before and after a period of intensive physical exercise training. In marked contrast, 
we included non-exercising individuals who differed in physical fitness level primarily 
based on daily life physical activities. Moreover, we add the interesting finding that a 
better vascular function is present in non-exercising older individuals who perform 
half an hour per day more on daily life activities.
Our finding of a better lower limb resistance artery endothelial function in the group 
with a higher physical fitness questions the underlying mechanism for this finding. 
Infusion of SNP, an endothelium independent vasodilator, did not result in differences 
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between both groups when data was presented as blood flow ratio. This indicates 
that the larger response to acetylcholine in the higher physical fitness group is unlikely 
explained by differences in smooth muscle cell sensitivity to nitric oxide, a finding 
which is in agreement with previous findings with sedentary older individuals and 
between sedentary vs. trained older individuals.24,25 Another mechanism for the 
difference in endothelium dependent vasodilation between our groups may relate to 
an increased NO production and/or release.1,25 However, the similar blood flow 
responses to NO synthase inhibitor L-NMMA in our study, suggests that the 
contribution of NO to the basal vascular tone was similar in both groups. This 
discrepancy might be due to the fact that previous studies either compared sedentary 
vs. endurance trained older individuals or performed an exercise training intervention, 
and therefore the differences in physical fitness were much larger than in our relative 
homogenous group.
The higher body fat percentage in the lower physical fitness group, may have 
impacted vascular function. Previous studies found that obesity, independent of 
other cardiovascular risk factors, relates to an impaired (conduit artery) endothelial 
function, partly due to higher levels of inflammatory markers.27 However, we did not 
include subjects with obesity and the difference in BMI was relatively small (2.5 kg/
m2). Moreover, we found no correlation between fat percentage or BMI and vascular 
function or hs-CRP (data not shown). Therefore, differences in BMI and fat percentage 
did not alter the major outcomes of our study.
The higher level of inflammatory marker hs-CRP in the lower physical fitness group is 
believed to reflect inflammation of the arterial wall. Hs-CRP is a strong independent 
predictor of cardiovascular adverse events in a large multivariate analysis,28 that even 
exceeds the predictive capacity of traditional LDL cholesterol level.29,30 Physical 
exercise has shown to have a beneficial effect in terms of reducing the concentration 
of several inflammatory markers,31,32 and some evidence supports the hypothesis 
that hs-CRP concentrations positively correlate with vascular dysfunction.33 In our 
study, we add the novel observation that a higher physical fitness level related to daily 
life activities, independent of exercise training, is associated with lower values of 
hs-CRP.
Another prominent finding was that the Lifetime Risk Score (LRS) was significantly 
better in the higher physical fitness group than in the lower physical fitness group, 
while the Framingham Risk Score (FRS) did not differ between groups. The additive 
of physical fitness, which is an established marker with predictive capacity for future 
cardiovascular morbidity and mortality,6,34 in the LRS results in a relevant difference 
in the 30-year cardiovascular disease mortality risk prediction. Thus, adding physical 
fitness seems to represent a more reliable risk prediction. This also reinforces our 
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findings with favourable differences seen in cardiovascular risk profile and vascular 
function in our higher physical fitness group.
Our result of the favourable effects of differences in physical fitness level, not related 
to exercise training, is supported by previous findings from a large meta-analysis 
performed by Löllgen et al in 2009.35 They included 38 studies involving more than 
271,000 participants of both sexes, age ranging from 20-80 years with different 
activity levels, from sedentary to vigorous activities. The most important risk reduction 
in cardiovascular and all cause mortality occurred in the change from sedentary 
behaviour to low or moderate physical activity levels with only a minor additional 
reduction with further increase of activity level. Our study adds to this by strong direct 
physiological measurements that even differences in physical fitness level related to 
daily life activities alone, are beneficial to the cardiovascular risk profile and vascular 
function.
Conclusion
In summary, we observed that differences in physical fitness in a representative 
group of 40 healthy older non-exercising individuals are related to a more favourable 
cardiovascular risk profile and a better vascular function. This study supports a 
physiological basis for the beneficial effects of differences in physical fitness level 
related to daily life activities on cardiovascular health in the older population. 
Therefore, older individuals should be encouraged to enhance their daily life activities.
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Abstract
Background. Physical activity is known to influence sleep efficiency. Relatively little 
is known about the relationship between physical activity and sleep efficiency in 
young and older humans and the impact of exercise training on sleep efficiency in 
healthy older individuals. Our aim was to determine the relationship between physical 
fitness and daily energy expenditure with sleep efficiency in young and older subjects, 
and assess the effect of 12-month exercise training on sleep efficiency in healthy 
older participants.
Methods. The relationship between physical fitness (maximal cycling test) and daily 
energy expenditure (accelerometry) with sleep efficiency (accelerometry) was 
examined cross-sectionally in 12 healthy young adults (27 ± 5 years) and 21 healthy 
older participants (69 ± 3 years). Subsequently, the effect of 12-month exercise 
training (n=11) or control period (n=10) on sleep efficiency in older participants was 
examined using a randomized controlled trial.
Results. Daily energy expenditure and sleep efficiency did not differ between young 
and older subjects. A significant correlation was found between energy expenditure 
and sleep efficiency (r=0.627, p=0.029) in young adults, but not in older participants 
(r=-0.158, p=0.49). Physical fitness did not correlate with sleep efficiency in either 
group. Exercise training significantly improved physical fitness (15.0%, p<0.001), but 
failed to alter sleep characteristics such as sleep efficiency, sleep onset latency and 
awakenings.
Conclusions. We found that young adults with higher daily energy expenditure have 
greater sleep efficiency, whilst this relationship is diminished with advanced age. In 
contrast, we found no correlation between physical fitness and sleep characteristics 
in healthy young or older participants, which may explain the lack of improvement in 
sleep characteristics in older participants with 12-month exercise training. Exercise 
training may be more successful in subjects with existing sleep disturbances to 
improve sleep characteristics rather than in healthy older subjects.
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Introduction
Impaired sleep quality is a frequently reported medical complaint,1 and sleep quality 
deteriorates with age.2,3 For example, 74-88% of the older population report sleep 
disturbances,3 whilst prevalence rates of insomnia in older subjects range between 
12-54%.3,4 The most common treatment for sleep disturbances is a pharmacological 
intervention.5,6 However, frequent use of sleep medication is associated with several 
adverse side effects (e.g. sedation, drowsiness, risk of falling and dependence),7,8 
which are more common in the older population.9,10 Therefore alternative strategies 
to improve sleep quality in this population are required.
Physical activity is known to influence sleep quality. Previous studies have found that 
higher energy expenditure during the day is associated with energy conservation and 
tissue restoration during sleep,11-13 whilst the exercise-induced increase in core body 
temperature may activate sleep-associated heat-loss mechanisms (see Driver et al13 
for an overview). In addition, physical exercise has been shown to have a positive 
influence on longer sleep duration.14-16 Indeed, epidemiological studies have 
demonstrated an association between exercise levels and sleep quality.17,18 Several 
studies showed that exercise training can improve subjective and objective measures 
of sleep in groups with sleep disturbances,19-21 whilst good sleepers might benefit 
less from exercise training due to a ceiling effect in sleep quality,22,23 As most previous 
studies predominantly focus on groups with (mildly) impaired sleep, relatively little is 
known about the impact of age per se on the relationship between physical fitness or 
energy expenditure and sleep efficiency; i.e. an objective measure for sleep quality.24 
Moreover, the potential effects of long-term (12 months) exercise training to improve 
sleep efficiency in healthy, older humans are not frequently examined.
The purpose of the current study was to (i) investigate the relationship between 
physical fitness and daily energy expenditure with sleep efficiency in young adults 
and older participants and (ii) using a randomized controlled trial to examine the 
effect of a 12-month exercise training program on sleep quality measures, such as 
sleep onset latency and sleep efficiency, in a group of healthy older participants. We 
hypothesized that a higher physical fitness and a higher daily activity level are both 
associated with a better sleep efficiency and that 12-months of exercise training will 
enhance sleep efficiency in healthy older participants.
Methods
Participants
Twenty-one healthy older participants (11 males and 10 females, age 69 ± 3 years) 
and twelve healthy young sex-matched controls (6 males and 6 females, age 27 ± 5 
years) were recruited from the local community (see Figure 3.1 for CONSORT 
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diagram). Older participants, at least 65 years of age, were screened extensively 
through medical history, physical examination and blood testing. Young adults were 
screened through medical history and physical examination. Both the older 
participants and the young adults had a sedentary lifestyle (less than one hour 
physical activity of at least moderate intensity per week examined by self-report 
questionnaire). All participants were free of self-reported sleep and mood disturbances 
and did not use sleep medication, anti-depressants or cardiovascular medication. 
Individuals with cardiovascular disease and diseases that may interfere with sleep 
quality such as obesity (BMI >30 kg/m2), diabetes mellitus and hypertension 
(<160/90 mmHg for older participants, <140/90 mmHg for young controls) were 
excluded. The local ethics committee approved the study and conformed to the 
Declaration of Helsinki, all participants gave their written informed consent before 
participation.
Experimental Design
Sleep efficiency was examined using accelerometry over a 7-day period. In addition, 
all participants performed a maximal cycling test to determine physical fitness level. 
Young participants did not undergo a 12-month intervention, unlike the older participants 
Figure 3.1 Consort-style flowchart regarding inclusion and drop-out of subjects 
for our study.
Assessed for eligibility (n = 52) 
Excluded after screening (n = 21) 
Declined to participate (n = 4) 
Allocated to exercise training (n = 12)  Allocated to control (n = 15) 
Analyzed (n = 11) 
Excluded from analysis (n = 0) 
Analyzed (n = 10) 
Excluded from analysis (n = 0) 
Randomized (n = 27) 
Lost to follow-up (n = 0) 
Dropout during study (n = 0) 
Insufficient data (n = 1) 
Lost to follow-up (n = 1) 
Dropout during study (n = 2) 
Insufficient data (n = 2) 
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who were randomly allocated after the baseline measurements to a 12-month 
intervention of either cycling exercise training or maintaining their current sedentary 
lifestyle (control). Participants in the control group were firmly instructed to maintain 
their normal physical activity level. All measurements were repeated after 6 and 12 
months. Efforts were made not to change medication throughout the intervention 
period, whilst participants who developed health problems that could interfere with 
sleep quality were excluded from the study.
Measurements
Energy expenditure and physical fitness
Energy expenditure. Daily energy expenditure (EE) was assessed using an activity 
monitor (SenseWear Pro3 Armband, SWA, Body Media) that was worn around the 
right upper arm. Sampling frequency was 32 Hz and data from the activity monitor 
were measured in 60 second epochs. The activity monitor measured 24 hours per 
day for 7 consecutive days. Each 24 hour interval was analyzed from 12:00 to 12:00 
the following day, and was included when the activity monitor recorded at least 1296 
minutes per 24-hour cycle (>90% of the total data). Data collected during the time in 
bed (see later for specific definition) was not included in the analysis for energy 
expenditure. Energy expenditure was calculated as total number of kilocalories (kcal) 
used per day. The activity monitor has been validated to examine energy expenditure 
in humans against indirect calorimetry, i.e. the gold standard to assess energy 
expenditure in resting and exercise conditions.25
Physical fitness. Physical fitness was assessed in all participants using a maximal 
exercise stress test on a bicycle ergometer (Lode, Excalibur Sport, Groningen, the 
Netherlands) with an incremental protocol (50 Watt and 10 Watt/min for older 
participants; 0 Watt and 20 Watt/min for young adults). During the test, participants 
were verbally encouraged to reach their maximum performance. Continuous 
measurement of oxygen consumption (VO2) was performed using an automatic gas 
analyzer (Oxycon alpha, Jaeger, Breda, the Netherlands). Peak oxygen uptake, in 
mlO2/min/kg, was taken as the average oxygen uptake of the last minute of the test 
and corrected for body weight. Heart rate was measured continuously with a 12-lead 
ECG. Criteria for the quality of the maximal performance test were: clinical signs of full 
exhaustion of the participant, respiratory quotient ≥1.10, finishing within 10 beats of 
the maximum predicted heart rate (=220-age), and flattening of VO2 uptake curve 
(≤150 mlO2 increase during the last minute).26 Three out of 4 criteria had to be met for 
the test to be successful. Furthermore, blood lactate (mmol/l) was measured before 
and 2 minutes after the test and the 10-point Borg scale was used to rate the perceived 
exertion. When criteria of maximal performance were not reached, the test was 
repeated after two weeks.
58
Chapter 3
Sleep characteristics
The accelerometer (SenseWear Pro3 Armband, SWA, Body Media) utilizes a 
combination of sensors (heat flux, galvanic skin response, skin temperature, near 
body ambient temperature) and a bi-axial accelerometer which allows for assessment 
of sleep characteristics. The SenseWear data were reduced to binary forms for ‘lying’ 
(‘0’ = no, ‘1’ = yes) and ‘sleeping’ (‘0’ = no, ‘1’ = yes). These data were used to 
determine the sleep onset latency, total sleep time, time in bed and the number of 
awakenings (see below). Each 24 hour interval was analyzed from 12:00 to 12:00 the 
following day for a detailed description of one entire sleeping episode. These data 
were analyzed using a customized analysis software system, which is independent of 
observer bias. Subsequently, sleep characteristics were averaged across the 7 days 
and used for further analysis. The activity monitor has been validated to examine 
sleep against polysomnography;27,28 i.e. a technique that is considered by many the 
gold standard to assess sleep physiology in humans.
Sleep onset latency. The sleep onset was defined as the first encounter of ten minutes 
of which at least 90% of the minutes were scored sleeping after positional change 
from upright to supine position (i.e. change from ‘0’ to ‘1’ for ‘lying’).29,30 The sleep 
onset latency was defined as the duration from the positional change to the start of 
the sleep onset. This definition is in agreement with various other studies that used 
accelerometry as an objective measure for sleep quality and efficiency.24,31,32
Total sleep time and sleep efficiency. The time in bed was defined as the duration 
from positional change from upright to supine position (i.e. change from ‘0’ to ‘1’ for 
‘lying’) to the first encounter of positional change from supine to upright after 
awakening (i.e. change from ‘1’ to ‘0’ for ‘lying’). The total sleep time was defined as 
the total sum of the minutes scored sleeping from sleep onset to the end of the 
sleeping episode. The sleep efficiency was calculated by: ([total sleep time/ time in 
bed]*100).24
Awakenings. The number of awakening is the amount of awake periods of at least 
one minute, excluding the final awakening before arising.24
Exercise Intervention
Exercise training was performed 3 times per week for 12 months on a cycling 
ergometer (Medgraphics, Corival Cycle Ergometer). Each exercise session was 
supervised and consisted of 10 minutes warming up at 60% of the individual heart 
rate reserve (calculated as ([(maximum heart rate – resting heart rate)*0.60] + resting 
heart rate)). This was followed by 30 minutes cycling exercise at 70-85% of the 
individual heart rate reserve and ended with 5 minutes cooling down. Heart rate was 
continuously monitored during exercise using heart rate monitors (Polar RS800; Polar 
Electro Oy, Kempele, Finland). Workload was individually adjusted throughout the 
training to correct for improvements in physical fitness.
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Statistical Analysis
Statistical analysis was performed with the use of Statistical Package for the Social 
Sciences (SPSS, version 16, Chicago, IL, USA). Exploration of distribution indicated 
the data were normally distributed, therefore baseline differences between the young 
adults and older participants were analyzed using unpaired t tests for continuous 
variables and Chi square test for categorical data. Correlations between physical 
fitness, energy expenditure and sleep parameters were determined using Pearson’s 
correlation coefficient. In the older participants, a two-way repeated measures 
ANOVA was used to analyze changes in physical fitness, energy expenditure and 
sleep efficiency outcome variables across the 12-month period (Time Points: 0, 6 and 
12 months), and to analyze differences between training versus control interventions. 
Data are presented as mean ± SD and the level for significance was set at α≤0.05.
Results
All subjects successfully completed our intervention study. Adherence to the exercise 
training sessions was 91 ± 7% (range 72-97% with a median of 92%). Adherence was 
defined as completing a training session of at least 30 minutes cycling at an intensity 
of >70% of the individual’s heart rate reserve. Subject characteristics of the two study 
groups are shown in Table 3.1. Young adults had a lower body mass index and higher 
physical fitness compared to the older participants. No differences in sleep onset 
latency, total sleep time and sleep efficiency were observed between young adults 
and older participants. A significant higher number of awakenings were evident in 
young adults compared with older participants (Table 3.1).
Correlation physical fitness/energy expenditure and  
sleep characteristics
A significant and positive correlation was found between daily energy expenditure 
and sleep efficiency in young adults (Figure 3.2). This correlation was not present in 
the older cohort (Table 3.2). Energy expenditure did not correlate with sleep onset 
latency, total sleep time and awakenings in young adults nor in older participants 
(Table 3.2). No correlation was found between physical fitness (VO2max) and sleep 
characteristics in young adults or older participants (Table 3.2).
Randomized controlled trial in older participants
No differences were found in baseline characteristics between both older groups 
prior to the 12-month intervention (Table 3.3). Nor were there differences in physical 
fitness, maximal workload or sleep characteristics between both older groups prior 
to the 12-month intervention (all p>0.05, Table 3.4). A significant increase in physical 
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Table 3.1 General and sleep characteristics in healthy young (n=12) and older 
participants (n=21).
Young participants Older participants p-value
General characteristics
   Age (years) 27 ± 5 69 ± 3 <0.001
   Height (cm) 178 ± 8 171 ± 8 0.02
   Weight (kg) 72.8 ± 9.2 74.0 ± 11.2 0.84
   Body mass index (kg/m2) 22.9 ± 2.3 25.1 ± 2.5 0.03
   VO2max (mlO2/kg/min) 40.3 ± 8.2 25.1 ± 4.3 <0.001
   Daily EE (kcal) 1739 ± 346 1773 ± 307 0.77
   Systolic BP (mmHg) 122 ± 8 131 ± 17 0.09
   Diastolic BP (mmHg) 74 ± 8 79 ± 11 0.20
Sleep characteristics
   Sleep onset latency (min) 9 ± 6 10 ± 6 0.88
   Total sleeping time (min) 400 ± 34 373 ± 53 0.12
   Sleep efficiency (%) 82 ± 5 82 ± 9 0.83
   Number of awakenings (n) 13 ± 2 9 ± 4 <0.001
Data are presented as mean ± standard deviation. P-value refers to an unpaired t test between young and 
older participants. Abbreviations: EE energy expenditure, BP blood pressure.
Figure 3.2 Correlation between energy expenditure (kcal) and sleep efficiency 
(%) in young adults (solid square) and older participants (open diamonds).
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Table 3.2 Correlation of physical fitness (VO2max) and energy expenditure  
(EE) with sleep characteristics (sleep onset latency, total sleep time, sleep 
 efficiency and number of awakenings) in young (n=12) and older participants 
(n=21).
Young  
Participants
p-value Older  
Participants
p -value
Physical fitness
   Sleep onset latency (min) 0.198 0.54 -0.046 0.84
   Total sleeping time (min) -0.162 0.62 -0.014 0.95
   Sleep efficiency (%) 0.273 0.39 -0.239 0.30
   Number of awakenings (n) 0.299 0.35 0.422 0.06
Energy expenditure
   Sleep onset latency (min) -0.167 0.60 0.138 0.55
   Total sleeping time (min) 0.231 0.47 -0.149 0.52
   Sleep efficiency (%) 0.627 0.029 -0.158 0.49
   Number of awakenings (n) -0.154 0.63 -0.013 0.96
Table 3.3 General characteristics of the older population included in the 
12-month intervention of either exercise training (n=11) or control group that 
maintained their physical activity level (n=10).
Exercise training Control p-value
Baseline characteristics
   Gender Male : Female 5  :  6 5  :  5
   Age (years) 68 ± 2 70 ± 2 0.08
   Height (cm) 173 ± 8 170 ± 7 0.49
   Weight (kg) 76.5 ± 12.4 71.3 ± 10.4 0.31
   Daily EE (kcal) 1863 ± 364 1675 ± 207 0.17
   Systolic BP (mmHg) 125 ± 12 137 ± 19 0.11
   Diastolic BP (mmHg) 76 ± 10 82 ± 13 0.31
Data are presented as mean ± standard deviation. P-value refers to an unpaired t test between both 
groups. Abbreviations: EE energy expenditure, BP blood pressure.
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fitness and maximal workload was found in older participants who performed the 
exercise training (Table 3.4). These findings indicate that our exercise training program 
was successful to improve physical fitness levels in healthy older individuals. A similar 
change across time was found in energy expenditure in both groups, with higher 
levels at 6 months (Table 3.4). However, we found no effect of the 12-month 
intervention on sleep onset latency, total sleep time, sleep efficiency and the number 
of awakenings (Table 3.4).
Discussion
The purpose of this study was to examine the impact of advanced age on the relation 
between physical fitness and daily energy expenditure with sleep characteristics. We 
have a number of unique findings in this study. First, a strong relationship between 
energy expenditure and sleep efficiency was found in young adults and this 
relationship was absent in the older population. Second, physical fitness and sleep 
characteristics were not significantly correlated in young adults or older participants. 
Finally, despite significantly improved physical fitness in healthy older participants, 
exercise training had no significant effect on sleep characteristics in this population. 
Collectively, these findings suggest that the relationship between energy expenditure 
and sleep efficiency is altered in healthy older participants compared with young 
peers. The absence of a correlation between physical fitness and sleep efficiency 
could explain the lack of improvement in sleep efficiency after a 12-month exercise 
training program in healthy older participants.
We found no significant differences in sleep time and sleep efficiency between young 
adults and older participants in our study. This finding is consistent with observations 
from Jean-Louis et al,33 but contrasts with others that reported that older age is 
associated with lower sleep efficiency.4,34 A potential explanation for the conflicting 
results is that some previous studies used sleep questionnaires to assess sleep 
efficiency,4 which are found to be less reliable than activity monitors to examine sleep 
efficiency.35 Another important difference between studies is that we included healthy 
participants without the presence or history of sleep problems, whilst others included 
older participants who were institutionalized 34 and who were likely to demonstrate 
altered sleep patterns.36 Finally, one previous study did not control for pharmacolog-
ical interventions 34 that may have interfered with sleep efficiency. An unexpected 
finding in our study relates to the higher number of awakenings in young adults than 
in older people, which contrasts with findings of previous studies.34,37 However, one 
previous study also found more awakenings in younger women using an actigraph.33 
Young adults may demonstrate more movement during sleep, which is not necessarily 
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associated with awake episodes. As a result, accelerometry may (incorrectly) identify 
these periods of higher activity level during sleep as awake periods.31,32,38 Collectively, 
we found no differences in sleep efficiency between young adults and older 
participants, which indicates that we have included healthy young adults and older 
participants without sleep disturbances.
We found a strong positive correlation between daily energy expenditure and sleep 
efficiency in young people. This finding is in agreement with meta-analyses indicating 
that sleep may improve following physical exercise of longer durations 14,16 and that 
duration, rather than intensity or time of day, might be more predictive of better 
sleep.14 Another study examined physical activity levels and found no significant 
association between day-to-day physical activity and sleep in healthy young and 
older subjects.23 However, they also found a small but significantly better self-reported 
sleep on the most active days compared to the least active days in young subjects. 
Although speculative, activation of thermoregulatory responses during periods of 
increased physical activity may relate to the positive correlation between daily energy 
expenditure and sleep efficiency in young adults.13 Physical activity, even when 
performed at moderate intensity such as walking 39,40 or cycling,41 causes a mild rise 
in core body temperature, and is followed by activation of heat-loss processes.42 
When performed in the evening, these responses may play a role during the initiation 
of sleep.43,44 However, the exact role of the thermoregulation to explain the link 
between activity level and sleep should be further examined. Another explanation 
relates to the ability of sleep for energy conservation and tissue restoration. Increased 
daily energy expenditure will deplete energy stores, leading to a larger energy 
restoration during sleep, which consequently is associated with an enhanced sleep 
efficiency.12,13 Finally, high catabolic activity during exercise is associated with a 
higher energy expenditure, which leads to elevated anabolic activity during sleep. 
The higher anabolic activity is believed to promote energy use for tissue restoration, 
but also contributes to improved sleep efficiency.11,13
An important and novel finding is that the positive relationship between energy 
expenditure and sleep efficiency is altered with advanced age, as older participants 
did not demonstrate a significant correlation. This observation raises questions about 
the potential mechanisms for the altered relationship between energy expenditure 
and sleep efficiency with advanced age. One potential explanation relates to the 
age-related degeneration of the suprachiasmatic nucleus in the hypothalamus.44 The 
suprachiasmatic nucleus is the major circadian pacemaker that coordinates 
behavioral and hormonal circadian rhythms, such as core body temperature, and 
initiates sleep through thermoregulatory responses.43 Degeneration of the suprachi-
asmatic nucleus in older individuals may play a role in their diminished rest-activity 
circadian rhythm.34 Another explanation relates to the ability of anabolic processes to 
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regulate sleep. Advanced age is associated with a smaller skeletal muscle mass,45 
but also inadequate protein intake.45,46 These changes may contribute to impaired 
anabolic processes in the older group and, therefore, to the impaired relation between 
energy expenditure and sleep efficiency in older participants. Taken together, our 
study provides the unique observation that advanced age leads to an attenuated 
relation between energy expenditure and sleep efficiency.
We found no correlation between physical fitness and sleep characteristics in young 
adults. This finding is in agreement with some studies,47,48 which also found that 
physical fitness does not determine sleep efficiency in young participants. Although 
others found a correlation between physical fitness and sleep quality,49 this study 
used subjective measures to assess sleep. We extend the findings of these previous 
studies that also healthy older individuals do not demonstrate a relation between 
physical fitness and sleep characteristics. These findings seem to contrast with the 
correlation between energy expenditure and sleep characteristics. Nevertheless, 
higher energy expenditure does not necessarily correlate with a higher physical 
fitness level.50 It is demonstrated that higher intensity daily activity levels (METs) 
rather than energy expenditure, relate to higher physical fitness.51 Indeed, also in our 
cohorts of healthy young adults and older participants, we found no significant 
correlation (r=0.086, p=0.64) between energy expenditure and physical fitness. 
Therefore, our results suggest that a higher physical fitness level per se does not 
contribute to an improvement of sleep characteristics in healthy individuals.
The lack of a relationship between physical fitness and sleep characteristics is 
confirmed by the findings of the 12-month exercise training in older individuals. Whilst 
a marked improvement in physical fitness and maximal workload was found, no 
changes in sleep characteristics were evident. Although some previous studies 
provided evidence that exercise training improves sleep quality in adults with (mild) 
sleep disturbances, these studies typically employ self-reported, subjective measures 
of sleep quality.19,21 When adopting objective measures of sleep, beneficial effects of 
exercise training on sleep characteristics are rare 52,53 or mild.20 Another important 
methodological difference is that previous studies included participants with 
moderate sleeping complaints, who are therefore more likely to benefit from an 
(exercise) intervention to alter sleep characteristics than participants with a normal 
sleep pattern,13 such as those included in our study. Subjects with normal sleep 
patterns show a ceiling effect when the effect of an intervention is examined aimed to 
improve sleep.13,22 Therefore, our finding that exercise training does not improve 
sleep characteristics in healthy older subjects, despite the improved physical fitness, 
further supports our finding that the relationship between energy expenditure and 
sleep is blunted with age.
66
Chapter 3
Limitations
A number of limitations should be considered. First, in this study accelerometry was 
used to measure sleep characteristics. Accelerometry is a valid and accurate method 
to assess sleep characteristics 27,28,32,38 and is used previously in sleep-activity 
studies.31,34 Accelerometry provides the advantage of providing an objective 
assessment of sleep characteristics in a home-based setting with little disruption to 
normal sleep pattern, whereas the use of polysomnography is impractical in a 
home-based setting and typically requires a laboratory visit. Nonetheless, the validity 
of the SenseWear to examine sleep loses some accuracy when sleep becomes more 
disturbed.28 Also, estimation of periods of wakefulness by the SenseWear is less 
accurate than sleep,28 which may impact the total sleep time variable, and therefore 
the calculation of sleep efficiency. Nevertheless, a previous study found minor 
discrepancy (14 minutes) between the SenseWear and polysomnography for the total 
sleep time.28 Whilst the use of the SenseWear is associated with some limitations, we 
have not included subjective measures of sleep quality in our study. Moreover, 
participants were not informed about the purpose of this study, which excludes the 
potential for subject bias. Therefore, based on the purpose and methodology of our 
study, accelerometry is an appropriate and valid tool to examine sleep efficiency. 
Another limitation of this study is that we included healthy older subjects without 
sleep disturbances. Inclusion of such a homogeneous group makes it difficult to 
extrapolate our results to different groups, whilst the absence of sleep disturbances 
resulted in low a priori chances to improve sleep characteristics. Also, the relatively 
small sample size may have contributed to the lack of improvement in sleep charac-
teristics after training. However, it should be taken into consideration that subjects 
trained for 12 months; i.e. a methodological design that corrected for potential 
seasonal influences and thereby excluded the potential influence of the daylight cycle 
on sleep characteristics.13,54 Taken together, our results indicate that exercise training 
in healthy older participants, without (a history of) sleep complaints, does not alter 
objective measures of sleep efficiency.
Conclusion
In conclusion, we found that young adults with higher daily energy expenditure have 
greater sleep efficiency, whilst this relationship is attenuated with advanced age. In 
contrast, we found no correlation between physical fitness and sleep characteristics 
in healthy young adults or older participants. This may explain the lack of improvement 
in sleep characteristics in healthy older participants with 12 months of exercise 
training. Exercise training may be more successful in subjects with existing sleep 
disturbances to improve sleep characteristics rather than in healthy older subjects.
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Abstract
Background: With aging cerebral blood flow velocity (CBFV) decreases. However, to 
what extent dynamic cerebral autoregulation and cerebrovascular carbon dioxide 
(CO2) reactivity are influenced by aging is unknown. The aim was to examine the 
dynamic responses of CBFV and cortical oxygenation to changes in blood pressure 
(BP) and arterial CO2 across different ages.
Methods: Fifty-eight participants in three age groups were included: young (n=20, 
24 ± 2 years), elderly (n=20, 66 ± 1 years), and older elderly (n=18, 78 ± 3 years). 
Cerebral blood flow velocity was measured using transcranial Doppler, simultaneously 
with oxyhemoglobin (O2Hb) using near-infrared spectroscopy and beat-to-beat 
blood pressure measurements using Finapres. Postural maneuvers were performed 
to induce blood pressure fluctuations. Cerebrovascular CO2 reactivity was tested 
with hyperventilation and CO2-inhalation.
Results: With age, CBFV decreased (young 59 ± 12 cm/s, elderly 48 ± 7 cm/s, older 
elderly 42 ± 9 cm/s, p<0.05) and cerebrovascular resistance increased (1.46 ± 0.58 
mmHg/cm/s, 1.81 ± 0.36 mmHg/cm/s, 1.98 ± 0.52 mmHg/cm/s, p<0.05). Normalized 
gain (autoregulatory damping) increased with age for BP-CBFV (0.88 ± 0.18, 1.31 ± 
0.30, 1.06 ± 0.34, p<0.05) and CBFV-O2Hb (0.10 ± 0.09, 0.12 ± 0.04, 0.17 ± 0.08, 
p<0.05) during the repeated sit-stand maneuver at 0.05 Hz. Even though the absolute 
changes in CBFV and CVRi during the cerebrovascular CO2 reactivity were higher in 
the young group, the percentage changes in CBFV, CVRi and O2Hb were similar in all 
age groups.
Conclusion: There was no decline in dynamic cerebral autoregulation and cerebro-
vascular CO2 reactivity with increasing age up to 86 years. Despite the decrease in 
cerebral blood flow velocity and increase in cerebrovascular resistance with 
advancing age, CBFV and cortical oxygenation were not compromised in these 
elderly during maneuvers that mimic daily life activities.
75
4
Cerebral perfusion and cortical oxygenation with aging
Introduction
Physiological aging is associated with well-recognized changes in the systemic and 
cerebral vasculature.1-3 Systemic vascular changes lead to an increased risk for cardio- 
vascular events while cerebrovascular adaptations enhance the risk of (ischemic) 
stroke. Furthermore, resting cerebral blood flow (CBF) is decreased in older 
individuals.4,5 Whether this decrease in CBF reflects a decrease in cerebral demand 
or a true diminution in blood flow, remains unknown. Likewise, whether aging leads 
to diminished cerebrovascular function remains unclear.
Cerebrovascular function can be studied using two physiological phenomena, 
namely dynamic cerebral autoregulation and cerebrovascular reactivity to carbon 
dioxide (CO2). Dynamic cerebral autoregulation reflects the ability of the brain to 
stabilize CBF despite rapid daily life changes in blood pressure.6-8 Dynamic cerebral 
autoregulation remains stable up to the age of 73 years,4,5,8 but has not been 
estimated in healthy elderly above this age. Most studies examined the effects of small 
blood pressure changes 9,10 instead of larger fluctuations in blood pressure during 
postural changes, which may provide a stronger challenge for dynamic cerebral 
autoregulation, and therefore may be more sensitive to detect changes in cerebro-
vascular function.11
Cerebrovascular reactivity to changes in carbon dioxide (CO2), the second phenomenon 
to study cerebrovascular function, declines significantly with increasing age up to 
90 year.12 Unfortunately, most studies investigated either the dynamic cerebral 
autoregulation 5,11,13,14 or the cerebrovascular CO2 reactivity,12,15-18 but the studies 
did not examine both aspects of the cerebrovascular system simultaneously.
Dynamic cerebral autoregulation and cerebrovascular CO2 reactivity are both directly 
related to the oxygenation of the brain tissue and therefore to human brain function.19,20 
The majority of studies of dynamic cerebral autoregulation and cerebrovascular CO2 
reactivity have used transcranial Doppler to obtain continuous measurements of 
cerebral blood flow velocity, together with continuous blood pressure measurements 
(Finapres). Transcranial Doppler does not provide information regarding the oxygenation 
of the brain. The addition of near-infrared spectroscopy can be used to measure 
concentrations of oxygenated and deoxygenated hemoglobin and provide estimates 
of cortical brain tissue oxygenation.21 Thus, by using Finapres and transcranial 
Doppler sonography (TCD) concomitantly with near-infrared spectroscopy (NIRS), it 
is possible to determine two different but dependent dynamic relationships, namely 
the relation between blood pressure and cerebral blood flow on the one hand and 
the relation between cerebral blood flow and cerebral cortical oxygenation on the 
other.19,20
This study aimed to investigate effects of age on dynamic cerebral autoregulation 
and cerebrovascular CO2 reactivity in order to examine cerebrovascular function by 
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investigating the relationship between blood pressure, cerebral blood flow and 
cerebral cortical oxygenation in a group of young, elderly, and older elderly subjects. 
The combination of examining dynamic cerebral autoregulation and cerebrovascular 
CO2 reactivity using both TCD and NIRS in this population is, to our knowledge, 
unique. We hypothesized that the cerebrovascular function and thereby the cortical 
oxygenation are diminished in healthy elderly aged 74 years and older compared with 
young subjects and with elderly below the age of 74 years. To investigate this 
hypothesis, beat-to-beat blood pressure, cerebral blood flow, and cortical oxygenation 
were simultaneously measured to investigate cerebrovascular hemodynamics during 
changes in blood pressure and changes in arterial CO2.
Methods
Ethical approval
The study was approved by the Medical Ethics Committee, and was performed 
according to the Declaration of Helsinki and Good Clinical Practice guidelines. All 
participants gave written informed consent.
Participants
Fifty-eight participants in three different age groups were included. A young group 
(young - mean age 24 ± 2 years, range 21 to 28 years), an older group (elderly - 
mean age 66 ± 1 years, range 65 to 69 years), and the oldest group (older elderly - 
mean age 78 ± 3 years, range 74 to 86 years). Participants were recruited at the 
Departments of Physiology and Geriatric Medicine, Radboud University Medical 
Center, Nijmegen, the Netherlands. All participants were extensively screened. 
Participants with hypertension (>160/90 mmHg), diabetes mellitus reported in 
medical history (fasting glucose >6.9 mmol/l), hypercholesterolemia (total cholesterol 
>7.5 mmol/l), body mass index >32.5 kg/m2, compromised cognition (Mini Mental 
State Examination <26) or cardiovascular or cerebrovascular diseases were excluded 
from participation. Furthermore, auscultation of the carotid arteries was performed 
and participants with significant atherosclerotic lesions in the carotid arteries 
indicated by murmurs were also excluded from participation. None of the participants 
were regularly seeing a general practitioner or medical specialist and were not using 
medication known to interfere with the cardiovascular system.
Instrumentation 
Heart rate and blood pressure. A three-lead electrocardiogram (ECG) was used for 
heart rate registration and measurement of the R-R interval. Beat-to-beat blood 
pressures (systolic, diastolic and mean arterial pressure (mean blood pressure)) were 
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continuously measured on the left index or middle finger using a photoplethysmo-
graphic cuff from the Finometer (Finapres Medical Systems, Amsterdam, the 
Netherlands). The left hand was held at heart level by a supporting sling to eliminate 
changes in hydrostatic gradient during measurements. During each maneuver data 
were collected without interruption in beat-to-beat blood pressure measurement. The 
return to flow calibration that is built-in in this Finometer to calibrate finger pressure to 
brachial artery pressure was performed between the different maneuvers. This 
procedure uses a brachial cuff that is inflated above systolic pressure and then 
gradually released.
Cerebral blood flow velocity (CBFV) in the middle cerebral artery was measured 
bilaterally using TCD with 2 MHz pulsed Doppler probes (Multi-Dop, DWL Medical 
systems, Singen, Germany). The CBFV signal of the middle cerebral artery was 
identified according to the criteria of Aaslid et al. using the signal depth, velocity, and 
wave characteristics.22 The TCD probes were fixed at a constant angle and positioned 
with a customized headband (Spencer technologies, Seattle, WA, USA) over the 
temporal window. Depth, sample volume and signal power of the TCD measurement 
were noted for each participant. If only one CBFV signal was available, this signal was 
used for analysis. This was the case in one young subject, five elderly and four older 
elderly. Unilateral measurements were performed consistently throughout the 
maneuvers in these individuals. In the majority, both left and right CBFV signal were 
available and of sufficient quality, and then the average of both CBFV signals was 
used. Several studies have demonstrated that the diameter of the middle cerebral 
artery does not change appreciably even during moderate alterations in blood 
pressure and end-tidal CO2.23-26 Assuming that the diameter of the insonated artery 
remains constant within a subject, changes in CBFV represent changes in CBF.
Frontal cortical oxygenation was measured using the validated technique of NIRS.27,28 
Changes in the concentration of oxygenated and deoxygenated hemoglobin (O2Hb 
and HHb, respectively) in the cerebral cortex were measured.19,29 The basic principle 
of NIRS is that near-infrared light penetrates the skull and brain, and is absorbed by 
the chromophores O2Hb and HHb that have different absorption spectra. Assuming 
constant light scattering, changes in concentrations of these chromophores lead to 
changes in light absorption, and from the reflected light these O2Hb and HHb 
concentrations can then be calculated using the modified Lambert-Beer law.30,31 
Two pairs of NIRS optodes were placed and tightly fixed over the left and right frontal 
cortex in the customized headband that locked the Doppler probes. We applied a 
continuous wave NIRS device with 3 light bundles with wavelengths 775 nm, 845 nm, 
and 904 nm (Oxymon, Artinis Medical Systems, Zetten, the Netherlands). An 
interoptode distance of 5.0 cm was used to minimize contamination from the 
extracerebral circulation and to maximize signal intensity.30 The differential pathlength 
factor, which accounts for the increased distance travelled by light due to scattering, 
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is age-dependent.32 At present however, no data are available on the actual variation 
of differential pathlength factor in adults aged above 50 years.30,32 The differential 
pathlength factor was set to 6.6 (corresponding to age 50) in all groups. Moreover, 
contributions from extracranial tissue, such as skin tissue, to NIRS measurements 
could not be excluded. However, these contributions are relatively small with an 
interoptode distance of at least 5.0 cm.20,21,29,33 Total hemoglobin (THb), the sum of 
O2Hb and HHb, is associated with local cerebral blood volume, whereas O2Hb is 
associated with local cerebral blood flow 21 in the frontal cortex.
Protocol
To standardize the measurements, participants were asked to refrain from heavy 
exercise 24 hours prior to the examinations, not to take caffeinated drinks or alcohol 
14 hours prior, and only have a small breakfast in the morning at least 2 hours before 
the visit. All participants were measured in the morning in a quiet and temperature 
controlled room. 
The following maneuvers were performed in a fixed order. The measurement started 
with a ten minute baseline in sitting rest. The different parts of the protocol were 
separated by two minutes sitting rest. For the repeated sit-stand maneuver, 
participants were coached to perform a repeated sit-stand maneuver at 0.05 Hz (10 
seconds sitting - 10 seconds standing) for five minutes.11,13 For the single squat-stand 
maneuver participants performed standing for one minute, then squatting for one 
minute and then again standing for five minutes. For the cerebrovascular CO2 
reactivity measurements, participants were instructed to hyperventilate with deep 
breaths at a frequency of 0.5 Hz (1 second breath in - 1 second breath out, 
demonstrated by the researcher during the measurement) for one minute to induce 
hypocapnia. After a recovery of two minutes, participants inhaled a CO2 gas mixture 
through a mouthpiece with a Y-valve connected to a five liter rubber bag. This bag 
was fed by a gas mix system that combines 21% oxygen with variable levels of CO2 
and N2, at a flow of 20 l/min. The concentration of CO2 was gradually increased from 
0% to 7% in the fourth minute (oxygen was kept constant at 21%, while N2 decreased 
from 79% to 72%), followed by a recovery period of two minutes. End-tidal CO2 
(EtCO2) was monitored via a nasal canule using a capnograph (N1000, Nellcor, 
Boulder, CO).
Data processing
All data were simultaneously recorded at 125 Hz for offline analysis (Oxysoft, Artinis 
Medical Systems, the Netherlands). A running average filter of 1 second was applied 
to the NIRS measurements to increase the signal to noise ratio and to reduce the 
heart beat and high frequency noise.30,31 Baseline heart rate, systolic, diastolic and 
mean blood pressure, systolic, diastolic and mean CBFV were calculated from the 
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baseline sitting rest measurement. Cerebrovascular resistance index (CVRi) was 
calculated as the ratio of mean blood pressure and CBFV. Spectral analysis was 
performed on beat-to-beat mean blood pressure, mean CBFV and O2Hb changes. 
Frequency and transfer function analysis 
All transfer function analyses were performed with commercially available software 
(DADiSP, DSP Development, Cambridge, MA). The signals were aligned with the time 
of the R wave peaks of the ECG. The time series were then linearly interpolated at 2 
Hz to obtain equidistant time intervals and detrended with third-order polynomial 
fitting. These data then were analyzed in windows containing data segments of 128 
points (64 seconds), with 50% overlap. A Hanning-window was applied for spectral 
estimation. This data segmentation is based on a trade-off between a reduction in 
spectral variance and keeping sufficient spectral resolution. Each Hanning-win-
dowed segment was fast-Fourier transformed and the periodograms were averaged 
to calculate the autospectrum of mean blood pressure, CBFV and O2Hb.19,34 Spectral 
power of oscillations was calculated as the area under the curve of the power 
spectrum density (PSD) plots. The HHb signal was excluded from analysis, since the 
signal demonstrated only very small changes.
Baseline measurement
For analysis of the baseline measurement a time period of 400 seconds was used. 
Transfer function analysis was performed according to 3 predefined frequency 
domains:34 very low frequency (VLF: 0.02-0.07 Hz), low frequency (LF: 0.07-0.20 Hz) 
and high frequency (HF: 0.20-0.35 Hz). The dynamic relationship between blood 
pressure as input and CBFV as output (mean blood pressure-CBFV) was determined 
with transfer function analysis. Since the spontaneous oscillations during baseline 
rest measurement in the O2Hb signal were very small and therefore coherence was 
insufficient (see the following paragraph) the relation CBFV-O2Hb was not assessed. 
Mean values of coherence, phase and gain of the transfer function were analyzed in 
the same frequency ranges as described in the previous paragraph. We have 
previously described these estimates in detail.8 In short, coherence tests the linearity 
of the relationship between input (mean blood pressure) and output (CBFV). 
Coherence approaching unity in a specific frequency suggests a linear relationship, 
whereas coherence approaching zero indicates no relationship between the signals, 
severe extraneous noise or a non-linear relationship.35,36 A coherence of 0.4 is 
considered the lower limit where transfer function estimates can be calculated with 
confidence.10,34 The phase shift quantifies the displacement in time of a signal relative 
to another signal. Normal autoregulation causes a positive phase shift between 
CBFV and blood pressure. Gain determines how changes in blood pressure are 
transmitted into CBFV. A low gain indicates an efficient autoregulation (damping), 
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whereas an increase in gain represents a diminished efficiency of the dynamic 
process of cerebral autoregulation. Normalized gain (Gain*CVRi) was used to reduce 
the influence of individual differences in absolute levels of blood pressure and CBFV 
on gain. Estimates of coherence, phase and gain were therefore only included if 
coherence was >0.4 in this study.11,13,34
Repeated sit-stand maneuver at 0.05 Hz
The repeated sit-stand maneuver causes oscillations that are much larger than the 
spontaneous oscillations that occur during baseline sitting rest position, therefore the 
dynamic relationship can be assessed with greater coherence. Transfer function 
analysis was performed in the very low frequency range 0.02-0.07 Hz. The dynamic 
relationships between blood pressure as input and CBFV as output (mean blood 
pressure-CBFV) and CBFV-O2Hb were determined. Data were also only included if 
coherence was >0.4. We have previously shown that upstream oscillations in CBFV 
induced by changes in blood pressure contribute importantly to the downstream 
brain tissue level oscillations in O2Hb.19 It is our experience that oscillations induced 
at a frequency of 0.05 Hz result in clear blood pressure and CBFV oscillations with 
good coherence whereas oscillations induced at a frequency of 0.1 Hz result in more 
noise and thereby loss of reliable data.13,19 Furthermore, in accordance with the high 
pass filter, dynamic cerebral autoregulation is mainly active in the low and very low 
frequency regions. 
Single squat-stand maneuver
For the single squat-stand maneuver we analyzed two time periods: 1) squatting and 
2) maximum decline after standing up from squatting. For this we used 30 seconds 
of steady state in squatting position (1) and the period of 5 consecutive seconds in 
which mean blood pressure and CBFV had decreased the most upon standing (2). 
Both absolute and relative changes in mean blood pressure and CBFV were 
calculated.
Cerebrovascular CO2 reactivity 
Regarding the analysis of the cerebrovascular CO2 reactivity, absolute and relative 
changes in heart rate, mean blood pressure, CBFV, CVRi and O2Hb were calculated. 
The full range of cerebrovascular CO2 reactivity was calculated,16 which represents 
the percentage change in CBFV from hypocapnia (hyperventilation) to hypercapnia 
(7% CO2-inhalation) relative to baseline CBFV: 
=((CBFVmax[7%CO2] - CBFVmin[hyperventilation]) / CBFVrest) * 100%. 
We also calculated the change in CBFV between hypocapnia and hypercapnia per 
mmHg change in EtCO2 between hypocapnia and hypercapnia.37
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Statistical analysis
Data are presented as mean ± standard deviation. Comparisons between the 
different age groups were performed using the one-way ANOVA with Bonferroni 
correction for multiple comparisons. We checked the data with the Hochberg method 
because of sample size differences (especially with the single squat-stand maneuver) 
and with the Games-Howell method because of different group variances. Since 
these three methods did not show relevant differences, we only mention the results 
from the one-way ANOVA with Bonferroni correction. Statistical significance was set 
at a p-value <0.05. All statistical analysis were executed using statistical software 
SPSS (SPSS, Inc, Chicago, IL, USA).
Results
Baseline characteristics for the three age groups are presented in Table 4.1. Body 
mass index was higher in the elderly compared with the young group (p<0.001) and 
the older elderly (p=0.05). There were no differences in baseline blood pressure or 
heart rate between the three groups. The young group had a higher mean CBFV 
compared with both elderly groups (p<0.01) and a lower CVRi compared with the 
older elderly (p<0.01).
Cerebral autoregulation for spontaneous oscillations  
(baseline measurement)
The transfer functions coherence, phase, gain and normalized gain derived from 
spontaneous oscillations in blood pressure and CBFV during baseline sitting position 
are presented in Table 4.2. In accordance with the high pass filter model, all 
participants (except for two individuals, both aged 65 years) showed a pattern with 
decreasing phase and increasing gain with increasing frequency of oscillations.
Below we will briefly summarize these transfer function parameters (see Table 4.2).
Power Spectrum Density (PSD): The older elderly overall had lower values for PSD for 
both blood pressure and CBFV in all frequency ranges compared to the younger age 
groups. However, these differences did not reach statistical significance for all 
comparisons (Table 4.2).
For transfer function analysis only data with coherence >0.4 were used. Coherence: 
There were no relevant differences in coherence results between age groups. The 
older elderly had a slightly lower coherence in the LF compared with the young group 
(p=0.001), but mean coherence remained well above 0.4. Phase: Values for phase 
were very similar across age groups, but young subjects had a higher mean phase 
in the VLF (where cerebral autoregulation is most active), this difference reached 
statistical significance when compared to younger elderly (p=0.023). However, VLF 
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phase did not differ between younger and older elderly. Gain: Table 4.2 lists absolute 
gain, which is sensitive to individual differences in CVFV or blood pressure, and 
normalized gain, which is not affected by absolute CBFV or blood pressure. Absolute 
gain was marginally higher in the LF compared with the elderly (p=0.05). Normalized 
gain revealed no differences between age groups in the VLF and LF range where 
cerebral autoregulation is active, however, normalized gain was higher in the HF in 
the older elderly compared with the young group (p=0.006).
Repeated Sit-Stand maneuver 0.05 Hz
The results from the repeated sit-stand maneuver are presented in Table 4.3. Two 
subjects (one in each elderly group) lost bilateral TCD signal, but the remaining 
unilateral TCD signal was of sufficient quality to use. CBFV was higher in the young 
group compared with both elderly groups (p<0.001), and the CVRi was lower in the 
young group compared with the older elderly (p=0.008).
Table 4.1  Baseline characteristics of the three groups.
 Young Elderly Older elderly
General characteristics 
   Male  :  Female (n) 9 : 11 13 : 7 15 : 3
   Age (years) 24 ± 2 *1,2 66 ± 1 *2 78 ± 3
   Age ranges (years) 21 - 28 65 - 69 74 - 86
   Body mass index (kg/m2) 22.3 ± 2.7 *1 26.8 ± 3.4 #2 24.2 ± 2.5
Hemodynamics 
   Systolic blood pressure (mmHg) 121 ± 22 128 ± 20 122 ± 22
   Diastolic blood pressure (mmHg) 62 ± 15 64 ± 14 56 ± 12
   Mean arterial pressure (mmHg) 82 ± 16 86 ± 15 78 ± 15
   Pulse pressure (mmHg) 59 ± 12 64 ± 11 66 ± 13
   Heart rate (beats/minute) 69 ± 10 66 ± 10 63 ± 7
Cerebral perfusion 
   Mean CBFV (cm/s) 59.2 ± 11.5 *1,2 48.2 ± 7.3 41.9 ± 8.9
   Systolic CBFV (cm/s) 94.4 ± 18.2 *1,2 77.4 ± 14.2 69.5 ± 15.0
   Diastolic CBFV (cm/s) 40.5 ± 8.4 *1,2 30.0 ± 5.2 24.7 ± 5.8
   CVRi (mmHg/cm/s) 1.46 ± 0.58 *2 1.81 ± 0.36 1.98 ± 0.52
Data are presented as mean ± standard deviation.  * p<0.05 compared with the elderly1 or older elderly2. 
# p=0.05 compared with the older elderly2. Abbreviations: CBFV cerebral blood flow velocity, CVRi cere-
brovascular resistance index.
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Table 4.2  Transfer function analyses mean blood pressure - cerebral blood 
flow velocity was used to examine the dynamic cerebral auto regulation during 
spontaneous blood pressure oscillations in sitting rest position.
 Young Elderly Older elderly
Coherence >0.4    
   VLF (n) 15 15 13
   LF (n) 20 17 15
   HF (n) 20 14 17
Coherence    
   VLF 0.53 ± 0.06 0.55 ± 0.09 0.52 ± 0.08
   LF 0.77 ± 0.11 *2 0.68 ± 0.15 0.62 ± 0.09
   HF 0.72 ± 0.13 0.77 ± 0.13 0.70 ± 0.15
Phase (rad)    
   VLF 0.99 ± 0.36 *1 0.69 ± 0.28 0.74 ± 0.24
   LF 0.49 ± 0.21 0.47 ± 0.23 0.51 ± 0.20
   HF 0.07 ± 0.15 0.11 ± 0.11 -0.01 ± 0.14
Gain (cm/s/mmHg)    
   VLF 0.60 ± 0.15 0.52 ± 0.15 0.50 ± 0.15
   LF 0.83 ± 0.18 #1 0.68 ± 0.20 0.70 ± 0.15
   HF 0.91 ± 0.25 0.84 ± 0.19 0.85 ± 0.20
Normalized Gain (%cm/s/%mmHg)   
   VLF 0.77 ± 0.29 0.93 ± 0.17 0.90 ± 0.23
   LF 1.16 ± 0.31 1.20 ± 0.31 1.43 ± 0.54
   HF 1.24 ± 0.32 *2 1.50 ± 0.24 1.65 ± 0.50
PSD BP (mmHg2/Hz)   
   VLF 8.16 ± 4.75 10.34 ± 6.54 *2 4.64 ± 2.24
   LF 4.22 ± 3.26 *1,2 2.28 ± 1.81 0.80 ± 0.50
   HF 0.62 ± 0.41 0.74 ± 0.70 0.37 ± 0.39
PSD CBFV ((cm/s)2/Hz)   
   VLF 6.41 ± 3.53 *2 6.36 ± 4.32 *2 2.79 ± 2.10
   LF 3.54 ± 2.80 *1,2 1.66 ± 1.23 0.54 ± 0.29
   HF 0.73 ± 0.57 *2 0.56 ± 0.47 0.28 ± 0.16
Data are presented as mean ± standard deviation. * p<0.05 compared with the elderly1 or older elderly2. 
# p=0.05 compared with the elderly1. Abbreviations: PSD power spectrum density, BP blood pressure, 
CBFV cerebral blood flow velocity, VLF very low frequency, LF low frequency, HF high frequency.
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Below we will briefly summarize these transfer function parameters (see Table 4.3).
Power Spectrum Density (PSD): The induced oscillations led, as expected, to higher 
PSD between baseline and the repeated sit-stand maneuver (p<0.001) for the three 
age groups (Tables 4.2 and 4.3).
Table 4.3  Transfer function analyses mean blood pressure - cerebral blood 
flow velocity (MAP-CBFV) and cerebral blood flow velocity - oxygenated hemo-
globin (CBFV-O2Hb) were used to examine the dynamic cerebral autoregulation 
and cortical oxygenation during induced blood pressure oscillations using the 
repeated sit-stand maneuver at 0.05 Hz.
 Young  
(n=20)
Elderly  
(n=20)
Older elderly 
(n=18)
Hemodynamics    
   Mean arterial pressure (mmHg) 89 ± 18 91 ± 15 88 ± 16
   Heart rate (beats/minute) 79 ± 8 75 ± 10 76 ± 9
Cerebral perfusion     
   CBFV (cm/s) 59.7 ± 9.9 *1,2 48.1 ± 8.3 45.2 ± 9.3
   CVRi (mmHg/cm/s) 1.54 ± 0.47 *2 1.91 ± 0.40 2.06 ± 0.63
Dynamic cerebral autoregulation   
MAP-CBFV n=19 n=19 n=16
   Coherence 0.63 ± 0.06 0.67 ± 0.08 0.63 ± 0.11
   Phase (rad) 0.73 ± 0.33 0.61 ± 0.21 0.80 ± 0.28
   Gain (cm/s/mmHg) 0.62 ± 0.17 0.70 ± 0.16 *2 0.55 ± 0.20
   Normalized Gain (%cm/s/%mmHg) 0.88 ± 0.18 *1 1.31 ± 0.30 *2 1.06 ± 0.34
CBFV–O2Hb n=13 n=16 n=14
   Coherence 0.54 ± 0.09 0.56 ± 0.08 0.50 ± 0.07
   Phase (rad) -0.64 ± 0.31 -0.41 ± 0.49 *2 -0.89 ± 0.25
   Gain (cm/s/mmHg) 0.07 ± 0.03 0.06 ± 0.02 0.08 ± 0.02
   Normalized Gain (%cm/s/%mmHg) 0.10 ± 0.09 #2 0.12 ± 0.04 0.17 ± 0.08
Power Spectrum Density    
   Blood pressure (mmHg2/Hz) 50.30 ± 22.27 62.77 ± 33.25 42.90 ± 18.20
   CBFV ((cm/s)2/Hz) 27.25 ± 14.34 *2 34.67 ± 17.69 *2 15.02 ± 6.03
   O2Hz ((μmol/l)2/Hz) 0.23 ± 0.17 029 ± 0.25 0.17 ± 0.09
Data are presented as mean ± standard deviation. * p<0.05 compared with the elderly1 or older elderly2. 
# p=0.05 compared with the older elderly2. Abbreviations: CBFV cerebral blood flow velocity, CVRi cerebro-
vascular resistance index, MAP mean arterial pressure, O2Hb oxygenated hemoglobin.
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As with spontaneous oscillations, PSD for blood pressure and CBFV appeared 
smaller in the oldest elderly, but this was only statistically significant for CBFV 
(p<0.05).
Due to inclusion of data with coherence >0.4, some participants were excluded from 
the transfer function analysis MAP-CBFV (n=4) and CBFV-O2Hb (n=15) as indicated 
in Table 4.3. Blood pressure-CBFV relationship: Similar to the transfer function 
analysis for spontaneous oscillations, there were no differences between age groups 
for coherence and phase during induced VLF oscillations at 0.05 Hz. However, gain 
and normalized gain were higher in the elderly group compared with the older elderly 
and for normalized gain also compared with the young group (Table 4.3). 
CBFV-O2Hb relationship: Phase shift between CBFV and O2Hb was lower in the 
elderly compared with the older elderly (p=0.003), and the normalized gain was 
marginally higher in the older elderly compared with the young group (p=0.05). 
When performing a non-parametric Spearman’s rho linear regression using all three 
groups combined (n=58) with transfer function analysis metrics and age, phase 
CBFV-O2Hb (r=-0.320, p=0.034), normalized gain MAP-CBFV (r=0.276, p=0.041) 
and normalized gain CBFV-O2Hb (r=0.454, p=0.002) were statistically significant, 
indicating a small decrease in phase (CBFV-O2Hb) and increase in gain (MAP-CBFV 
and CBFV-O2Hb) with advancing age.
Single squat-stand maneuver
Table 4.4 and figure 4.1 present the results from the single squat-stand maneuver. 
Nine older elderly were included in this analysis since not all older elderly performed 
this maneuver due to comorbidity, e.g. osteoarthritis of hip or knee. The squat-stand 
maneuver induced large changes in blood pressure and CBFV, but overall, there 
were no differences in relative changes in blood pressure and CBFV between age 
groups. Heart rate increased significantly more in the young group compared with 
both elderly groups (p<0.001), but the absolute and percentage changes in mean 
blood pressure were similar in all groups. The CBFV was lower and CVRi was higher 
with increasing age during both squat and stand position (p<0.01). The fall in 
absolute CBFV upon standing was largest in young subjects (p=0.013), however 
relative changes did not differ between age groups. The absolute decrease in CVRi 
with standing was larger in the elderly compared with the young group (p=0.029).
Cerebrovascular CO2 reactivity
Table 4.5 presents the results from hyperventilation and CO2-inhalation measurement. 
In the older elderly group, 17 participants successfully completed this maneuver. 
Hyperventilation and CO2-inhalation led to significant changes in EtCO2 in all groups 
(p<0.01), resulting in substantial changes in mean blood pressure, CBFV, CVRi and 
O2Hb. Absolute CBFV was highest and CVRi was lowest in the youngest age group 
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throughout the measurement. Absolute changes in CBFV and CVRi during hyper-
ventilation and CO2-inhalation were also highest in the young group. However, relative 
changes expressed as percentage changes from baseline were similar for all ages 
(Table 4.5).
Table 4.4  Single squat-stand maneuver was used to examine the cerebral per-
fusion and cortical oxygenation during an orthostatic hypotension challenge test 
in healthy subjects, mimicking daily life activities.
 
Young 
(n=20)
Elderly 
(n=20)
Older elderly 
(n=9)
Squat    
   Mean arterial pressure (mmHg) 87 ± 16 96 ± 16 102 ± 14
   Heart rate (beats/minute) 75 ± 10 72 ± 12 *2 83 ± 8
   CBFV (cm/s) 64.4 ± 11.0 *1,2 50.5 ± 9.4 46.0 ± 8.4
   CVRi (mmHg/cm/s) 1.40 ± 0.44 *1,2 1.99 ± 0.46 2.29 ± 0.60
Stand    
   Mean arterial pressure (mmHg) 58 ± 15 61 ± 10 69 ± 13
   Heart rate (beats/minute) 104 ± 10 *1,2 84 ± 13 88 ± 8
   CBFV (cm/s) 47.7 ± 10.1 *1,2 39.2 ± 6.7 33.3 ± 5.5
   CVRi (mmHg/cm/s) 1.29 ± 0.58 *2 1.62 ± 0.28 *2 2.11 ± 0.54
Hemodynamic response    
    Mean arterial pressure (mmHg) -29 ± 7 -35 ± 14 -33 ± 9
   %  Mean arterial pressure (mmHg) -34 ± 8 -36 ± 10 -33 ± 7
    Heart rate (beats/minute) 29 ± 10 *1,2 11 ± 6 5 ± 3
   %  Heart rate (beats/minute) 40 ± 18 *1,2 16 ± 10 6 ± 4
    CBFV (cm/s) -16.7 ± 5.2 *1 -11.3 ± 6.6 -12.7 ± 4.2
   %  CBFV (cm/s) -26.2 ± 7.5 -21.5 ± 10.7 -27.2 ± 6.0
    CVRi (mmHg/cm/s) -0.11 ± 0.20 *1 -0.37 ± 0.35 -0.18 ± 0.39
    O2Hb (μmol/l) -2.22 ± 1.04 -2.72 ± 1.42 -2.98 ± 1.06
Data are presented as mean ± standard deviation. * p<0.05 compared with the elderly1 or older elderly2. 
Abbreviations: CBFV cerebral blood flow velocity, CVRi cerebrovascular resistance index, O2Hb oxygenated 
hemoglobin, = standing minus squatting, %  percentage change between standing and squatting compared 
to the squat values.
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Figure 4.1 This image shows the blood Pressure (A), cerebral blood flow velocity 
(CBFV; B) and cortical oxygenation (oxygenated hemoglobin O2Hb; C) responses 
of the three groups during the single squat-stand maneuver. The vertical dashed 
line indicates the moment of standing after 1 minute squat. The solid black line 
represents the young group, the solid grey line the elderly, and the dashed grey 
line the older elderly.
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Table 4.5  Changes in hemodynamics, cerebral blood flow velocity (CBFV)  
and cortical oxygenation (O2Hb) in response to changes in carbon dioxide  
(cerebrovascular CO2 reactivity) with hypocapnia (hyper ventilation) and hyper-
capnia (CO2-inhalation).
 Young  
(n=20)
Elderly  
(n=20)
Older  
elderly  
(n=17)
Baseline    
   Mean arterial pressure (mmHg) 81 ± 16 85 ± 13 84 ± 9
   Heart rate (beats/minute) 78 ± 9 *2 70 ± 12 66 ± 9
   CBFV (cm/s) 59.8 ± 10.8 *1,2 43.6 ± 7.6 44.3 ± 10.4
   CVRi (mmHg/cm/s) 1.40 ± 0.41 *1,2 2.05 ± 0.42 2.02 ± 0.56
   O2Hb (μmol/l) -0.18 ± 0.99 0.08 ± 0.92 0.03 ± 0.84
   EtCO2 (mmHg) 28.8 ± 3.0 31.0 ± 2.3 31.2 ± 3.8
Hyperventilation    
   Mean arterial pressure (mmHg) 70 ± 20 74 ± 10 70 ± 11
   Heart rate (beats/minute) 93 ± 14 *1,2 75 ± 12 75 ± 9
   CBFV (cm/s) 36.0 ± 9.5 *1,2 26.6 ± 5.2 26.6 ± 5.7
   CVRi (mmHg/cm/s) 1.99 ± 0.69 *1,2 2.87 ± 0.69 2.74 ± 0.76
   O2Hb (μmol/l) -1.61 ± 2.09 -1.20 ± 0.81 -1.64 ± 1.74
   EtCO2 (mmHg) 18.3 ± 3.1 16.0 ± 5.8 *2 20.4 ± 4.4
CO2-inhalation    
   Mean arterial pressure (mmHg) 96 ± 18 103 ± 21 108 ± 16
   Heart rate (beats/minute) 81 ± 12 *1 71 ± 8 78 ± 8
   CBFV (cm/s) 97.2 ± 19.5 *1,2 76.3 ± 15.5 75.9 ± 14.8
   CVRi (mmHg/cm/s) 1.02 ± 0.27 *1,2 1.42 ± 0.30 1.46 ± 0.32
   O2Hb (μmol/l) 3.83 ± 2.11 3.55 ± 2.79 4.07 ± 2.71
   EtCO2 (mmHg) 50.4 ± 4.5 49.0 ± 6.6 52.3 ± 4.3
CO2-inhalation - Hyperventilation    
    Mean arterial pressure (mmHg) 26 ± 18 26 ± 19 38 ± 13
   Full range mean arterial pressure (%) 33 ± 21 35 ± 24 45 ± 16
    Heart rate (beats/minute) -11 ± 18 *2 -4 ± 11 2 ± 8
   Full range heart rate (%) -15 ± 25 *2 -5 ± 17 4 ± 14
    CBFV (cm/s) 61.2 ± 17.2 #1,2 49.7 ± 13.8 49.3 ± 12.4
   Full range CBFV (%) 102 ± 20 115 ± 27 114 ± 30
    CBFV /  EtCO2 (cm/s/mmHg CO2) 1.95 ± 0.64 *1,2 1.52 ± 0.37 1.55 ± 0.34
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Discussion
The aim of the present study was to examine the influence of different ages on 
dynamic cerebral autoregulation and cerebrovascular CO2 reactivity in combination 
with the assessment of cerebral cortical oxygenation. The main findings are that in 
individuals above the age of 70 (age 74 to 86 years in this study) dynamic cerebral 
autoregulation and cerebrovascular CO2 reactivity retain normal function. Cerebral 
blood flow and cortical oxygenation were not compromised in these elderly during 
maneuvers that mimic daily life activities and during changes in arterial CO2.
Cerebral autoregulation
An intact dynamic cerebral autoregulation is characterized by a high pass filter with 
decreasing phase and increasing gain with increasing frequency domains.34,35 For 
spontaneous oscillations during baseline sitting, the transfer function parameters all 
followed this pattern in all three age groups, and all older elderly adhered to the high 
pass filter model. Moreover, the hallmark of dynamic cerebral autoregulation, i.e. the 
necessary adaptation of CVRi upon a decrease in blood pressure (e.g. when standing 
after squatting) in order to maintain sufficient CBF, was intact in older individuals. The 
current study showed that dynamic cerebral autoregulation in this oldest age group 
was comparable to a group of young subjects and to a group of older adults below 
the age of 70 years. Moreover, the efficiency of the dynamic cerebral autoregulatory 
Table 4.5   Continued.
 Young  
(n=20)
Elderly  
(n=20)
Older  
elderly  
(n=17)
CO2-inhalation - Hyperventilation    
    CVRi (mmHg/cm/s) -0.97 ± 0.48 *1 -1.45 ± 0.57 -1.28 ± 0.58
   Full range CVRi (%) -67 ± 18 -70 ± 21 -63 ± 23
    EtCO2 (mmHg) 32 ± 6 33 ± 7 32 ± 5
   Full range EtCO2 (%) 114 ± 31 107 ± 24 98 ± 36
    O2Hb (μmol/l) 5.44 ± 2.45 4.75 ± 2.76 5.71 ± 2.99
Data are presented as mean ± standard deviation. * p<0.05 compared with the elderly1 or older elderly2.  
# p=0.05 compared with the elderly1 or older elderly2. Abbreviations: CBFV cerebral blood flow velocity, 
CVRi cerebrovascular resistance index, O2Hb oxygenated hemoglobin, EtCO2 end-tidal CO2,  change 
between CO2 inhalation and hyperventilation.
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response, as reflected by the phase of the transfer function analysis during the 
repeated sit-stand maneuver, was similar in the three age groups indicating that the 
response time to restore the CBFV after blood pressure changes was comparable 
between the groups.
There were important differences in baseline cerebral hemodynamics between the 
three age groups. CBFV decreased and CVRi increased with advancing age. Since 
there were no differences in blood pressure between the different age groups, the 
increased CVRi with aging is could be due either to reduced cerebral blood flow or to 
changes in the characteristics of the blood vessels. It is known that arterial walls 
become thicker, stiffer, and vascular elasticity diminishes with aging, thereby 
increasing vascular resistance.2,3,38 Indeed, Gommer et al. found that higher 
peripheral vascular resistance correlated with higher CVRi.39 In this study, we did not 
measure absolute cerebral blood flow (in ml/min/100 gram of brain tissue) and 
therefore we are unable to differentiate between these two explanations for the 
increased CVRi. The transfer function parameters gain and normalized gain, on the 
other hand, are also thought to be affected by vascular stiffness. Despite the increase 
in CVRi with age, there was no consistent difference in (normalized) gain with 
increasing age, as gain was not higher in the older elderly compared with the younger 
elderly. Nevertheless, linear regression did show a significant increase for normalized 
gain MAP-CBFV and CBFV-O2Hb with age.
Taken together, we postulate that dynamic cerebral autoregulation is not compromised 
by the effects of physiological aging up to the age of 86 years.
Cerebrovascular CO2 reactivity
The relative change in CBFV during changes in EtCO2 was similar in the three age 
groups. In other words, the ability to vasoconstrict or vasodilatate in response to 
changes in arterial CO2 is preserved with aging. This finding is in contrast with literature 
that young subjects have a greater cerebrovascular CO2 reactivity compared with older 
subjects.12 Cerebrovascular CO2 reactivity can be affected by structural vascular 
properties as well as vascular endothelial function.9,40 Vascular endothelium is an 
important regulatory organ that modulates the tone of the underlying vascular smooth 
muscle cells and maintains cardiovascular homeostasis by contributing to vasocon-
striction and vasodilation.41 It is known that the endothelial function in reduced with 
aging.40 Despite these potential vascular changes with aging, the percentage change 
in CBFV and O2Hb in response to changes in CO2 were similar for all groups.
Cortical oxygenation
The dynamic relation between oscillations in CBFV and cortical O2Hb may reflect a 
regulatory mechanism to maintain brain tissue oxygenation.31,42 The relationship 
between blood pressure, CBFV and O2Hb lends support to the notion that upstream 
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oscillations in CBFV induced by changes in blood pressure contribute importantly to 
the downstream brain tissue level oscillations in O2Hb.19 It must be acknowledged 
that NIRS also measures O2Hb in venous blood besides merely the arterial blood 
supply. However, the NIRS method has been validated to measure changes on 
cerebral cortical tissue level and the dynamic changes in O2Hb have been related to 
changes in the arterial and arteriolar component, with little change in the venous 
compartment which remains relatively constant.27,28 NIRS can be influenced by 
blood in the extracranial tissue (skin), however, the interoptode distance of 5.0 cm 
that we used has been shown to measure intracranial cerebral hemodynamic 
changes in O2Hb and HHb with negligible influence of skin blood flow.21 
In the current study, repeated sit-stand maneuvers induced strong blood pressure 
oscillations, which resulted in strong CBFV oscillations leading to O2Hb oscillations 
with sufficient coherence to perform transfer function analysis of the relation 
CBFV-O2Hb. The phase between CBFV and O2Hb was negative in all three groups, 
indicating that O2Hb oscillations follow those of CBFV with a time delay caused by 
transit time of blood. The gain of the transfer function analysis between CBFV and 
O2Hb might reflect either damping of the CBFV fluctuations (perhaps by distensible 
arterioles or capillaries) resulting in smaller or larger oscillations in cortical 
oxygenation. Gain may, however, also be influenced by metabolic reserve and its 
effect on oxygenated hemoglobin, or by a reduced diffusion of oxygen leading to 
enhanced oscillations in O2Hb in response to changes in CBFV.19
With increasing age, the phase lag between CBFV and O2Hb became larger, whereas 
the normalized gain became higher. This is in line with results from patients with 
Alzheimer’s disease, a disease in which cerebral microvasculature is affected. In 
these Alzheimer patients, the phase lag was larger and gain was higher between 
CBFV and O2Hb at 0.05 Hz compared with age-matched controls.19 Possibly, the 
microvasculature in older individuals becomes compromised compared with young 
individuals. We speculate that increased microvascular tortuosity (which leads to 
increased vessel length and thereby transit time, as has been demonstrated in arterial 
spin labeling studies) could explain the larger phase shift, and that reduced 
distensibility and concomitant reduced damping could explain larger gain.
The single squat-stand maneuver elicited a reduction in O2Hb in the frontal cortex, 
which was similar in all groups. This challenging maneuver, which is comparable with 
activities in daily life, such as standing up from a chair, or putting on a sock or shoe, 
does not seem to compromise oxygenation of the frontal cortex in healthy older 
individuals. This would confirm our observation of preserved dynamic cerebral 
autoregulation based on TCD in these healthy subjects. These compensatory 
mechanisms may however fail in case of more severe stress (for example during 
septic shock) or with diseases that further compromise cerebral macro- and micro-
vasculature like Alzheimer’s disease.
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Limitations
In order to induce larger hemodynamic oscillations, a repeated sit-stand maneuver 
was applied. The induced large blood pressure oscillations during the repeated 
sit-stand maneuver provide strong and physiological relevant hemodynamic 
perturbations and lead to an improved estimation of the transfer function parameters 
and higher power spectrum density and thereby increases reliability of the 
assessment.11,13 However, the maneuver could be seen as aerobic exercise and may 
thereby affect our measurements. However, Ogoh et al.43 found that mild to moderate 
intensity exercise did not impair dynamic cerebral autoregulation. It is possible that 
the older elderly experienced the repeated sit-stand maneuver as mild exercise, 
however compared with baseline values their heart rate did not increase more than in 
the other two groups, nor did the EtCO2 change relevantly compared with baseline. 
Thus, confounding effects of aerobic exercise during the repeated sit-stand maneuver 
are less likely.
Cerebral blood flow velocity was measured in the middle cerebral artery and NIRS 
was obtained from the frontal cortex, which receives blood supply from the anterior 
cerebral artery and the middle cerebral artery.19 We assumed that relative changes of 
CBFV would be similar between the middle and anterior cerebral artery in response 
to blood pressure changes, and thus the supplying anterior cerebral artery most 
likely reacts similar as the middle cerebral artery.
The cut-off point of a coherence <0.4 remains questionable. Theoretically, excluding 
persons with low coherence might lead to the exclusion of participants with very 
efficient cerebral autoregulation. However, using the cut-off point warranted optimal 
data quality and reduced the signal-to-noise ratio. Furthermore, excluding low 
coherence <0.4 was performed in all age groups and considering our findings of 
sufficient cerebral autoregulation in all age groups, it is highly unlikely that the use of 
this cut-off value has influenced our results.
Conclusion
We have shown that a group of healthy older individuals up to the age of 86 years old 
shows an overall preserved dynamic cerebral autoregulation and cerebrovascular 
CO2 reactivity leading to a sufficient cerebral cortical oxygenation. The preserved 
dynamic cerebral autoregulation and cerebrovascular CO2 reactivity were observed 
despite the decrease in cerebral blood flow velocity and increase in cerebrovascular 
resistance index with advancing age.
Acknowledgements. We thank the participants for their devotion and participation.
93
4
Cerebral perfusion and cortical oxygenation with aging
References
1. Ferrari AU, Radaelli A, Centola M. Invited review: Aging and the cardiovascular system. Journal of Applied 
Physiology 2003;95:2591-2597.
2. Lakatta EG, Levy D. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises: 
Part i: Aging arteries: A “set up” for vascular disease. Circulation 2003;107:139-146.
3. O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: A clinical perspective. Journal of the 
American College of Cardiology 2007;50:1-13.
4. Lipsitz LA, Mukai S, Hamner J, Gagnon M, Babikian V. Dynamic regulation of middle cerebral artery 
blood flow velocity in aging and hypertension. Stroke 2000;31:1897-1903.
5. Sorond FA, Khavari R, Serrador JM, Lipsitz LA. Regional cerebral autoregulation during orthostatic 
stress: Age-related differences. Journals of Gerontology. Series A, Biological Sciences and Medical 
Sciences 2005;60:1484-1487.
6. Panerai RB. Assessment of cerebral pressure autoregulation in humans--a review of measurement 
methods. Physiological Measurement 1998;19:305-338.
7. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovascular and Brain 
Metabolism Reviews 1990;2:161-192.
8. van Beek AH, Claassen JA, Rikkert MG, Jansen RW. Cerebral autoregulation: An overview of current 
concepts and methodology with special focus on the elderly. Journal of Cerebral Blood Flow and 
Metabolism 2008;28:1071-1085.
9. Diehl RR, Diehl B, Sitzer M, Hennerici M. Spontaneous oscillations in cerebral blood flow velocity in 
normal humans and in patients with carotid artery disease. Neuroscience Letters 1991;127:5-8.
10. Diehl RR, Linden D, Lucke D, Berlit P. Spontaneous blood pressure oscillations and cerebral 
autoregulation. Clinical Autonomic Research 1998;8:7-12.
11. Claassen JA, Levine BD, Zhang R. Dynamic cerebral autoregulation during repeated squat-stand 
maneuvers. Journal of Applied Physiology 2009;106:153-160.
12. Bakker SL, de Leeuw FE, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM. Cerebral haemodynamics 
in the elderly: The rotterdam study. Neuroepidemiology 2004;23:178-184.
13. van Beek AH, Olde Rikkert MG, Pasman JW, Hopman MT, Claassen JA. Dynamic cerebral autoregulation 
in the old using a repeated sit-stand maneuver. Ultrasound in Medicine and Biology 2010;36:192-201.
14. Narayanan K, Collins JJ, Hamner J, Mukai S, Lipsitz LA. Predicting cerebral blood flow response to 
orthostatic stress from resting dynamics: Effects of healthy aging. American Journal of Physiology 
Regulatory Integrative and Comparative Physiology 2001;281:R716-722.
15. Claassen JA, Zhang R, Fu Q, Witkowski S, Levine BD. Transcranial doppler estimation of cerebral blood 
flow and cerebrovascular conductance during modified rebreathing. Journal of Applied Physiology 
2007;102:870-877.
16. Ringelstein EB, Sievers C, Ecker S, Schneider PA, Otis SM. Noninvasive assessment of co2-induced 
cerebral vasomotor response in normal individuals and patients with internal carotid artery occlusions. 
Stroke 1988;19:963-969.
17. van Beek AH, de Wit HM, Olde Rikkert MG, Claassen JA. Incorrect performance of the breath hold 
method in the old underestimates cerebrovascular reactivity and goes unnoticed without concomitant 
blood pressure and end-tidal co(2) registration. Journal of Neuroimaging 2011;21:340-347.
18. Dineen NE, Panerai RB, Brodie F, Robinson TG. Effects of ageing on cerebral haemodynamics assessed 
during respiratory manoeuvres. Age and Ageing 2011;40:199-204.
19. van Beek AH, Lagro J, Olde-Rikkert MG, Zhang R, Claassen JA. Oscillations in cerebral blood flow and 
cortical oxygenation in alzheimer’s disease. Neurobiology of Aging 2012;33:428 e421-431.
20. van Beek AH, Sijbesma JC, Jansen RW, Rikkert MG, Claassen JA. Cortical oxygen supply during 
postural hypotension is further decreased in alzheimer’s disease, but unrelated to cholinesterase-inhib-
itor use. Journal of Alzheimer’s Disease 2010;21:519-526.
21. Reinhard M, Wehrle-Wieland E, Grabiak D, Roth M, Guschlbauer B, Timmer J, Weiller C, Hetzel A. 
Oscillatory cerebral hemodynamics--the macro- vs. Microvascular level. Journal of the Neurological 
Sciences 2006;250:103-109.
94
Chapter 4
22. Aaslid R, Markwalder TM, Nornes H. Noninvasive transcranial doppler ultrasound recording of flow 
velocity in basal cerebral arteries. Journal of Neurosurgery 1982;57:769-774.
23. Newell DW, Aaslid R, Lam A, Mayberg TS, Winn HR. Comparison of flow and velocity during dynamic 
autoregulation testing in humans. Stroke 1994;25:793-797.
24. Serrador JM, Picot PA, Rutt BK, Shoemaker JK, Bondar RL. Mri measures of middle cerebral artery 
diameter in conscious humans during simulated orthostasis. Stroke 2000;31:1672-1678.
25. Giller CA, Bowman G, Dyer H, Mootz L, Krippner W. Cerebral arterial diameters during changes in blood 
pressure and carbon dioxide during craniotomy. Neurosurgery 1993;32:737-741; discussion 741-732.
26. Kirkham FJ, Padayachee TS, Parsons S, Seargeant LS, House FR, Gosling RG. Transcranial 
measurement of blood velocities in the basal cerebral arteries using pulsed doppler ultrasound: Velocity 
as an index of flow. Ultrasound in Medicine and Biology 1986;12:15-21.
27. Brady KM, Lee JK, Kibler KK, Smielewski P, Czosnyka M, Easley RB, Koehler RC, Shaffner DH. 
Continuous time-domain analysis of cerebrovascular autoregulation using near-infrared spectroscopy. 
Stroke 2007;38:2818-2825.
28. Smielewski P, Kirkpatrick P, Minhas P, Pickard JD, Czosnyka M. Can cerebrovascular reactivity be 
measured with near-infrared spectroscopy? Stroke 1995;26:2285-2292.
29. Mehagnoul-Schipper DJ, Vloet LC, Colier WN, Hoefnagels WH, Jansen RW. Cerebral oxygenation declines 
in healthy elderly subjects in response to assuming the upright position. Stroke 2000;31:1615-1620.
30. Claassen JA, Colier WN, Jansen RW. Reproducibility of cerebral blood volume measurements by near 
infrared spectroscopy in 16 healthy elderly subjects. Physiological Measurement 2006;27:255-264.
31. Rowley AB, Payne SJ, Tachtsidis I, Ebden MJ, Whiteley JP, Gavaghan DJ, Tarassenko L, Smith M, Elwell 
CE, Delpy DT. Synchronization between arterial blood pressure and cerebral oxyhaemoglobin 
concentration investigated by wavelet cross-correlation. Physiological Measurement 2007;28:161-173.
32. Duncan A, Meek JH, Clemence M, Elwell CE, Fallon P, Tyszczuk L, Cope M, Delpy DT. Measurement of 
cranial optical path length as a function of age using phase resolved near infrared spectroscopy. 
Pediatric Research 1996;39:889-894.
33. Mehagnoul-Schipper DJ, Colier WN, Jansen RW. Reproducibility of orthostatic changes in cerebral 
oxygenation in healthy subjects aged 70 years or older. Clinical Physiology 2001;21:77-84.
34. Zhang R, Zuckerman JH, Giller CA, Levine BD. Transfer function analysis of dynamic cerebral 
autoregulation in humans. American Journal of Physiology 1998;274:H233-241.
35. Giller CA. The frequency-dependent behavior of cerebral autoregulation. Neurosurgery 1990;27:362-368.
36. Marmarelis VZ. Coherence and apparent transfer function measurements for nonlinear physiological 
systems. Annals of Biomedical Engineering 1988;16:143-157.
37. Bailey DM, Marley CJ, Brugniaux JV, Hodson D, New KJ, Ogoh S, Ainslie PN. Elevated aerobic fitness 
sustained throughout the adult lifespan is associated with improved cerebral hemodynamics. Stroke 2013
38. Monahan KD. Effect of aging on baroreflex function in humans. American Journal of Physiology 
Regulatory Integrative and Comparative Physiology 2007;293:R3-R12.
39. Gommer ED, Martens EG, Aalten P, Shijaku E, Verhey FR, Mess WH, Ramakers IH, Reulen JP. Dynamic 
cerebral autoregulation in subjects with alzheimer’s disease, mild cognitive impairment, and controls: 
Evidence for increased peripheral vascular resistance with possible predictive value. Journal of 
Alzheimer’s Disease 2012;30:805-813.
40. Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clinical Science 
(London) 2011;120:357-375.
41. Glasser SP, Selwyn AP, Ganz P. Atherosclerosis: Risk factors and the vascular endothelium. American 
Heart Journal 1996;131:379-384.
42. Iadecola C, Park L, Capone C. Threats to the mind: Aging, amyloid, and hypertension. Stroke 
2009;40:S40-44.
43. Ogoh S, Fadel PJ, Zhang R, Selmer C, Jans O, Secher NH, Raven PB. Middle cerebral artery flow velocity 
and pulse pressure during dynamic exercise in humans. American Journal of Physiology Heart and 
Circulatory Physiology 2005;288:H1526-1531.
95
4
Cerebral perfusion and cortical oxygenation with aging

Chapter 5
The effect of an advanced  
glycation end-product crosslink breaker 
and exercise training on vascular function 
in older individuals:
a randomized factorial design trial
Madelijn H. Oudegeest-Sander
Marcel G.M. Olde Rikkert
Paul Smits
Dick H.J. Thijssen
Arie P.J. van Dijk
Benjamin D. Levine
Maria T.E. Hopman
Experimental Gerontology 2013;48:1509-1517
98
Chapter 5
Abstract
Background: Aging leads to accumulation of irreversible advanced glycation 
end-products (AGEs), contributing to vascular stiffening and endothelial dysfunction. 
When combined with the AGE-crosslink breaker Alagebrium, exercise training 
reverses cardiovascular aging in experimental animals. This study is the first to 
examine the effect of Alagebrium, with and without exercise training, on endothelial 
function, arterial stiffness and cardiovascular risk in older individuals.
Methods: Forty-eight non-exercising individuals (mean age 70 ± 4 years) without 
manifest diseases or use of medication were allocated into 4 groups for a 1-year 
intervention: Exercise training & Alagebrium (200 mg/day); Exercise training & 
placebo; No exercise training & Alagebrium (200 mg/day); and no exercise training & 
placebo. We performed a maximal exercise test (VO2max) and measured endothelial 
function using venous occlusion plethysmography and intra-arterial infusion of 
acetylcholine, sodium nitroprusside and NG-monomethyl-L-arginine. Arterial stiffness 
was measured using pulse wave velocity, and cardiovascular risk was calculated 
using the Lifetime Risk Score (LRS).
Results: In the exercise training groups, Lifetime Risk Score and VO2max improved 
significantly (23.9 ± 4.5 to 27.2 ± 4.6 mlO2/min/kg, p<0.001). Endothelial response 
to the vasoactive substances did not change, nor did arterial stiffness in any of the 
four groups.
Conclusion: One year of exercise training significantly improved physical fitness and 
lifetime risk for cardiovascular disease without affecting endothelial function or arterial 
stiffness. The use of the AGE-crosslink breaker Alagebrium had no independent 
effect on vascular function, nor did it potentiate the effect of exercise training. Despite 
the clinical benefits of exercise training for older individuals, neither exercise training 
nor Alagebrium (alone or in combination) was able to reverse the vascular effects of 
decades of sedentary aging within one year of intervention.
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Introduction
Advanced age is associated with an increased risk for cardiovascular diseases, at 
least partly because of age-related changes in vessel characteristics that lead to 
arterial stiffening and endothelial dysfunction.1,2 Another detrimental age-related 
impact on arterial vessels is the accumulation of Advanced Glycation End-products 
(AGEs) in the arterial wall.3-5 AGEs are the end-product of a non-enzymatic reaction 
with sugar derivatives that leads to irreversible protein-protein crosslinks. This 
process occurs continuously and ultimately results in an accumulation of complex 
arrangements of cross-linked proteins and AGEs.3-5 When AGEs link to long-lived 
proteins, such as collagen in the arterial wall, they contribute to arterial stiffening.3-5 
Furthermore, AGEs bind to specific AGE-binding receptors on endothelial cells and 
quench nitric oxide, thereby leading to endothelial dysfunction.4-6
Based on the potential role of AGEs in the development of endothelial dysfunction 
and arterial stiffness, i.e., characteristic vascular adaptations that relate to the 
increased cardiovascular risk in the older population, therapeutic strategies that 
reverse the process of AGE formation and accumulation may have beneficial 
potential. A pharmacologic agent has been created to specifically break already 
formed AGE-crosslinks.7 This drug, a thiazolium-derivative known as Alagebrium, 
breaks established AGE-crosslinks between proteins.8 Previous animal studies and 
initial phases I and II patient studies demonstrated a reduced vascular stiffness and 
improved endothelial function.3,8,9 Whether older individuals, who typically demonstrate 
endothelial dysfunction and stiffer arteries, also benefit from an AGE-crosslink breaker 
is currently unknown.
Physical exercise training is a potent stimulus not only to reduce cardiovascular risk, 
but also to improve endothelial function and arterial stiffness.10-12 Preliminary work in 
rats suggested that the combination of exercise training and an AGE-crosslink 
breaker reverses cardiovascular adaptations to advanced age in rats.13 Whether 
AGE-crosslink breakers enhance the cardiovascular benefits from exercise training in 
humans is currently unknown. Therefore, the aim of our study was to examine the 
effects of a 1-year treatment with the AGE-crosslink breaker Alagebrium on endothelial 
function, arterial stiffness and cardiovascular risk in healthy older individuals, and 
combine this intervention in a factorial design with exercise training. The primary 
hypothesis was that both 1-year AGE-crosslink breakers and aerobic exercise training 
improve endothelial function and arterial stiffness. An additional hypothesis was the 
presence of a superior effect on endothelial function and arterial stiffness when both 
interventions were combined.
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Methods
Ethics Statement 
The study was performed according to Good Clinical Practice standards, and 
approved by the Medical Ethics Committee (Arnhem/Nijmegen, the Netherlands). All 
participants gave written informed consent. This study is registered at Clinical Trial.
gov (NCT01417663).
Participants
Forty-eight older individuals (age 70 ± 4 years), who did not perform regular (≤1 hour/
week) exercise for the last 5-10 years, were recruited from the local community (Figure 5.1). 
All participants were non-smoking subjects, aged 65 years or older, without diseases 
or disorders that could compromise physical activity, were not regularly seeing a 
general practitioner or medical specialist and were not using medication known to 
interfere with the cardiovascular system or hormone replacement therapy. None of 
our participants have (a history of) cardiovascular disease. Furthermore, participants 
with hypertension (>160/90 mmHg), diabetes mellitus, hypercholesterolemia (total 
cholesterol >7.5 mmol/l) and body mass index >32.5 kg/m2 were excluded from 
participation. Because of our assessment of endothelial function in the lower limbs, 
we also excluded participants with the presence of significant atherosclerotic lesions 
in the lower limbs found with physical examination indicated by murmers over the 
femoral artery or the absence of peripheral pulsations of the dorsalis pedis artery 
and/or posterior tibial artery. 
Experimental Design
After an extensive medical screening, participants were allocated to 4 different 
intervention groups according to a factorial design for a 1-year intervention: 1) 
Exercise training & Alagebrium; 2) Exercise training & placebo; 3) No exercise training 
(control) & Alagebrium; and 4) No exercise training (control) & placebo.
Measurements were performed before, during (6 months) and after one year. First, 
participants were clinically evaluated to be healthy. Then, we performed non-invasive 
vascular measurements of the common femoral artery diameter and central pulse 
wave velocity (i.e., arterial stiffness). On a separate day, participants performed an 
incremental maximal bicycle exercise stress test. Before and after the 1-year inter -
vention, we also assessed lower limb endothelial function using venous occlusion 
plethysmography and intra-arterial infusion of vasoactive substances. This measurement 
was performed on a separate day.
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One year intervention
Exercise training
The randomization procedure for exercise training was performed with 48 envelopes. 
Exercise training was performed 3 times/week for 12 months on a cycle ergometer 
(Medgraphics, Corival Cycle Ergometer, St Paul, MN, USA). Each exercise session 
consisted of 10 minutes warm up, followed by 30 minutes of cycling exercise at 
70–85% of the individual heart rate reserve and ended with 5 minutes cool down. 
Heart rate was continuously monitored (Polar RS800; Polar Electro Oy, Kempele, 
Finland). Workload was individually adjusted throughout the training to enhance 
physical fitness. The researchers were blinded during data analysis.
Alagebrium vs. placebo
Participants were randomized to AGE-crosslink breaker Alagebrium 100 mg twice a 
day or placebo (twice a day). This dose of Alagebrium, produced by Synvista 
Therapeutics, was selected as the lowest dose that was effective in both animal 14,15 
and human 3,8 studies to maximize efficacy and minimize toxicity. Double-blind 
randomization was controlled by the university hospital pharmacist and was kept 
strictly confidential during the study. Compliance with the study drug was controlled 
by asking participants to keep a journal and sign the time of each ingestion. Every 3 
months, this journal was compared with the (empty) strips of tablets.
Measurements
General characteristics
All participants underwent clinical evaluations including measurements of body 
composition. Blood pressure measurements were performed three times in the 
supine position using a manual sphygmomanometer around the left arm after a 10 
minute rest. Venous blood samples were taken after an overnight fast to measure 
lipid levels, glucose and glycosylated haemoglobin (HbA1c). In addition, high 
sensitivity C-reactive protein (hs-CRP) was examined as a measure of inflammation.
Incremental maximal bicycle exercise stress test
An incremental maximal exercise stress test on a bicycle ergometer (Lode, Excalibur 
Sport, Groningen, the Netherlands) was performed to measure maximal oxygen 
uptake (VO2max).16 After 3 minutes rest, participants started cycling at a workload of 
50Watt, which was increased by 10 Watt/minute. Continuous measurement of oxygen 
uptake (VO2) was performed using an automatic gas analyzer (Oxycon alpha, Jaeger, 
Breda, the Netherlands). Peak oxygen uptake (mlO2/min/kg) was calculated as the 
average oxygen uptake during the last minute of the test and then scaled for body 
weight and lean body mass.
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Cardiovascular risk
The Lifetime Risk Score (LRS) is based on an algorithm that incorporates gender, 
age, systolic blood pressure, diabetes mellitus, total cholesterol, smoking, body 
mass index, and physical fitness.17,18 The LRS has a strong predictive capacity for 
future cardiovascular mortality.17,18
Vascular measurements
Vascular measurements were performed under standardized conditions. Participants 
were asked to refrain from coffee, tea, alcohol, chocolate, vitamin C supplements or 
fruit 14 hours prior and fasting overnight prior to the examinations. Room temperature 
was set at 22 ± 1 °C.
Common femoral artery diameter. Using high-resolution echo ultrasonography with a 
7.5 MHz linear array transducer (Picus, Pie Medical Benelux, Maastricht, the 
Netherlands) we measured the right common femoral artery (CFA) diameter 2 cm 
proximal to the bifurcation.19 The percentage change in arterial diameter was 
calculated and used for analysis.
Arterial stiffness. We measured systemic arterial stiffness using central pulse wave 
velocity (PWV).20 A three lead electrocardiogram (ECG) was used for R-wave 
detection. The pulse wave was measured by echo-Doppler ultrasound (WakiLoki 
Doppler, 4 MHz, Atys) at the left carotid artery and right CFA.
Lower limb endothelial function. Endothelial function of the lower limb was measured 
from resistance artery blood flow responses using venous occlusion plethysmogra-
phy during intra-arterial infusion of vasoactive substances 21,22 in the upper leg, 
previously described in detail by Kooijman et al..23 In short, an intra-arterial cannula 
was introduced into the right CFA at the level of the inguinal ligament. This cannula 
was used for intra-arterial administration of vasoactive substances and for intra-arterial 
blood pressure monitoring. Bilateral blood flow in the upper legs was measured by 
ECG-triggered venous occlusion plethysmography. Mercury-in-silastic strain gauges 
were placed at mid thigh to quantify changes in leg volume from changes in upper 
leg blood flow.
After instrumentation and at least 45 minutes after cannulation of the femoral artery, 
infusion of the vasoactive substances started. We infused the endothelium dependent 
vasodilator acetylcholine (ACh), the endothelium independent vasodilator sodium 
nitroprusside (SNP), and the nitric oxide synthase inhibitor NG-monomethyl-L-argi-
nine (L-NMMA). Acetylcholine was administered at 1, 4, 16, 32 and 64 μg/mL/100mL 
leg volume, SNP 0.06, 0.20 and 0.60 μg/mL/100mL leg volume, and L-NMMA 0.05, 
0.10, 0.20 and 0.40 mg/mL/100mL leg volume. The order of infusion was fixed and 
each substance was infused for 5 minutes. During each substance infusion, the calf 
circulation was occluded by inflating cuffs directly below the knee to suprasystolic 
values (≥220 mmHg) to avoid the use of high dosages with subsequent possible 
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systemic effects of the vasoactive substances.23 Two consecutive infusions were 
performed before deflating the lower leg cuffs to restore normal blood flow for 5 
minutes. During these 5 minutes of recovery, 0.9% saline (or 5% glucose during SNP 
measurements) was infused to maintain a constant flow rate. Between administration 
of different substances a 20 minute rest period was inserted with continuous flow of 
0.9% saline.
Besides changes in blood flow, the blood flow ratio between the infusion and control 
leg was also calculated to correct for possible systemic effects.
Statistical Analysis
Statistical analysis was performed using the Statistical Package for the Social 
Sciences (SPSS, Chicago, IL, USA). Data are presented as mean ± standard 
deviation (SD), except for the figures in which mean ± standard error of the mean 
(SEM) are used. At baseline, a one-way ANOVA (Analysis of variance) comparison 
was performed between the 4 groups with Bonferroni correction. Differences between 
the 4 groups in response to the 1-year intervention were analyzed using the Linear 
Mixed Model. The interaction between exercise training and Alagebrium was analyzed 
(Time*Training*Medication), and both individual effects of exercise training vs. no 
exercise training and Alagebrium vs. placebo were analyzed (Time*Training and 
Time*Medication, respectively). Changes in blood flow and blood flow ratio responses 
to increasing dosages of vasoactive substances were also analyzed using the Linear 
Mixed Model at baseline and after one year. Statistical significance was set at a 
(2-sided) p-value <0.05.
Sample size was calculated for an effect of Alagebrium and exercise training on 
endothelial function. Based on previous studies 11,12,23 that examined the influence of 
physical activity on endothelial function using intra-arterial infusion of ACh, SNP, and 
L-NMMA, a group size of 10 subjects is sufficient to detect relevant changes in 
endothelial function of 3.9 ml/min/dl with exercise training with a power of >0.95, 
given a standard deviation of 4.7 ml/min/dl and an Δ-error of 0.05. Moreover, based on 
previous work from our lab,19 8 subjects would allow for a power of >0.95 to detect a 
change in arterial compliance with exercise training of 0.015 mm2/mmHg given a 
standard deviation of 0.01 mm2/mmHg and an alpha error of 0.05. The magnitude of 
both of these changes would be considered clinically and physiologically significant. 
Due to the long intervention period and possibility for drop-outs, group sizes of 12 
participants were created.
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Results
Four individuals, 1 per intervention arm, did not finish the intervention due to reasons 
unrelated to the intervention (Figure 5.1). At baseline, we found no differences 
between the 4 groups in gender, age, and physical fitness (Table 5.1). Also, no 
differences were observed in cardiovascular risk factors, e.g. body composition, 
blood pressure, total cholesterol, triglycerides, glucose, HbA1c, and hs-CRP among 
the 4 groups at baseline (Table 5.1). Drug compliance was high with >95% of the 
drug taken.
One year of exercise training significantly improved physical fitness by 15% 
(Time*Training p<0.001, Figure 5.2). Alagebrium did not influence physical fitness 
(Time*Medication p=0.969 and Time*Training*Medication p=0.757). 
The 1-year intervention did not alter body composition, blood pressure, lipid levels, 
glucose, and HbA1c in any of the 4 groups (all p>0.10, Table 5.1). A small interaction 
effect was seen in hs-CRP when combining the 4 groups (Time*Training*Medication 
p=0.048). However, neither the individual effect of exercise training, nor the individual 
effect of medication had a significant influence on hs-CRP levels (Time*Training 
p=0.194 and Time*Medication p=0.987, respectively). Furthermore, no overall 
difference was seen in hs-CRP before and after one year (n=44, pre 1.83 ± 1.38 mg/l 
vs. post 1.60 ± 1.14 mg/l, paired t-test p=0.166).
Cardiovascular risk prediction
Lifetime Risk Score significantly improved after exercise training (Time*Training 
p=0.014), with an 8% decrease in 30-year risk prediction. Alagebrium did not change 
LRS or alter the impact of exercise training on Lifetime Risk Score (Time*Medication 
p=0.972 and Time*Training*Medication p=0.476, respectively, Figure 5.3).
Vascular measurements
Common femoral artery diameter. Due to technical problems, we had to exclude 7 
participants from the echo Doppler measurements. Exercise training was associated 
with an increase in CFA diameter of 6% (Time*Training p=0.043). Use of the 
AGE-crosslink breaker Alagebrium did not change CFA diameter or alter the 
magnitude of effect observed with exercise training (Time*Medication p=0.948 and 
Time*Training*Medication p=0.837, respectively, Table 5.2).
Arterial stiffness. We did not observe changes in arterial stiffness measured with 
pulse wave velocity after any of the four 1-year interventions (Table 5.2).
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Figure 5.2 Exercise training groups (solid lines: with Alagebrium ; with placebo 
) significantly improved their physical fitness, while the control groups (dashed 
lines: with Alagebrium ; with placebo ) showed a small, non-significant, decline 
in VO2max.
Figure 5.3 Lifetime Risk Score improved significantly in the exercise training 
groups (solid lines: with Alagebrium ; with placebo ) while the control groups 
(dashed lines: with Alagebrium ; with placebo ) did not change significantly. 
Alagebrium had no influence on the Lifetime Risk Score.
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Figure 5.4 Mean blood flow response to intra-arterial infusion of vasoactive sub- 
stances. No changes were observed in mean blood flow response to increasing 
dosage of vasoactive substances between any of the four groups during the year 
of intervention: exercise training & Alagebrium (solid line + ), exercise training & 
placebo (solid line + ), control & Alagebrium (dashed line + ), and control & placebo 
(dashed line + ). Pre = baseline measurements, post = after 1-year interventions.
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Figure 5.5 Blood flow ratio response to intra-arterial infusion of vasoactive sub- 
stances. No changes were observed in blood flow ratio (infusion/control leg) 
response to increasing dosage of vasoactive substances between any of the four 
groups during the year of intervention: exercise training & Alagebrium (solid line + ), 
exercise training & placebo (solid line + ), control & Alagebrium (dashed line + ), 
and control & placebo (dashed line + ). Pre = baseline measurements, post = 
after 1-year interventions.
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Endothelial function. All participants received ACh and SNP, and by design 24 
participants were given L-NMMA. Due to technical problems, 8 participants were 
excluded from analyses (Figure 5.1). We found no significant effect of the interventions 
(exercise training, Alagebrium, or both) on blood flow or blood flow ratio responses 
to the incremental doses of ACh, SNP or L-NMMA (all p>0.10, Figures 5.4 and 5.5). 
In addition, no differences were observed among the four groups in blood flow or 
blood flow ratio responses to the pharmacological stimuli at baseline as well as after 
one year of intervention (Figures 5.4 and 5.5).
Discussion
We examined the effects of the AGE-crosslink breaker Alagebrium, alone and in 
combination with aerobic exercise training on endothelial function, arterial stiffness 
and cardiovascular risk in sedentary older individuals. Although our interventions 
were performed successfully (i.e., improvement in physical fitness of 15% and drug 
intake compliance of >95%), none of the interventions improved endothelial function 
or arterial stiffness. Nonetheless, the Lifetime Risk Score improved significantly in the 
exercise training groups, while the AGE-crosslink breaker was not associated with 
any further improvement. Therefore, the cardioprotective effects of 1-year exercise 
training in previously sedentary older subjects cannot be potentiated by the 
AGE-crosslink breaker Alagebrium, nor be explained by improvements in endothelial 
function or arterial stiffness.
Our primary outcome measure, the endothelial function, was measured using 
intra-arterial infusion of (incremental doses of) vasoactive drugs, which is widely 
considered to be the “gold standard”.21,22 Despite a 15% improvement in physical 
fitness and >95% compliance in drug intake, neither endothelium-dependent or 
-independent vasodilation, nor the contribution of nitric oxide to basal vascular tone, 
changed in any group over the intervention period. While most studies investigating 
Alagebrium have focused on arterial and ventricular stiffness, only one study 
examined the influence of short term (8 weeks) Alagebrium on endothelial function.9 
They reported an improvement in brachial artery endothelial function. However, this 
outcome was measured in 10 patients with isolated systolic hypertension (versus our 
healthy older individuals), in a different vascular bed (i.e., a conduit artery in the upper 
arm versus resistance vessels in the lower limbs in the present study), and using the 
widely used method of flow mediated dilation; i.e., an indirect method to measure 
endothelial function.
Even though there is consistency in the literature about the positive effects of exercise 
training on improving endothelial function in patient groups in whom endothelial 
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function is initially depressed, the effect of exercise training on endothelial function of 
subjects with marginal endothelial dysfunction is less obvious.19,24,25 In contrast to 
several exercise training studies that reported improved endothelial function in the 
brachial artery after training,2,11,12 the endothelial function in the lower limbs did not 
improve in our study groups. A first explanation may relate to differences in vascular 
responses between the arms and legs, with lower limbs being less responsive to 
exercise training as the lower limbs already demonstrate a higher activity level than 
the upper limbs during daily living (e.g., during walking, cycling, climbing the 
stairs).26,27 Another explanation for this discrepancy may be the long duration of 
exercise training in our study. Indeed, previous studies found that exercise training 
initially leads to functional adaptations (improved endothelium), followed by structural 
adaptations (increase in vascular diameter) when exercise training continues, 
allowing endothelial function to return towards baseline levels.24 Interestingly, we 
observed an increase in CFA diameter in the exercise training groups, most likely as 
a result of the repeated exposure of elevation in shear stress on the arterial wall 
during exercise.24 Subsequently, functional endothelial responses might have 
returned to baseline near the end of our study. However, this remains speculative 
since we did not perform repeated measures to assess the time course of endothelial 
function.
We found no change in arterial stiffness after our interventions. The observation of 
unaltered stiffness after training is in line with a recent study that found that intrinsic 
structural characteristics of the arterial wall remained unaffected in previously 
sedentary elderly after one year of exercise training.28 However, both animal and 
human studies found that Alagebrium decreased arterial stiffness.8,9,15,29 In our 
study, we found a small, albeit non-significant, trend of Alagebrium to improve central 
PWV. More recently, the combination of Alagebrium with exercise training, in a design 
similar to the present study but performed in rats, reversed the effects of cardiovascular 
aging in older sedentary rats.13 Differences between studies not only in doses of 
Alagebrium and exercise, but also in species examined may explain these results.
An important difference between our study and previous human studies that 
examined AGE-crosslink breakers is the inclusion of patient populations versus 
non-diseased participants in our study. Cardiovascular patients demonstrate a priori 
endothelial dysfunction and arterial stiffening that likely exceeds that of non-diseased, 
sedentary older individuals. Therefore, interventions in such populations are more 
amenable to an improvement. Nonetheless, the rationale of our study to examine 
older individuals is strong, since it is known that this population is associated with an 
increased cardiovascular risk, has decreased endothelial function and reports stiffer 
arteries compared with young individuals.1,2,10-12
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This study represents the longest duration of therapy with an AGE-crosslink breaker 
in humans reported in the literature, while we are the first to combine AGE-crosslink 
breakers with exercise training in humans. Some short duration (open-label) 
AGE-crosslink breaker studies with patient groups found an improvement in 
endothelial function 9 and a decrease in arterial and possibly myocardial stiffness,8,9,29 
while a longer 9-month study with stable heart failure patients showed no 
improvements in cardiac function with Alagebrium.30
Whilst the lack of improvement in endothelial function and arterial stiffness after a 
1-year intervention is somewhat disappointing, our results strongly reinforce previous 
suggestions that vascular changes induced by biological aging and physical 
inactivity cannot be easily reversed. According to Byberg et al.,31 it takes several 
years for middle-aged men to achieve a decrease in (all cause) mortality after 
becoming physically active after years of physical inactivity. Also in our study, we 
included older subjects who have not performed (regular) exercise for the last several 
years. Thus, despite the strong rationale for direct effects of AGE-crosslink breaker 
Alagebrium and exercise training on the arterial wall, our 1-year intervention may be 
insufficient to undo the negative effects of decades of sedentary aging.
Despite the absence of a direct effect on the vasculature, significant improvement in 
physical fitness has important health benefits.31,32 Physical fitness has recently been 
demonstrated to have the strongest predictive capacity for future cardiovascular 
diseases and all-cause mortality.33,34 Indeed, the improvement in physical fitness in 
the exercise training groups importantly contributed to the significant improvement in 
Lifetime Risk Score, while Alagebrium did not have any (additional) effects. Therefore, 
it must be emphasized that, despite the absence of a direct vascular effects, the 
performance of a 1-year exercise training program in previously sedentary elderly 
resulted in a significant and clinically meaningful reduction in risk for future 
cardiovascular disease.
Limitations and strengths
The use of invasive and highly valid measures of endothelial function, the long 
intervention period with a unique combination of novel interventions, and the high 
compliance with drug-intake and exercise training represent unique aspects of our 
study. Nonetheless, our study has a number of potential limitations. For example, 
power analysis supported a sample size of 8-10 participants per group to detect 
relevant differences with a small chance of type II error. Even though not all participants 
could be included in the analysis of the endothelial function, even the Control & 
Alagebrium group (n=10) failed to show differences after the one year intervention. 
Nor were there trends in any of the other groups. Thus, even if all data from the 
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venous occlusion plethysmography could have been used, it is unlikely that a physi-
ologically meaningful improvement in endothelial function was missed. Also, arterial 
stiffness, with presumably sufficient participants per group, did not improve with 
these interventions. This suggests that the beneficial effects of exercise training on 
cardiovascular risk are not explained by improvements in endothelial function or 
arterial stiffness. Another potential limitation is that we did not measure blood levels 
and pharmacokinetics of Alagebrium. However, we were meticulous at ensuring 
compliance with the study medication. Moreover, the doses used in this study were 
comparable to the doses used in other pre-clinical and clinical trials where an effect 
of Alagebrium to break AGE-crosslinks was evident.3,8,14,15
Conclusion
One year of exercise training in older individuals significantly improved physical 
fitness and lifetime risk for cardiovascular disease without affecting endothelial 
function or arterial stiffness. The use of the AGE-crosslink breaker Alagebrium had no 
independent effect on vascular function, nor did it potentiate the effect of endurance 
training. Despite the benefits and cardioprotective effects of exercise training for 
older individuals, neither exercise nor Alagebrium (either alone or in combination) 
was able to reverse the effects of decades of sedentary aging on the vasculature.
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General discussion
“We cannot solve our problems with the same thinking we used  
when we created them.” Albert Einstein (1879-1955)
When we started the research described in this thesis several years ago, the studies 
concerning the effects of advanced glycation end-products (AGEs) on the cardio- 
vascular system and the influence of the AGE-crosslink breaker Alagebrium thereon 
were very promising. The first animal 1-4 and human studies showed beneficial effects 
of Alagebrium in improving cardiovascular stiffness 5,6 and endothelial function.7 
Unexpectedly, a large randomized clinical trial with patients with chronic heart failure 
showed no improvements in physical fitness level or diastolic heart function.8 
Together with our colleagues from the Institute of Exercise and Environmental 
Medicine, Dallas, Texas, USA, we found no changes in arterial stiffness, endothelial 
function or in cardiac left ventricular hemodynamics and geometry in a group of 
non-exercising older individuals without clinical or symptomatic cardiovascular 
diseases.9,10 The hypothesis that Alagebrium could reduce cardiovascular 
complications in patients with diabetes, hypertension, heart failure and aging was 
based on the beneficial animal and human studies. Surprisingly, in our studies 
Alagebrium did not show these beneficial effects and the question remains what the 
overall conclusion on the potential effects of Alagebrium in humans should be.
In this chapter I will discuss the rationale of AGEs in aging physiology, followed by an 
overview of literature with studies involving Alagebrium and possible explanations for 
the different outcomes. Next, the knowledge concerning plasma AGEs and tissue 
AGEs will be discussed, and new data will be presented on the influence of exercise 
training and Alagebrium on plasma AGEs. I will conclude this general discussion with 
a reconsideration of advanced glycation end-products in human aging and options 
for future research will be addressed on how to improve healthy aging by addressing 
the AGE challenges.
AGEs in aging physiology
AGEs (patho)physiology
AGEs are formed when a reducing sugar non-enzymatically reacts with a biological 
amine from a protein, lipid or amino acid to produce a Schiff base. This initial reaction 
is swift, highly reversible and can undergo further chemical rearrangements to form 
a more stable glycated protein, an Amadori product. This is still reversible, but it can 
undergo structural rearrangements through a series of reactions such as oxidation, 
dehydration and degradation to form irreversible complex arrangements of 
crosslinked proteins, the Advanced Glycation End-products or AGEs.11-14 Due to the 
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irreversible nature of AGEs, they accumulate with aging leading to unfavorable 
situations and age-related complications.15-17
Multiple mechanisms have been proposed by which AGEs are detrimental in aging 
physiology. First, AGEs damage cells and tissues by forming cross-links with proteins 
in the extracellular matrix.18 These crosslinks result in a decrease in elasticity and 
increase of stiffness of tissues.19,20 Second, circulating AGEs bind to cellular receptors 
(RAGEs) and activate cell signaling pathways with subsequent modulation of gene 
expression, cascades of inflammatory responses and induction of oxidative 
stress.21-24 Oxidative stress, on the other hand, increases the formation of AGEs 
resulting in a vicious cycle.25 Third, intracellular glycation of proteins may lead to 
impaired cell function and reduction of the expression of endothelial nitric oxide 
synthase (eNOS) leading to endothelial dysfunction.26 Furthermore, AGEs quench 
nitric oxide (NO) leading directly to inactivation of NO and induce the expression of 
the potent vasoconstrictor endothelin-1 leading to a further deterioration of endothelial 
function.12,27,28 Since AGEs accumulate slowly over the years, older individuals 
encounter more effects of AGEs and this may contribute to the development of 
cardiovascular diseases.
AGEs and cardiovascular diseases
AGEs affect virtually every tissue in the body,19 but the most examined and elaborate 
influence of AGEs is that on the cardiovascular system. The best evidenced 
consequence of AGEs is the accumulation in the extracellular matrix that contributes 
to stiffening of the arterial walls and myocardium.11,15,20,29 Arterial stiffening induces 
arterial systolic hypertension and an increase in pulse pressure, which is a strong 
predictor for the development of cardiovascular morbidity and mortality.30-32 Besides 
the accumulation of AGEs in the arterial walls, AGEs also accumulate in the 
myocardium which leads to stiffening of the myocardium resulting in heart failure. 
Both conditions, arterial and myocardial stiffening, are associated with age-related 
diseases and mortality.
Besides the influence of AGEs on structural vascular changes, AGEs also influence 
the endothelial function. Healthy vascular endothelium plays a crucial role in the 
protection of cardiovascular diseases by protecting against the development of 
 atherosclerosis and maintaining vascular tone and homeostasis.33,34 As mentioned 
above, AGEs activate RAGEs causing cascades of inflammatory responses, induction 
of oxidative stress, reduced availability of NO, and induction of endothelin-1. This all 
contributes to endothelial dysfunction which precedes the development of athero-
sclerosis and thereby increases the risk for cardiovascular and cerebrovascular 
diseases.35 Endothelial function is known to decrease with aging.36
The exact interaction between the development of age-related diseases and the 
influence of accumulation of AGEs thereon remains unclear. Probably AGEs are part 
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of the accumulation of molecular and cellular damage that is accompanied with 
aging, and thus AGEs may contribute to age associated morbidity and mortality.
The rationale for the AGE-crosslink breaker 
Alagebrium as a cardiovascular drug
The recognition that AGEs play a role in the development of cardiovascular diseases 
was driving the search for novel agents that could interact with the AGE-patho-
physiology and thereby lower cardiovascular risk. In 1996 a new agent was created, 
phenylthiazolium bromide, to specifically break already formed AGE-crosslinks.37 
Even though this drug was not further developed because of the instability in aqueous 
solutions,38 it provided proof of concept that AGE-crosslink breakers are potential 
pharmacological drugs. Based on this experience, ALT-711, also known as Alagebrium, 
a thiazolium derivative (3-phenacyl-4,5-dimethylthiazolium chloride) was developed 
in 1998 as the highly potent breaker of AGE-crosslink between proteins.5 Multiple 
animal 1-4,39,40 and human studies 5-7 suggested that by cleaving AGE-crosslinks, 
Alagebrium could restore compliance of the aged and/or diabetic vasculature and 
the myocardium. Thus, the development of Alagebrium was a unique opportunity to 
reduce the cardiovascular risk and thereby improve the quality of life in populations 
at risk for cardiovascular diseases.
The next paragraphs will provide an overview of current literature concerning both 
animal and human studies (Table 6.1), and possible explanations for the different 
outcomes will be presented.
Animal studies
Primarily two animal models were used to examine the effects of Alagebrium: rats 
with streptozotocin-induced diabetes 1,4 and aged animals (dogs,2 monkeys 3 or rats 
39,40). The first in vivo study published was in 1998 by Wolffenbuttel et al..1 They found 
that three weeks treatment with Alagebrium (daily 1.0 mg/kg body weight) in diabetes 
induced rats reversed the large artery stiffness and reduced collagen crosslinking in 
the tail tendon. In 2003, Candido et al.4 confirmed that Alagebrium reduced the AGE 
deposition and collagen crosslinking in the myocardium of diabetic rats with a higher 
daily dose of 10.0 mg/kg body weight during sixteen weeks. Furthermore, the 
reduction in left ventricular mass and brain natriuretic peptide (BNP) expression 
suggested an improved cardiac function.
Besides studies with diabetic rats, also animal models of aging have been examined 
with similar findings. Asif et al.2 found a significant reduction of approximately 40% 
in age-related left ventricular stiffness in aged dogs after four weeks of treatment of 
Alagebrium (daily 1.0 mg/kg body weight). These results were confirmed in older 
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rhesus monkeys with improvements of arterial compliance and left ventricular function 
after three weeks treatment with Alagebrium (1.0 mg/kg body weight every other 
day).3 Similar to the study by Candido et al.4 in diabetic rats, Guo et al.39 found the 
reduction in AGE deposition and collagen crosslinking in the myocardium of aged 
rats and a reduction in left ventricular mass and improved diastolic function with a 
daily dose of 10.0 mg/kg body weight during sixteen weeks. Recently, an interesting 
study in which the individual and combined effects of four weeks of exercise training 
Table 6.1   Overview of literature.
Animal studies Population Trial design Dose of Alagebrium Positive/Negative outcome
Wolffenbuttel et al.  1 Diabetes induced rats Open label study 1 mg/kg body weight Positive
1998, PNAS 1-3 weeks 
Asif  et al.  2 Young and aged dogs Open label study 1 mg/kg body weight Positive
2000, PNAS 4 weeks 
Vaitkevicius et al.  3 Older rhesus monkeys Open label study 1 mg/kg every other day Positive
2001, PNAS Double crossover 3 weeks 
Candido et al.  4 Diabetes induced rats Open label study 10 mg/kg body weight Positive
2003, Circ Res 16 weeks 
Guo et al.  39 Young and aged rats Open label study 10 mg/kg body weight Positive
2009, J Geront Biol Sci 16 weeks 
Steppan et al.  40 Young and aged rats Randomized, placebo controlled trial 1 mg/kg body weight Positive
2012, Exp Gerontol Not blinded 4 weeks 
Patient studies
Kass et al.  5 Systolic hypertension Randomized, placebo controlled trial 210 mg per day Positive
2001, Circulation Double blind 8 weeks
Little et al.  6 Diastolic heart failure Open label study 210 mg twice daily Positive
2005, J Cardiac Failure LV ejection fraction ≥50%. 16 weeks
Zieman et al.  7 Isolated systolic hypertension Open label study 210 mg twice daily Positive
2007, J Hypertension Single blind 8 weeks
Hartog et al.  8 Chronic heart failure Randomized, placebo controlled trial 200 mg twice daily Negative
2011, Eur J Heart Failure LV ejection fraction <45%. Double blind 9 months
Healthy older individuals
Fujimoto et al. 9 
2013
Healthy older non-exercising 
individuals
Randomized, placebo controlled trial
Double blind
100 mg twice daily
12 months
Negative, except for a minor improvement in
LV stiffness when combined with exercise training
Oudegeest-Sander et al.  10
2013
Healthy older non-exercising 
individuals
Randomized, placebo controlled trial
Double blind
100 mg twice daily
12 months
Negative
Abbreviation: LV left ventricle
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and Alagebrium 1.0 mg/kg body weight were examined on cardiovascular properties 
in sedentary older rats, showed that the combination of exercise training and 
Alagebrium had synergistic effects, and significantly improved systolic and diastolic 
cardiac function, and decreased vascular stiffness in a rat model of aging.40 
In summary, the animal studies showed beneficial effects of Alagebrium on 
cardiovascular compliance, left ventricular function, AGE accumulation, and collagen 
crosslinking.
Table 6.1   Overview of literature.
Animal studies Population Trial design Dose of Alagebrium Positive/Negative outcome
Wolffenbuttel et al.  1 Diabetes induced rats Open label study 1 mg/kg body weight Positive
1998, PNAS 1-3 weeks 
Asif  et al.  2 Young and aged dogs Open label study 1 mg/kg body weight Positive
2000, PNAS 4 weeks 
Vaitkevicius et al.  3 Older rhesus monkeys Open label study 1 mg/kg every other day Positive
2001, PNAS Double crossover 3 weeks 
Candido et al.  4 Diabetes induced rats Open label study 10 mg/kg body weight Positive
2003, Circ Res 16 weeks 
Guo et al.  39 Young and aged rats Open label study 10 mg/kg body weight Positive
2009, J Geront Biol Sci 16 weeks 
Steppan et al.  40 Young and aged rats Randomized, placebo controlled trial 1 mg/kg body weight Positive
2012, Exp Gerontol Not blinded 4 weeks 
Patient studies
Kass et al.  5 Systolic hypertension Randomized, placebo controlled trial 210 mg per day Positive
2001, Circulation Double blind 8 weeks
Little et al.  6 Diastolic heart failure Open label study 210 mg twice daily Positive
2005, J Cardiac Failure LV ejection fraction ≥50%. 16 weeks
Zieman et al.  7 Isolated systolic hypertension Open label study 210 mg twice daily Positive
2007, J Hypertension Single blind 8 weeks
Hartog et al.  8 Chronic heart failure Randomized, placebo controlled trial 200 mg twice daily Negative
2011, Eur J Heart Failure LV ejection fraction <45%. Double blind 9 months
Healthy older individuals
Fujimoto et al. 9 
2013
Healthy older non-exercising 
individuals
Randomized, placebo controlled trial
Double blind
100 mg twice daily
12 months
Negative, except for a minor improvement in
LV stiffness when combined with exercise training
Oudegeest-Sander et al.  10
2013
Healthy older non-exercising 
individuals
Randomized, placebo controlled trial
Double blind
100 mg twice daily
12 months
Negative
Abbreviation: LV left ventricle
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Humans studies with cardiovascular patients
Human studies have primarily examined patient populations with either increased 
arterial stiffening (systolic hypertension and increased pulse pressure) 5,7 or myocardial 
stiffening (heart failure).6,8 After phase I clinical studies with Alagebrium, Kass et al.5 
performed the first human study, a randomized, double blind, placebo controlled 
trial in patients with arterial stiffening. Alagebrium 210 mg per day or placebo (2-to-1 
design) was given for eight weeks. Pulse pressure lowered and large artery compliance 
improved with Alagebrium compared with the placebo group. Another study that 
examined patients with isolated systolic hypertension used Alagebrium 210 mg twice 
daily for eight weeks in a single arm, open label trial.7 On group average Alagebrium 
resulted in a marginal enhancement in brachial artery endothelial function in ten 
patients in this study.
Furthermore, the effect of Alagebrium was studied in patients with diastolic heart 
failure and preserved left ventricular ejection fraction.6 This was again a single arm, 
open label trial in which Alagebrium 210 mg twice daily was used for sixteen weeks. 
Treatment resulted in a regression of left ventricular mass, improvement in left ventricular 
diastolic properties and subjectively perceived quality of life by the patients. The most 
recent randomized, double blind, placebo controlled, clinical trial examined heart 
failure patients with a reduced left ventricular ejection fraction and the influence of 
Alagebrium 200 mg twice daily or placebo during nine months.8 This study found no 
changes in exercise tolerance or in systolic or diastolic cardiac function.
Humans studies with healthy older individuals
Up to recently, only patients with arterial stiffness or heart failure have been examined 
with the AGE-crosslink breaker Alagebrium. However, even though researchers 
acknowledge the role of AGE accumulation with aging and induced age-related 
cardiovascular diseases, the older population had not yet been the subject of AGE- 
intervening investigations while this is a particularly interesting population to study 
due to the growing aging population. Therefore, we started an Alagebrium study in 
healthy older sedentary individuals together with our colleagues from the Institute of 
Exercise and Environmental Medicine, Dallas, Texas, USA (Table 6.1).9,10 Even though 
it is known that older individuals have stiffer arteries, stiffer myocardium and 
endothelial dysfunction,36,41,42 we did not find the results as were expected based on 
previous literature. Besides a modest improvement on age-related cardiac left 
ventricular stiffness when Alagebrium was combined with exercise training for a year, 
we did not find a significant improvement in arterial stiffness, endothelial function, 
hemodynamics or cardiac geometry.
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In summary, most patient oriented studies showed a positive effect of Alagebrium on 
cardiovascular structure and function, however, the more recent human studies with 
a long duration of intervention did not show beneficial effects of Alagebrium.
Importantly, in all human studies Alagebrium was well tolerated independent of 
dosage or duration. In the randomized trials, side effects were reported equally 
between the Alagebrium and placebo groups.5,6,8-10 Most common side effects were 
gastrointestinal symptoms and infections.
Understanding the different study outcomes
What could explain the differences between the convincing beneficial results from 
animal studies, the first human studies and the negative findings in the more recent 
human studies? Differences in study population, study design, dosage and duration, 
and measurement techniques may, at least partly, explain the different results.
Study population
Four clinical patient studies have been published: two with arterial stiffening 5,7 and 
two with heart failure patients.6,8 Three of these studies have shown beneficial results. 
The randomized clinical trial including heart failure patients (n=102, mean age 62 
years) with reduced ejection fraction (≤45%) showed no improvement in cardiac 
function or in exercise tolerance after nine months Alagebrium 400 mg per day,8 while 
the other (open label) study including heart failure patients (n=23, mean age 71 
years) with preserved ejection fraction (≥50%) did find an improvement in cardiac 
function after sixteen weeks 420 mg per day.6 In both studies an equal ratio of patients 
were in New York Heart Association (NYHA) class II or III (ratio 3:2). Even though we 
cannot completely exclude that the difference between the involvement of systolic 
dysfunction could influence these results, patient selection does not seem to explain 
the main differences in results between these two studies. There is, however, an 
important difference in risk of bias due to the study design (see below).43
Cardiovascular patients are more likely to show improvements when using Alagebrium 
compared with healthy older individuals. Since AGEs accumulate with aging, healthy 
older individuals are likely to improve cardiovascular compliance with the use of 
Alagebrium.12,44,45 The aged animal models showed improvements in cardiovascular 
stiffness and function with Alagebrium.2,3,39,40 Steppan et al.40 showed in aged rats 
that Alagebrium combined with exercise training had a synergistic effect and 
significantly improved cardiac function and decreased vascular stiffness. It was 
therefore unexpected that our trial 10 and the one from our colleagues in Dallas, 
Texas, USA,9 did not show relevant improvements in vascular and myocardial 
structure and function in older individuals after one year Alagebrium intervention nor 
with the combined intervention with exercise training.
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Apparently, the effect of Alagebrium is different in animals versus humans. In addition, 
it seems that Alagebrium has a more pronounced effect in cardiovascular patients 
than in healthy older individuals.
Study design
The animal studies were all open label studies. Two of the patient studies 6,7 were 
open label and two were randomized clinical trials 5,8 of which Kass et al.5 increased 
power by using a 2-to-1 design favoring Alagebrium. Thus, only two of the ten 
published studies examining the effects of Alagebrium before 2013 were randomized, 
placebo controlled, double blinded trials, of which only one with an equal distribution 
between Alagebrium and placebo.8 Open label trials are more likely to be (uninten-
tionally) biased, especially when analyzing interpretable data.43 Therefore, results 
and conclusion from these studies should be interpreted with caution. The two 
high-quality clinical trials showed conflicting results with one study showing a positive 
effect of Alagebrium on arterial stiffening 5 and one study finding no effect on cardiac 
stiffening.8 Our recent studies in healthy older individuals add new high quality clinical 
trials without profound beneficial effects of Alagebrium on cardiovascular structure 
and function.9,10
Dosage and duration
Dosage and duration of Alagebrium were different in most animal and human studies. 
The animal models used daily dosages ranging from 0.5 mg/kg body weight to 10.0 
mg/kg body weight per day for one to sixteen weeks. The human studies used 
dosages between 200 mg and 420 mg per day with durations from eight to fifty-two 
weeks. Dosage did not seem to influence the outcomes, since both higher and lower 
dosages resulted in positive or negative results. For example, 210 mg per day (eight 
weeks) resulted in improved arterial compliance,5 while 200 mg per day (twelve 
months) did not.10 Also, 420 mg per day (sixteen weeks) improved left ventricular 
diastolic function,6 while 400 mg per day (nine months) did not.8
On the other hand, it seems odd that the long duration interventions (nine and twelve 
months) 8-10 did not show the beneficial effects to the same degree as the short-term 
(eight and sixteen weeks) studies.5-7 In animals, the duration did not influence the 
beneficial results since all studies (one to sixteen weeks) showed improvements in 
cardiovascular structure and function, even though three weeks Alagebrium resulted 
in a larger improvement in carotid artery compliance in diabetic rats than one week 
Alagebrium.1 In older rhesus monkeys three weeks was sufficient to improve the 
carotid artery compliance and left ventricular function. The improved vascular 
compliance persisted over time with a gradual return to baseline 39 weeks after 
treatment was stopped.3
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It is difficult to explain why long-term intervention clinical studies with Alagebrium did 
not show beneficial effects whereas short-term intervention studies did. One could 
speculate that Alagebrium works primarily in the initial phase and that in the long-term 
intervention studies the effect has already faded. If this is the case, this would mean 
that Alagebrium has no use as a long-term intervention to improve the cardiovascular 
system.
Measurement techniques
Differences in measurement techniques are likely to explain part of the different 
outcomes. For example, cardiac function was measured invasively with catheteriza-
tion and pressure-volume curves 2,9,40 and non-invasively using echocardiogra-
phy.2,3,6,8 The invasive measurement is more accurate, especially when used in 
decapitated or anesthetized animals due to minimization of the influence of stress, 
breathing, blood pressure, and depression of the autonomic nerves system. Magnetic 
resonance imaging (MRI) 6 and echocardiography 3,39 were used to measure cardiac 
mass. It is known that MRI is more sensitive to measure cardiac mass than echocar-
diography, whereas decapitating animals 4,39 to measure cardiac mass is more 
sensitive than MRI. Possibly, the use of echocardiography in the randomized, double 
blind, placebo controlled, clinical trial that examined heart failure patients with a 
reduced left ventricular ejection fraction 8 was not sensitive enough to measure small 
changes induced with Alagebrium. On the other hand, the study performed in Dallas, 
Texas, USA, showed only a modest improvement in left ventricular stiffening and not 
on other invasively or sensitively measured cardiac parameters.9 However, these 
were healthy older individuals and may have been less amenable to benefit from 
Alagebrium compared with heart failure patients.
Arterial stiffness was measured using different techniques, for example using MRI to 
calculate thoracic aorta distensibility,6 echo Doppler to calculate pulse wave 
velocity,5,40 and arterial pressure waveforms and carotid augmentation index were 
measured using tonometry.3,5,7 In addition, repeated measurements improve 
statistical findings.3 Furthermore, one of the advantages of animal studies is the 
ability to perform both in vivo and in vitro measurements of arterial stiffness and 
carotid artery compliance 1 and to take myocardial biopsies to measure the actual 
AGE-crosslinks and tissue AGE accumulation using sophisticated techniques, such 
as electron microscopy and mitochondrial DNA measures.4,39
Endothelial function was measured with different methods. It was measured invasively 
in the resistance vessels in the lower limb in our study (Chapter 5) 10 with intra-arterial 
infusion of vasoactive substances and venous occlusion plethysmography, which is 
considered to be the gold standard.46,47 It was also measured non-invasively in the 
conduit artery of the arm using the frequently used method of flow mediated dilation.7 
This is, however, an indirect method to measure endothelial function and is more 
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susceptible to personal interpretation during analysis, especially when used in an 
open label study.7
Recapitulating, the differences in measurement techniques do not easily explain the 
different outcomes. There are studies with positive outcomes using sophisticated 
and excellent measurement techniques, and also studies with weaker techniques. 
The contrary is also seen that studies without beneficial findings used sophisticated 
and invasive measures, but also non-invasive measures.
In conclusion, neither the differences between the animal and human studies, nor the 
differences between the multiple human studies can be easily explained. Perhaps a 
mismatch exists between the translation from animal to human studies. This has 
been described before and may be due to failure of the animal models to mimic 
clinical diseases or functions adequately.48 However, this does not explain the 
discordance between the human studies concerning Alagebrium. This discordance 
is most likely due to the inclusion of different populations (patients versus healthy 
older individuals) as well as study design and study duration. 
Does Alagebrium break the established 
AGE-crosslink in human tissues?
One of the most important questions remains unanswered: does Alagebrium in fact 
break the established AGE-crosslink in human (cardiovascular) tissues? In tail 
tendons and in myocardial biopsies of rats, Alagebrium has been shown to reduce 
crosslinking of matrix proteins.1,4,39 On the contrary, the accumulation of AGEs in the 
skin of heart failure patients did not change with 9 months use of Alagebrium.8 None 
of the human studies has, due to eligible reasons, examined the AGE deposition 
before and after the use of Alagebrium in different cardiovascular tissues, e.g. 
myocardial biopsies or samples of the arterial walls. In addition to the inconclusive 
results, we cannot be certain that Alagebrium actually works as an AGE-crosslink 
breaker in cardiovascular tissues in humans. Contemplating the current data from 
this thesis and literature, it is not likely that Alagebrium will have a relevant impact on 
cardiovascular morbidity and mortality in the (healthy) aging population.
Plasma AGEs and tissue AGEs
In addition to the remaining uncertainties concerning Alagebrium, the interaction and 
clinical relevance between the level of plasma AGEs and tissue AGEs are still unclear. 
Accumulation of AGEs occurs throughout all organs, including in skin, neural, renal, 
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vascular and cardiac tissue.49,50 Numerous AGEs have been described. The most 
well known and extensively examined are Ne-(carboxyethyl)lysine (CEL), which is a 
putative marker of intracellular protein glycation, Ne-(carboxymethyl)lysine (CML), 
which is the major non-crosslinking AGE and the potent ligand of RAGE (AGE-RAGE 
axis), and pentosidine, which is one of the cross-linking AGEs.13,18,51,52 Even though 
multiple studies have confirmed positive associations between elevated levels of 
circulating AGEs and a variety of cardiovascular diseases in individuals with or 
without type 2 diabetes mellitus and with or without pre-existing cardiovascular 
diseases,52-56 lack of associations have also been found.57-59 Furthermore, it is 
uncertain whether elevated levels of plasma AGEs adequately reflect the burden of 
the glycation pathway in tissues,60 because intracellular glycation is thought to be the 
major local source of AGEs and not all AGEs may end up in the circulation.57,61 
Since many questions concerning plasma and tissue AGEs are still unanswered, we 
tried to gain more insight by examining the levels of plasma AGEs and linking these 
to cardiovascular measurements and interventions such as exercise training and the 
use of Alagebrium. In this section we analyzed two sets of data using our sedentary 
older individuals and using unique data with healthy aging athletes. 
Plasma AGEs and vascular stiffening
It is difficult to obtain human cardiovascular biopsies to examine the relation between 
plasma and tissue AGEs. Therefore, a derivative parameter of tissue AGEs could be 
used, such as arterial stiffness. To obtain some insight in this complex interplay 
between plasma and tissue AGEs, we examined the correlations between protein- 
bound plasma AGEs and pulse wave velocity (PWV) as an indicator of arterial 
stiffness in healthy older individuals (population described in Chapter 5). We found a 
negative correlation between CEL and both the central and peripheral pulse wave 
velocity in healthy older individuals (Table 6.2), and no significant correlation for the 
other AGEs. Thus, with increasing levels of pulse wave velocity (increased arterial 
stiffness), the level of plasma CEL declined. This is contradictory to what we expected 
and reinforces the gap in current understanding of the relation and interaction 
between plasma AGEs and tissue AGEs. They almost appear to be two separate 
identities. This is in line with the variable results of multiple investigations that either 
found or did not find an association between the level of plasma AGEs and the 
presence of cardiovascular diseases. 52-61
Influence of exercise training on plasma AGEs
Since it is known that AGEs are formed under the influence of oxidative stress, 
strategies to reduce the production of oxidative stress may reduce the amount of 
AGEs. Exercise training is renowned for its beneficial cardiovascular effects,62-64 and 
lifelong exercise training prevents age-related endothelial dysfunction by preserving 
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nitric oxide availability due to reducing oxidative stress.65 Thus, one could hypothesize 
that exercise training, and especially lifelong exercise training, reduces oxidative 
stress and increases the anti-oxidant capacity and nitric oxide availability, and 
thereby reduces the formation of AGEs. Furthermore, lifelong endurance training 
protects from the development of age-related cardiovascular stiffening,66 possibly by 
reducing the accumulation of AGEs. With these theories in mind, we compared the 
effects of lifelong exercise training with a long-term sedentary lifestyle on the level of 
plasma AGEs in healthy older individuals without clinical cardiovascular diseases. 
For this purpose, we combined two study populations of healthy individuals that were 
either lifelong athletes or sedentary individuals (Table 6.3). The lifelong athletes 
exercised between three to seven sessions a week at moderate to high intensity level 
for at least one hour per session for at least the past twenty years. The sedentary 
individuals did not perform regular exercise (≤1 hour per week) during the last 5-10 
years (described in Chapter 5).
Lifelong exercise training
Unlike we hypothesized the lifelong athletes had significantly higher levels of protein 
bound CML and CEL, and a substantially higher level of pentosidine compared with 
the sedentary individuals (Figure 6.1). We also found a positive correlation between 
physical fitness level (expressed as VO2max (mlO2/min/kg body weight)) and CML 
(Figure 6.2). It seems that (lifelong) exercise training might induce the production of 
AGEs. One can speculate on the mechanisms. Perhaps exercise training induces 
(temporarily) more oxidative stress, especially during high intensity training,67 as 
performed by the lifelong athletes, and thereby stimulates the formation of AGEs. 
Nevertheless, this does not explain the discrepancy between the increased levels of 
plasma AGEs and the tissue induced beneficial effects of lifelong exercise training on 
endothelial function and cardiovascular stiffening.66 
Table 6.2  Correlation between levels of protein-bound plasma AGEs and 
 central and peripheral pulse wave velocity (PWV) in 44 healthy older individuals.
CML CEL Pentosidine
Central PWV r = -0.130
p = 0.417
r = -0.340
p = 0.030
r = -0.061
p = 0.706
Peripheral PWV r = -0.284
p = 0.076
r = -0.344
p = 0.030
r = -0.017
p = 0.915
Statistical analysis: Pearson correlation using SPSS 20.0.
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Table 6.3   Characteristics of the lifelong athletes versus sedentary individuals.
Lifelong  
athletes
Sedentary  
individuals
p-value
General characteristics N = 12 N = 44
   Gender (M  :  F) 12  :  0 25  :  21
   Age (years) 64 ± 8 70 ± 4 0.001
   VO2max (mlO2/min/kg) 44.7 ± 10.3 24.4 ± 4.3 <0.001
Hemodynamics
   Systolic blood pressure (mmHg) 140 ± 12 133 ± 13 0.061
   Diastolic blood pressure (mmHg) 85 ± 11 78 ± 9 0.022
   Pulse Pressure (mmHg) 55 ± 10 53 ± 9 0.620
Blood samples
   Glucose (mmol/l) 4.6 ± 0.3 5.0 ± 0.5 0.002
   HbA1c (%) 5.5 ± 0.3 5.7 ± 0.3 0.174
   Total cholesterol (mmol/l) 5.5 ± 0.8 5.4 ± 0.9 0.812
Data are presented as mean ± standard deviation. Statistical analysis: unpaired t-test.
Figure 6.1 The lifelong athletes (light bars) have significantly higher levels of 
protein bound Ne-(carboxymethyl)lysine (CML) and Ne-(carboxyethyl)lysine (CEL) 
and a substantially higher level of pentosidine compared with the sedentary 
individuals (dark bars).
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Short-term exercise training
One year of exercise training did not change the level of plasma AGEs (Table 6.4). It 
is known that one year of exercise training does not induce major improvements in 
cardiovascular stiffening after decades of physical inactivity.9,10,68 In the same line, 
tissue AGEs may not change sufficiently with one year exercise training after decades 
of physical inactivity. On the other hand, based on the possible formation of oxidative 
stress and/or anti-oxidants with exercise training, a change in plasma AGEs was 
expected. Goto et al.67 showed that moderate intensity exercise training augments 
endothelium function through an increased production of nitric oxide (NO), whereas 
high-intensity exercise training increases plasma concentrations of oxidative stress. 
Our training intervention was moderate to high intensity, thus a noteworthy increase 
in oxidative stress was not anticipated. On the contrary, a slight decrease in plasma 
AGEs was expected due to an increase in anti-oxidant capacity with moderate 
intensity training.
Influence of Alagebrium on plasma AGEs
In search of understanding the results in this thesis, we also analyzed the plasma 
AGEs in relation to the one year Alagebrium intervention. The level of plasma AGEs 
did not change with the use of Alagebrium or placebo (Table 6.4). Alagebrium, which 
Figure 6.2 A significant correlation was found between physical fitness level 
(expressed as VO2max) and protein bound Ne-(carboxymethyl)lysine (CML). This 
figure shows the correlation with the combined populations of the lifelong athletes 
(n=12, half open grey circles) and the sedentary individuals (n=44, closed circles). 
However, the correlation remains statistically significant when using the more 
homogenous group of only the sedentary individuals (n=44, r=0.327, p=0.037).
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should break tissue AGE-crosslinks, would not directly influence the plasma AGEs. 
However, it has been shown that Alagebrium reduces oxidative stress in aged rats 
that were treated with Alagebrium (high dose 10 mg/kg body weight) during 16 
weeks.39 Therefore, the anti-oxidant function of Alagebrium, which has also been 
described in laboratory settings,69,70 was thought to lead to lower levels of plasma 
AGEs with the one year treatment, especially in combination with the exercise training.
The lack of change in plasma AGEs with the use of Alagebrium, could be due to the 
differences in AGEs. There are AGEs that are more specific to intracellular damage, 
like CEL. CML, on the other hand, is more prominent in plasma and is known to be a 
potent ligand of the AGE-receptor (RAGE). Pentosidine is known to form crosslinks 
and was perhaps more susceptible to Alagebrium.18,52 Nevertheless, the common 
denominator in the formation of AGEs is oxidative stress 25 and Alagebrium has been 
shown to have anti-oxidant properties 39,69,70 and was, therefore, expected to lower 
the level of AGEs, especially in combination with exercise training. It can be argued 
that it takes several months to years for irreversible AGEs to form,13,14 but then the one 
year intervention should have been sufficient to show some changes. Furthermore, 
the blood samples were taken at multiple time-points (baseline and after 3, 6 and 12 
months), in fasting state under standardized conditions and kidney function was 
good in all participants. However, we did not take the diet into account. Thus, it is 
possible that dietary intake of AGEs could have influenced our results. Nevertheless, 
the variation between participants was similar and there were no outlier values within 
participants during the year intervention, thus the influence of diet is unlikely to have 
influenced our results relevantly.
The issue of plasma and tissue AGEs
The unexpected results concerning the plasma AGEs and the influence of lifelong 
and short-term exercise training, with and without the combination with Alagebrium, 
do not directly result in more insight into the relation between plasma AGEs and 
tissue AGEs. The cardiovascular effects that are likely to be induced by the tissue 
AGEs, e.g. cardiovascular stiffening, are contrary to the levels of plasma AGEs in 
lifelong athletes, e.g. higher levels of plasma AGEs with less cardiovascular stiffening. 
Also, the anti-oxidant effect of exercise training and of Alagebrium cannot be 
confirmed by changes in the levels of plasma AGEs. This reinforces the necessity to 
further investigate the relation between plasma and tissue AGEs in humans. 
Especially, if new treatment options for cardiovascular and/or age-related diseases 
aiming at AGE interventions will be examined.
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Chapter 6
Future implications for research on AGEs
Considering the data on Alagebrium and its influence on the cardiovascular system 
in relation with age-related changes, it must be noticed that the results in literature 
and this thesis are not supporting a clinically relevant effect of long-term use in 
healthy older individuals. At this moment, Alagebrium is not an evidence based 
method to reduce cardiovascular morbidity and mortality in cardiovascular patient 
populations or healthy older individuals. Even though accumulation of AGEs plays a 
role in (patho)physiology of cardiovascular and age-related diseases, the exact 
mechanism between plasma AGEs and tissue AGEs and, more importantly, ways to 
influence the detrimental effects of AGEs remain unknown. The most interesting 
topics for future research should first consider some basic questions. How are 
plasma AGEs and tissues AGEs related? What favors AGE accumulation in different 
tissues, besides the level of oxidative stress, and what are modifiable routes? Only 
after answering these questions, we may study how AGEs can be influenced to 
reduce the cardiovascular risk and burden in cardiovascular patients and aging 
individuals. Could lifestyle changes, such as reducing dietary intake of AGEs, 
positively influence plasma and/or tissue AGEs? Or could weight reduction and 
slowing down the epidemic of type 2 diabetes mellitus help to lower the AGEs burden 
and could this be a pathway towards improved cardiovascular outcomes?
Physical activity and exercise training have been shown to improve physical fitness 
and cardiovascular health in older individuals.62-64 However, these benefits could not 
be extrapolated to differences in plasma AGEs, since higher levels of plasma AGEs 
were found in lifelong athletes and no changes were found in plasma AGEs with one 
year of exercise training. Major direct effects of AGEs on cardiovascular parameters 
should, therefore, be hypothesized with caution.
Having translated preliminary work from bench to bedside, research should return to 
the bench again. The multiple metabolic pathways involved in plasma and tissue 
AGEs and the cardiovascular and age-related consequences should be disentangled 
first. In the meantime, exercise interventions should be used much more at the 
bedside, also in older individuals. We added some evidence to these well proven 
beneficial effects of exercise on cardiovascular aging. Remaining physically fit, also 
by maintaining regular daily life activities, prolongs healthy and independent living in 
older individuals.71 Therefore, encouraging individuals of all ages, but especially 
children and older individuals, to engage in physical activities will improve health 
worldwide, and especially in the sedentary and aging western societies. As such, the 
rhetorical question ’to exercise or not to exercise´  will translate itself in the physiological 
consequence of aging slowly or aging more rapidly. However, far more complex is 
the question t´o AGE or not to age’.
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Summary
On average, aging is characterized by a progressive decline in function across 
multiple organ systems and a reduced ability to maintain homeostasis. With 
advancing age, the incidence of chronic diseases, e.g. cardiovascular diseases, 
increases. Despite multiple interventions, such as stimulation of physical activity, 
cardiovascular diseases remain the leading cause of morbidity and mortality in 
modern societies, and especially in the aging population. Besides advancing age, 
risk factors such as physical inactivity and the accumulation of advanced glycation 
end-products (AGEs) are important contributing factors in the development of 
cardiovascular diseases. Increased arterial stiffness and endothelial dysfunction are 
known to play key roles in this age-related process. Even though exercise training has 
been shown to be beneficial and accumulation of AGEs is detrimental, the (combined) 
effect of exercise training and the developmental AGE-crosslink breaker Alagebrium 
in older individuals has not yet been examined. Therefore, the general aim of this 
thesis was to elucidate the individual and combined effects of exercise training and 
the AGE-crosslink breaker Alagebrium on different aspects of the vascular system in 
older individuals without pre-existing symptomatic cardiovascular diseases.
Chapter 1 presents an outline of the studies included in this thesis with extensive 
background information on aging, the effects of aging on the cardiovascular and 
cerebrovascular system, the influence of exercise training on vasculature in older 
individuals, the role of AGEs in the pathophysiology of cardiovascular diseases, and 
the influence of the experimental drug the AGE-crosslink breaker Alagebrium on the 
cardiovascular system. At the end of this first chapter, the aims and hypotheses of the 
individual chapters are presented.
In Chapter 2 we examined the influence of a lower or higher physical fitness level, 
due to daily life activities, on vascular function in a homogenous group of older 
non-exercising individuals. Vascular function was measured invasively using the 
upper leg model with intra-arterial infusion of vasoactive substances. We used the 
endothelium dependent vasodilator acetylcholine (ACh), the endothelium independent 
vasodilator sodium nitroprusside (SNP), and the nitric oxide synthase inhibitor 
NG-monomethyl-L-arginine (L-NMMA). Responses in blood flow changes were 
measured using venous occlusion plethysmography. Cardiovascular lifetime risk 
score was calculated using predictors such as age, gender, body mass index, 
diabetes mellitus, smoking, blood pressure, lipid levels and physical fitness level. The 
group with the higher physical fitness level had a better cardiovascular lifetime risk 
score and vascular function compared with the group with a lower physical fitness 
level. This study provides a physiological basis that supports the beneficial effects of 
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differences in physical fitness level related to daily life activities on cardiovascular 
health. Therefore, older individuals should be encouraged to enhance their daily life 
activities.
Chapter 3 describes the influence of physical activity on sleep characteristics in a 
group of young adults and older individuals. A one year exercise training program 
was performed with the older individuals to examine the influence of exercise training 
on sleep characteristics. We found that young adults with higher daily energy 
expenditure have a greater sleep efficiency, whilst this relationship was attenuated 
with advanced age. In contrast, we found no correlation between physical fitness and 
sleep characteristics in healthy young adults or older participants. This may explain 
the lack of improvement in sleep characteristics in healthy older participants with 12 
months of exercise training. Exercise training may be more successful in subjects 
with existing sleep disturbances to improve sleep characteristics rather than in 
healthy older individuals without sleep problems.
The effect of age on cerebrovascular function is described in Chapter 4. Significant 
differences were found in cerebral blood flow between the young and older individuals 
with a decline in cerebral blood flow velocity and an increase in cerebrovascular 
resistance with age. Nevertheless, the group of healthy older individuals, up to the 
age of 86 years, that we examined were able to maintain sufficient cerebral perfusion 
and cortical oxygenation by preservation of the dynamic cerebral autoregulation and 
cerebrovascular CO2 reactivity during maneuvers that mimic daily life activities.
The main results of this thesis are presented in Chapter 5 where the effects of a one 
year intervention with either exercise training and/or the use of the AGE-crosslink 
breaker Alagebrium 100 mg twice daily on cardiovascular health in older individuals 
are described. Even though one year of exercise training in older individuals 
significantly improved physical fitness and cardiovascular lifetime risk score, 
endothelial function and arterial stiffness did not improve. The use of the AGE-crosslink 
breaker Alagebrium had no independent effect on endothelial function, nor did it 
potentiate the effect of exercise training. Despite the clinical benefits and cardiopro-
tective effects of exercise training for older individuals, neither exercise training nor 
Alagebrium (either alone or in combination) was able to reverse the effects of decades 
of sedentary aging on the vasculature.
Chapter 6 reviews the knowledge that has been gained in the field of AGEs and the 
AGE-crosslink breaker Alagebrium throughout the past decade. The first animal and 
human studies showed promising results of Alagebrium in improving cardiovascular 
stiffness and endothelial function. Unexpectedly, recent clinical trials showed no or 
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only minor improvements in cardiovascular structure and function. Possible 
explanations are provided for the different study outcomes between the animal and 
human studies. For instance, a mismatch between animal to human studies is 
possible which may be due to failure of the animal models to mimic clinical diseases 
or functions adequately. Furthermore, discordances between the human studies 
concerning Alagebrium are discussed, such as inclusion of different populations 
(patient versus healthy older individuals), study design and study duration, and 
measurement techniques. 
In addition, we tried to gain more insight in how plasma and tissue AGEs may be 
linked by examining the levels of plasma AGEs and linking this to cardiovascular 
measurements. Furthermore, we examined the influence of lifelong and short-term 
(one year) exercise training and the use of Alagebrium on plasma AGEs. These 
results did not directly lead to more insight into the relation between plasma AGEs 
and tissue AGEs. This reinforces the necessity to further investigate the relation 
between plasma and tissue AGEs in humans. 
Finally, future perspectives and new research topics are presented and the importance 
of remaining physically fit, also by maintaining regular daily life activities, to prolong 
healthy and independent living in older individuals, is accentuated.
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In dit hoofdstuk geef ik een overzicht van de bevindingen die in dit proefschrift worden 
beschreven. Daarbij worden medisch-wetenschappelijke termen zoveel mogelijk 
achterwege gelaten en beschrijf ik de onderzoeksresultaten in begrijpelijke alledaagse 
taal.
Veroudering
Men zegt vaak “oud worden is een zegen, oud zijn valt tegen”. Bekende tekenen van 
veroudering zijn onder andere het krijgen van grijze haren, rimpels en achteruitgang 
in beweeglijkheid en zelfstandigheid. Daarnaast komen ook vaker chronische ziekten 
voor, zoals hart- en vaatziekten. Aangezien de bevolking steeds ouder wordt en 
mensen dus steeds meer te maken krijgen met ongemakken en ziekten die gepaard 
gaan met veroudering, wordt er veel onderzoek gedaan hoe we de negatieve 
gevolgen van veroudering kunnen verminderen.
Bij veroudering treedt er onder andere een verstijving van de wand van de bloedvaten 
op (vaatstijfheid). De toegenomen vaatstijfheid zorgt ondermeer voor hoge bloeddruk 
en verhoogde kans op een hartaanval of beroerte. Daarnaast vermindert de functie 
van de binnenbekleding van de bloedvaten (vaatfunctie). De vaatfunctie zorgt voor 
een verwijding of vernauwing van de bloedvaten ten behoeve van de juiste 
doorbloeding van de spieren en organen. Tevens beschermt een goede vaatfunctie 
tegen het ontstaan van opstoppingen en afsluitingen in bloedvaten. Een belangrijke 
oorzaak voor het ontstaan van vaatstijfheid en verminderde vaatfunctie zijn 
versuikerde eiwitten. Deze versuikerde eiwitten worden in het Engels “Advanced 
Glycation End-products”, ofwel AGEs, genoemd. De stapeling van AGEs vindt bij 
iedereen plaats maar omdat oudere personen meer tijd hebben gehad om deze 
AGEs te stapelen, ondervinden zij er meer hinder van. Nu is een belangrijke vraag 
hoe we de vaatstijfheid en verminderde vaatfunctie bij ouderen kunnen verbeteren.
Onlangs is er een nieuw medicijn ontwikkeld dat in dieronderzoeken heeft aangetoond 
dat het de versuikerde eiwitten kan afbreken en daarmee de vaatstijfheid en 
vaatfunctie kan verbeteren. Dit medicijn heet de “advanced glycation end-product 
(AGE-) crosslink breaker”, ofwel Alagebrium. In gezonde oudere personen is dit 
geneesmiddel nog niet onderzocht, maar het is de verwachting dat Alagebrium de 
vaatstijfheid en de vaatfunctie zal verbeteren. Het is al wel bekend dat lichamelijke 
beweging en sporten erg gezond zijn voor het hart en de bloedvaten, ook bij oudere 
personen. Dit brengt ons tot het belangrijkste doel van dit proefschrift: meer inzicht 
krijgen in de (gecombineerde) effecten van Alagebrium en van sporten op het 
functioneren en op de structuur van bloedvaten bij gezonde oudere personen.
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Hoofdstuk 1 Introductie van het proefschrift
In dit hoofdstuk wordt uitgebreide achtergrond informatie gegeven over veroudering, 
de invloed van veroudering op de bloedvaten in het menselijk lichaam, de effecten 
van sporten op de vaatfunctie bij ouderen, de rol die AGEs spelen in het ontstaan van 
hart- en vaatziekten, en potentiële effecten van het nieuwe geneesmiddel Alagebrium. 
Aan het einde van dit hoofdstuk worden de doelstellingen en verwachtingen 
beschreven van de individuele hoofdstukken van dit proefschrift.
Hoofdstuk 2 De invloed van lichamelijke conditie op de vaatfunctie 
bij niet-sportende ouderen
In dit hoofdstuk onderzoeken we de invloed van een lagere of hogere lichamelijke 
conditie (fysieke fitheid) ten gevolge van dagelijkse activiteiten op de vaatfunctie in 
een groep niet-sportende ouderen. De vaatfunctie werd gemeten door via een infuus 
in de slagader van het bovenbeen drie verschillende middelen in te brengen. Deze 
middelen zorgden voor een verwijding of vernauwing van de bloedvaten waardoor 
de doorbloeding in het bovenbeen veranderde. Deze verandering in doorbloeding 
werd gemeten door zogenaamde kwiktouwtjes die oprekken of inkrimpen. Daarnaast 
werd het risicoprofiel voor het ontstaan van hart- en vaatziekten berekend. Dit werd 
berekend met een formule waarbij onder andere leeftijd, geslacht, verhouding lengte 
en gewicht, aanwezigheid van suikerziekte, rookgedrag, bloeddruk, cholesterolwaar-
den en lichamelijke conditie werden meegenomen. De groep met de hogere 
lichamelijke conditie had een betere vaatfunctie. Zij reageerden beter op de 
verschillende middelen om de doorbloeding te veranderen. Tevens hadden zij een 
gunstiger risicoprofiel voor hart- en vaatziekten vergeleken met de groep met een 
lagere lichamelijke conditie. Dit onderzoek ondersteunt de theorie dat de hoeveelheid 
dagelijkse lichamelijke activiteiten een gunstig effect hebben op de gezondheid van 
hart- en bloedvaten. Op grond hiervan moeten oudere personen meer gestimuleerd 
worden om hun dagelijkse lichamelijke activiteiten uit te breiden en meer te gaan 
bewegen.
Hoofdstuk 3 De invloed van lichamelijk conditie en dagelijks 
energieverbruik op de slaapeigenschappen bij jongeren en ouderen
Dit hoofdstuk beschrijft de relatie tussen lichamelijke conditie en dagelijks energie-
verbruik op de slaapeigenschappen in een groep jongeren en een groep ouderen. 
Daarnaast werd er gedurende een jaar een sporttrainingsprogramma uitgevoerd 
door een groep oudere personen om de invloed van sporttraining op de slaapeigen-
schappen te onderzoeken. Onze resultaten tonen aan dat de jongeren met een hoger 
dagelijks energieverbruik een betere slaapkwaliteit hebben, terwijl dit verband bij 
oudere personen is verzwakt. Desondanks vonden we geen verband tussen 
lichamelijke conditie en slaapeigenschappen bij jongeren en bij oudere personen. Dit 
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kan een verklaring zijn waarom de slaapeigenschappen van ouderen niet verbeterden 
na een jaar sporttraining. Sporttraining is waarschijnlijk alleen effectief bij personen 
met aanwezige slaapproblematiek om de slaapeigenschappen te verbeteren en niet 
bij gezonde oudere personen zonder slaapklachten.
Hoofdstuk 4 Evaluatie van hersendoorbloeding en 
zuurstofvoorziening in verschillende leeftijdsgroepen
De invloed van leeftijd op de hersendoorbloeding en zuurstofvoorziening van de 
hersenen wordt in dit hoofdstuk beschreven. Hierbij hebben we in drie leeftijdsgroepen 
(jongeren van 21-28 jaar, jongere ouderen van 65-69 jaar en oudere ouderen van 
74-86 jaar) de hersendoorbloeding, de zuurstofvoorziening van de hersenen en de 
bloeddruk gemeten tijdens verschillende lichaamshoudingen en ademhalings-
oefeningen. Onze resultaten tonen dat met het toenemen van de leeftijd de hersen-
doorbloeding daalt en de weerstand in de hersenbloedvaten stijgt. Desalniettemin 
zijn gezonde oudere personen (tot 86 jaar) in staat om onder dagelijkse omstandig-
heden de hersendoorbloeding en zuurstofvoorziening van de hersenen voldoende 
in stand te houden.
Hoofdstuk 5 De (gecombineerde) effecten van Alagebrium en 
sporten op de vaatfunctie bij gezonde ouderen
De belangrijkste resultaten van dit proefschrift zijn gepresenteerd in dit hoofdstuk. 
Hierin zijn de (gecombineerde) effecten van het nieuwe medicijn de AGE-crosslink 
breaker Alagebrium en van sporten onderzocht op de gezondheid van de bloedvaten 
(vaatfunctie en vaatstijfheid) bij gezonde oudere personen. In dit onderzoek werden 
de deelnemers verdeeld over 4 groepen: In groep 1 gingen de deelnemers een jaar 
sporten en namen zij dagelijks de Alagebrium in. Groep 2 ging ook een jaar sporten 
maar zij kregen dagelijks een placebo tablet (een neppil). De deelnemers in Groep 3 
gingen niet sporten maar zij namen wel dagelijkse de Alagebrium in. Tot slot Groep 4, 
deze deelnemers hoefden niet te sporten en zij kregen een placebo tablet. Dit was 
de controle groep om de effecten van een jaar veroudering op de bloedvaten te 
onderzoeken. 
Ondanks dat een jaar sporttraining de lichamelijke conditie aanzienlijk verbeterde, 
evenals het risicoprofiel op het ontstaan van hart- en vaatziekten, verbeterde de 
vaatfunctie en vaatstijfheid niet. De Alagebrium had geen invloed op de vaatfunctie 
en het versterkte het effect van de sporttraining niet. Van sporten is reeds aangetoond 
dat het een gunstig en beschermend effect heeft op het ontstaan van hart- en 
vaatziekten, ook bij oudere personen. Desondanks waren de sporttraining en 
Alagebrium in onze studie niet in staat om gedurende een jaar de negatieve gevolgen 
van jarenlange lichamelijke inactiviteit bij oudere personen ongedaan te maken.
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Hoofdstuk 6 Discussie van het proefschrift 
Dit hoofdstuk geeft een overzicht van de kennis die de afgelopen jaren is opgedaan 
over de versuikering van eiwitten en de effecten van Alagebrium. De eerste dieron-
derzoeken gaven aanwijzingen dat Alagebrium de stijfheid van hart en bloedvaten en 
de vaatfunctie kan verbeteren. Onverwachts, toonden de studies van de afgelopen 
paar jaar met mensen weinig of geen effect op de stijfheid van hart en bloedvaten en 
de vaatfunctie. Mogelijke verklaringen hiervoor kunnen zijn dat de vertaling van 
dieronderzoek naar mensgebonden onderzoek niet goed is verlopen. Daarnaast 
worden de verschillen tussen de diverse mensgebonden onderzoeken besproken 
om de uiteenlopende resultaten te begrijpen. De mensgebonden onderzoeken 
verschillen onder andere in onderzoekspopulatie, studie opzet, studie duur en 
meetmethoden. 
Vervolgens hebben we gekeken naar een mogelijk verband tussen de AGEs die in 
het bloed zitten en de AGEs die in de organen zitten. Daarbij hebben we het effect 
van levenslang versus kortdurend (een jaar) sporten op de AGEs in het bloed 
onderzocht. Dit was om te onderzoeken of sporten invloed heeft op de AGEs, en of 
dat een mogelijke verklaring zou kunnen zijn voor de gunstige effecten van sporten 
op de gezondheid van hart en bloedvaten. Deze resultaten gaven niet direct meer 
duidelijkheid in het werkingsmechanisme van de AGEs. Het leverde juist meer vragen 
op. Dit benadrukt dat het verband tussen de AGEs in het bloed en de AGEs in de 
weefsels nader moet worden onderzocht. 
Tot slot, worden er aanbevelingen en suggesties gedaan voor toekomstig onderzoek 
en wordt het belang van lichamelijke beweging nogmaals benadrukt. Met name voor 
de ouder wordende samenleving zijn lichamelijke beweging en dagelijkse lichamelijke 
activiteiten van groot belang om de gezondheid en het zelfstandig functioneren van 
ouderen te bevorderen.
Eindconclusie
De belangrijkste conclusies van mijn onderzoek zijn dat de gunstige effecten van 
Alagebrium bij mensen nader onderzocht moeten worden. Momenteel is het 
onvoldoende bewezen dat Alagebrium de gezondheid van hart en bloedvaten bij 
gezonde ouderen of bij patiënten verbetert. Daarnaast moet het verband tussen de 
AGEs in het bloed en de AGEs in de weefsels nader onderzocht worden in de hoop 
dat dit kan leiden tot een geschikt geneesmiddel om hart- en vaatziekten te 
verminderen. 
Van sporten zijn de gunstige effecten voor hart en bloedvaten reeds aangetoond in 
verschillende patiëntengroepen en bij gezonde personen. Ondanks dat 1 jaar sporten 
geen effect had op de vaatfunctie en vaatstijfheid, lieten de deelnemers in ons 
onderzoek een verbetering zien van hun lichamelijke conditie en van het risicoprofiel 
op het ontstaan van hart- en vaatziekten. Lichamelijke beweging en sporten zijn voor 
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alle leeftijden van groot belang ter bevordering van de gehele gezondheid. Het is dus 
nooit te laat om te beginnen met sporten.
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Dankwoord
”Education is an admirable thing, but it is well to remember from time to time that 
nothing that is worth knowing can be taught.” Oscar Wilde (1854-1900)
Dankwoord
Waar moet ik beginnen… Er zijn zoveel mensen die de afgelopen jaren een bijdrage 
hebben geleverd aan dit onderzoek. Ik zal beginnen met de belangrijkste personen: 
de deelnemers aan dit onderzoek. Zonder jullie hulp, medewerking en toewijding was 
er nooit een letter in dit proefschrift verschenen. Niet alleen hebben jullie een positieve 
bijdrage geleverd aan de medische wetenschap, maar ook aan mij als persoon en 
als arts. Ik heb veel van jullie geleerd. Dank jullie wel!
Uiteraard zijn er meerdere personen die ik graag wil bedanken voor hun bijdrage aan 
dit onderzoek en zonder wie ik dit project nooit tot een goed einde had kunnen 
brengen. Mocht je naam er niet persoonlijk tussen staan, dan bedank ik je hierbij 
voor je inzet en hulp bij dit onderzoek.
Het belangrijkste fundament van een promotieonderzoek is een goed promotieteam. 
Beste Maria, wat heb jij een energie, kracht, optimisme en positieve instelling. Ik heb 
veel bewondering voor de wijze waarop je de afdeling draaiende houdt en iedereen 
weet te enthousiasmeren voor nieuwe ideeën. Ik wil je graag bedanken voor je 
verruimende blik en de manier waarop je de niet altijd even duidelijke resultaten, wist 
te veranderen in heldere uitkomsten. Zonder jouw inzet, sturing en begeleiding was 
het nooit gelukt om het onderzoek tot een goed einde te brengen.
Beste Marcel, dank voor je vertrouwen in een positief einde van het proefschrift. Ik 
ben je erg dankbaar voor de extra tijd die je me gegeven hebt om het onderzoek te 
kunnen afronden en mijn draai in de kliniek te kunnen hervinden. Dankzij jouw vin-
dingrijkheid, leerzame input op de artikelen en aanhoudend optimisme is het gelukt 
om het onderzoek af te ronden en de overstap naar de kliniek te maken. Veel dank 
daarvoor.
Beste Arie, we kennen elkaar sinds 2004 toen ik onderzoek kwam doen bij je op de 
afdeling cardiologie. Jij hebt me de prachtige kanten van de cardiologie getoond en 
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